var title_f9_45_9936="Bronchoalveolar lavage in PAP";
var content_f9_45_9936=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PULM%2F82575&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PULM%2F82575&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Bronchoalveolar lavage in alveolar proteinosis",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 224px; height: 314px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    First two liters of proteinaceous material lavaged, as it appears after sedimentation. Three layers can be visualized: an upper foamy layer, a clear white middle layer, and a thick layer of dense proteinaceous material at the bottom. Lavages are repeated until the return fluid is clear.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     From Keller, CA, Frost, A, Cagle, PT, Abraham, JL, Chest 1995; 108:277.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f9_45_9936=[""].join("\n");
var outline_f9_45_9936=null;
var title_f9_45_9937="EB nevi 6";
var content_f9_45_9937=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=DERM%2F86608&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=DERM%2F86608&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 596px\">",
"   <div class=\"ttl\">",
"    Unpigmented epidermolysis bullosa nevi",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 576px; height: 432px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Two unpigmented \"shagreen\" EB nevi on the chest and the upper arm of a 65-year-old patient with junctional EB.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: Dedee F Murrell, MD, Johann Bauer, MD, and Martin Laimer, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f9_45_9937=[""].join("\n");
var outline_f9_45_9937=null;
var title_f9_45_9938="Exclusion of the distal esophagus";
var content_f9_45_9938=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=SURG%2F66616&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=SURG%2F66616&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 491px\">",
"   <div class=\"ttl\">",
"    Exclusion of the distal esophagus",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 471px; height: 447px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    This figure depicts the mobilized distal esophagus being prepared for division. By excluding the distal esophagus, gastric contents are prevented from contaminating the mediastinum through a perforated thoracic esophagus.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f9_45_9938=[""].join("\n");
var outline_f9_45_9938=null;
var title_f9_45_9939="UV lesions III";
var content_f9_45_9939=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ALLRG%2F54877&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ALLRG%2F54877&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 488px\">",
"   <div class=\"ttl\">",
"    Urticarial vasculitis",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 468px; height: 309px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Urticarial patch with central ecchymosis.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f9_45_9939=[""].join("\n");
var outline_f9_45_9939=null;
var title_f9_45_9940="Moxifloxacin (ophthalmic): Patient drug information";
var content_f9_45_9940=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"disclaimer\">",
"   The content on the UpToDate website is not intended nor recommended as a substitute",
"for medical advice, diagnosis, or treatment.  Always seek the advice of your own physician or",
"other qualified health care professional regarding any medical questions or conditions.  The",
"use of this website is governed by the",
"   <a href=\"/home/terms-use\" target=\"_blank\">",
"    UpToDate Terms of Use",
"   </a>",
"   &copy;2013 UpToDate, Inc.",
"  </div>",
"  <div id=\"drugTitle\">",
"   Moxifloxacin (ophthalmic): Patient drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   <p>",
"    (For additional information",
"    <a class=\"drug drug_general\" href=\"UTD.htm?18/10/18595?source=see_link\">",
"     see \"Moxifloxacin (ophthalmic): Drug information\"",
"    </a>",
"    and",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?5/50/5924?source=see_link\">",
"     see \"Moxifloxacin (ophthalmic): Pediatric drug information\"",
"    </a>",
"    )",
"   </p>",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F9347894\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Moxeza&trade;;",
"     </li>",
"     <li>",
"      Vigamox&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F9347895\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      Vigamox&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yya-os drugH1Div\" id=\"F10024279\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What is this drug used for?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2691501",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is used to stop or treat eye infections.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt coi-os drugH1Div\" id=\"F10024278\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What do I need to tell my doctor before I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2702554",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have an allergy to moxifloxacin or any other part of this drug.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2705171",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are allergic to any drugs, foods, or other substances. Tell your doctor about the allergy and what signs you had, like rash; hives; itching; shortness of breath; wheezing; cough; swelling of face, lips, tongue, or throat; or any other signs.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yye-os drugH1Div\" id=\"F10024283\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some things I need to know or do while I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696717",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Check all drugs you are taking with your doctor. This drug may not mix well with some other drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697641",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Tell your doctor if you are pregnant or plan on getting pregnant. You will need to talk about the benefits and risks of using this drug while you are pregnant.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697636",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Tell your doctor if you are breast-feeding. You will need to talk about any risks to your baby.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyf-os drugH1Div\" id=\"F10024284\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects of this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698333",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Short-term pain after use.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyh-os drugH1Div\" id=\"F10024286\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects that I need to call my doctor about right away?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698721",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you think there has been an overdose, call 1-800-222-1222 (the American Association of Poison Control Centers), your local poison control center (file://www.aapcc.org), or emergency room (ER) right away.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699066",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Signs of an allergic reaction, like rash; hives; itching; red, swollen, blistered, or peeling skin with or without fever; wheezing; tightness in the chest or throat; trouble breathing or talking; unusual hoarseness; or swelling of the mouth, face, lips, tongue, or throat.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699086",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Sudden change in eyesight, eye pain, or irritation.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698603",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Any rash.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698977",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Side effect or health problem is not better or you are feeling worse.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyc-os drugH1Div\" id=\"F10024281\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     How is this drug best taken?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696130",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       To gain the most benefit, do not miss doses.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696185",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Use as you have been told, even if you are feeling better.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2694913",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       For the eye only.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696257",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Wash your hands before and after use.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2695783",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Take out contact lenses before using this drug. Lenses may be put back in 15 minutes after this drug is given. Do not put contacts back in if your eyes are irritated or infected.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2694779",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not touch the container tip to the eye, lid, or other skin.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696124",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Tilt your head back and drop drug into the eye.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2694401",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       After use, keep your eyes closed. Put pressure on the inside corner of the eye. Do this for 1 to 2 minutes. This keeps the drug in your eye.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2695618",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Space each eye drug by 5 minutes.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyd-os drugH1Div\" id=\"F10024282\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What do I do if I miss a dose?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696583",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Use a missed dose as soon as you think about it.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696496",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If it is close to the time for your next dose, skip the missed dose and go back to your normal time.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696485",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not use 2 doses or extra doses.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696457",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not change the dose or stop this drug. Talk with the doctor.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyi-os drugH1Div\" id=\"F10024287\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     How do I store and/or throw out this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699335",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Store at room temperature or in a refrigerator. Do not freeze.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyj-os drugH1Div\" id=\"F10024288\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     General drug facts",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699675",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If your symptoms or health problems do not get better or if they become worse, call your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699673",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not share your drugs with others and do not take anyone else's drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699678",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep all drugs out of the reach of children and pets.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699709",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have any questions about this drug, please talk with your doctor, pharmacist, or other health care provider.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s3302581",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       In Canada, take any unused drugs to the pharmacy. Also, visit file://www.hc-sc.gc.ca/hl-vs/iyh-vsv/med/disposal-defaire-eng.php#th to learn about the right way to get rid of unused drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699671",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       These are not all of the side effects that may occur. If you have questions about side effects, call your doctor. Call your doctor for medical advice about side effects.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699683",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Talk with the doctor before starting any new drug, including prescription or OTC, natural products, or vitamins.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 12262 Version 33.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1003-201.65.114.212-1237D62C13-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f9_45_9940=[""].join("\n");
var outline_f9_45_9940=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F9347894\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F9347895\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10024279\">",
"      What is this drug used for?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10024278\">",
"      What do I need to tell my doctor before I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10024283\">",
"      What are some things I need to know or do while I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10024284\">",
"      What are some side effects of this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10024286\">",
"      What are some side effects that I need to call my doctor about right away?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10024281\">",
"      How is this drug best taken?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10024282\">",
"      What do I do if I miss a dose?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10024287\">",
"      How do I store and/or throw out this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10024288\">",
"      General drug facts",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"UTD.htm?18/10/18595?source=related_link\">",
"      Moxifloxacin (ophthalmic): Drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_pediatric\" href=\"UTD.htm?5/50/5924?source=related_link\">",
"      Moxifloxacin (ophthalmic): Pediatric drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"UTD.htm?21/29/21976?source=related_link\">",
"      Moxifloxacin (systemic): Drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"UTD.htm?2/51/2870?source=related_link\">",
"      Moxifloxacin (systemic): Patient drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f9_45_9941="MRI non-retracted partial tear of hamstring tendons";
var content_f9_45_9941=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=RADIOL%2F83906&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=RADIOL%2F83906&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 618px\">",
"   <div class=\"ttl\">",
"    MRI of non-retracted partial tear of hamstring tendons",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 598px; height: 227px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    The MRI of the thighs using Fast STIR sequence in the coronal plane (A, with arrows in same image B) reveals a fluid collection (green arrow) in the proximal insertion of the hamstrings on to the ischial tuberosity (yellow arrow). The red arrow points to the hamstring tendon. These findings demonstrate a high grade detachment without gross retraction.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Richard Waite, MD and Patrick Casey, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f9_45_9941=[""].join("\n");
var outline_f9_45_9941=null;
var title_f9_45_9942="Macroovalocytes";
var content_f9_45_9942=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=HEME%2F74901&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=3\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=HEME%2F74901&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=3\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic2\" style=\"width: 1040px;\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Macroovalocytes in vitamin B12 deficiency",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 398px; height: 259px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Peripheral smear shows marked macroovalocytosis in a patient with vitamin B12 deficiency.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Stanley L Schrier, MD.",
"    </div>",
"   </div>",
"  </div>",
"  <div class=\"figure\" style=\"width: 450px\">",
"   <div class=\"ttl\">",
"    Normal peripheral blood smear",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 393px; height: 257px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    High power view of a normal peripheral blood smear. Several platelets (black arrows) and a normal lymphocyte (blue arrow) can also be seen. The red cells are of relatively uniform size and shape. The diameter of the normal red cell should approximate that of the nucleus of the small lymphocyte; central pallor (red arrow) should equal one-third of its diameter.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Carola von Kapff, SH (ASCP).",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f9_45_9942=[""].join("\n");
var outline_f9_45_9942=null;
var title_f9_45_9943="Posttreatment follow-up for men with testicular germ cell tumors";
var content_f9_45_9943=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"1\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Posttreatment follow-up for men with testicular germ cell tumors",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?9/45/9943/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?9/45/9943/contributors\">",
"     William K Oh, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?9/45/9943/contributors\">",
"     Jerome P Richie, MD, FACS",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?9/45/9943/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?9/45/9943/contributors\">",
"     Philip W Kantoff, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?9/45/9943/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?9/45/9943/contributors\">",
"     Don S Dizon, MD, FACP",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?9/45/9943/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Jul 5, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Testicular germ cell tumors (GCTs) have become one of the most curable solid neoplasms, due to improved staging and surgical techniques, the use of platinum-based combination chemotherapy, and the availability of serum tumor markers (beta subunit of human chorionic gonadotropin [&beta;-hCG], alpha fetoprotein [AFP], and lactate dehydrogenase [LDH]) to monitor for the response to treatment and the presence of occult disease. For men with testicular GCTs, the five-year survival rate is over 95 percent. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?13/7/13432?source=see_link\">",
"     \"Overview of the treatment of testicular germ cell tumors\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?37/58/38822?source=see_link\">",
"     \"Serum tumor markers in testicular germ cell tumors\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The follow-up and surveillance for recurrence in men who have completed their initial definitive treatment for testicular cancer will be reviewed here. The use of serum tumor markers during the initial treatment of testicular germ cell tumors is discussed separately.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?37/58/38822?source=see_link&amp;anchor=H17#H17\">",
"       \"Serum tumor markers in testicular germ cell tumors\", section on 'Monitoring response to therapy'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?3/16/3334?source=see_link\">",
"       \"Active surveillance following orchiectomy for stage I testicular germ cell tumors\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     ONCOLOGIC FOLLOW-UP",
"    </span>",
"    &nbsp;&mdash;&nbsp;At the conclusion of treatment, surveillance is appropriate for:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Men with low-risk stage I testicular GCTs treated with orchiectomy alone. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?3/16/3334?source=see_link\">",
"       \"Active surveillance following orchiectomy for stage I testicular germ cell tumors\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Men with a complete response, defined as normal posttreatment serum tumor markers (AFP, &beta;-hCG,",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      LDH) and no evidence of disease on imaging studies.",
"     </li>",
"     <li>",
"      Men with a partial response, defined as stable or declining tumor markers (without normalization). This may be associated with evidence of persistent disease on imaging.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Routine follow-up care for men who have successfully completed therapy for testicular cancer consists of periodic history and physical examinations (including testicular examination), assessment of serum tumor markers (&beta;-hCG, AFP,",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    LDH), and radiographic studies.",
"   </p>",
"   <p>",
"    Factors that influence the nature and intensity of follow-up after completion of initial definitive therapy include the histology (seminoma versus nonseminomatous germ cell tumors [NSGCT]), risk of recurrence, and treatment (particularly the use of surgery or radiation therapy to treat the retroperitoneal lymph nodes).",
"   </p>",
"   <p>",
"    Men who have rising tumor markers",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    radiographically documented progressive disease following treatment should be evaluated for recurrent disease. (See",
"    <a class=\"local\" href=\"#H13\">",
"     'Detection of recurrent disease'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h2\">",
"     Duration of follow-up after treatment",
"    </span>",
"    &nbsp;&mdash;&nbsp;The intensity of follow-up is guided in part by the probability of relapse over time.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      For men with seminoma, the median time to relapse is 13 to 16 months (range 2 to 108 months), but up to one-third of relapses occur more than three years after completion of treatment [",
"      <a class=\"abstract\" href=\"UTD.htm?9/45/9943/abstract/1,2\">",
"       1,2",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      For men with NSGCT, over 95 percent of relapses occur within the first two years following orchiectomy [",
"      <a class=\"abstract\" href=\"UTD.htm?9/45/9943/abstract/3\">",
"       3",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Although most relapses occur within the first five years for both seminoma and NSGCT, late recurrences are rare but can occur [",
"    <a class=\"abstract\" href=\"UTD.htm?9/45/9943/abstract/4,5\">",
"     4,5",
"    </a>",
"    ]. In one study that evaluated 1949 patients, 10 of 1123 men with seminoma (0.8 percent) and 15 of 826 men with NSGCT (1.8 percent) recurred more than five years after the original diagnosis [",
"    <a class=\"abstract\" href=\"UTD.htm?9/45/9943/abstract/4\">",
"     4",
"    </a>",
"    ]. Other series have reported a higher incidence of late recurrences [",
"    <a class=\"abstract\" href=\"UTD.htm?9/45/9943/abstract/6,7\">",
"     6,7",
"    </a>",
"    ], but these may be subject to referral bias.",
"   </p>",
"   <p>",
"    Therefore, follow-up is most intensive during the first one to two years after treatment and then gradually decreases. However, most groups now recommend that follow-up continue for at least ten years following initial treatment because of the risk of late relapse. The treatment of relapsed testicular germ cell tumors is discussed elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?2/56/2954?source=see_link\">",
"     \"Treatment of relapsed and refractory testicular germ cell tumors\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1040491266\">",
"    <span class=\"h2\">",
"     Monitoring approaches",
"    </span>",
"    &nbsp;&mdash;&nbsp;The basic approaches used to monitor a man following definitive therapy for a testicular GCT include:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      History and physical examination (See",
"      <a class=\"local\" href=\"#H4\">",
"       'History and physical examination'",
"      </a>",
"      below.)",
"     </li>",
"     <li>",
"      Serum tumor markers (See",
"      <a class=\"local\" href=\"#H5\">",
"       'Serum tumor markers'",
"      </a>",
"      below.)",
"     </li>",
"     <li>",
"      Imaging of the chest, abdomen, and pelvis (See",
"      <a class=\"local\" href=\"#H6\">",
"       'Radiographic studies'",
"      </a>",
"      below.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    There are no prospective, randomized trials that have defined the optimal follow-up strategy for men who have completed their initial treatment. (See",
"    <a class=\"local\" href=\"#H7\">",
"     'Guidelines for follow-up'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h3\">",
"     History and physical examination",
"    </span>",
"    &nbsp;&mdash;&nbsp;Posttreatment history and physical examination should be performed on the same schedule as measurement of tumor markers. Close attention should be paid to cervical and supraclavicular nodal regions, the abdominal exam (for the presence of masses or hepatomegaly), and the presence of neurologic signs or symptoms. (See",
"    <a class=\"local\" href=\"#H7\">",
"     'Guidelines for follow-up'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    Routine testicular examination at each visit should also be performed because of the higher incidence of contralateral testis cancer in men with unilateral GCTs and of testis cancers in men with primary extragonadal germ cell tumors. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?2/25/2457?source=see_link\">",
"     \"Epidemiology of and risk factors for testicular germ cell tumors\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?9/52/10058?source=see_link\">",
"     \"Extragonadal germ cell tumors involving the mediastinum and retroperitoneum\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?15/41/16025?source=see_link&amp;anchor=H773414877#H773414877\">",
"     \"Approach to the care of long-term testicular cancer survivors\", section on 'Contralateral testicular cancer'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h3\">",
"     Serum tumor markers",
"    </span>",
"    &nbsp;&mdash;&nbsp;For men who have completed definitive therapy, tumor markers should be measured at the same frequency as the history and physical exam. The three most commonly elevated tumor markers in men with testicular GCTs are &beta;-hCG, AFP, and LDH. Of these, AFP is the most sensitive to detect relapsed disease while LDH is the least sensitive and specific for germ cell tumors [",
"    <a class=\"abstract\" href=\"UTD.htm?9/45/9943/abstract/8\">",
"     8",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    For men with NSGCTs, serum concentrations of &beta;-hCG",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    AFP are elevated in 85 percent of patients at diagnosis. Following treatment, periodic measurements of serum &beta;-hCG and AFP represent the most sensitive means of detecting early relapse. (See",
"    <a class=\"local\" href=\"#H900677617\">",
"     'NSGCT'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    For men with seminoma, the value of monitoring serum tumor markers is of unclear value, as relapse is almost always detected by exam or by imaging [",
"    <a class=\"abstract\" href=\"UTD.htm?9/45/9943/abstract/8,9\">",
"     8,9",
"    </a>",
"    ]. &beta;-hCG is increased in 15 to 20 percent of those with advanced disease. However, AFP, by definition, is never elevated in patients with pure seminoma [",
"    <a class=\"abstract\" href=\"UTD.htm?9/45/9943/abstract/10\">",
"     10",
"    </a>",
"    ]. Although LDH is a less sensitive and less specific tumor marker than either &beta;-hCG or AFP, it may be the only elevated marker in some men with seminoma. (See",
"    <a class=\"local\" href=\"#H900677624\">",
"     'Seminoma'",
"    </a>",
"    below and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?37/58/38822?source=see_link&amp;anchor=H2#H2\">",
"     \"Serum tumor markers in testicular germ cell tumors\", section on 'Human chorionic gonadotropin'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?37/58/38822?source=see_link&amp;anchor=H8#H8\">",
"     \"Serum tumor markers in testicular germ cell tumors\", section on 'Alpha fetoprotein'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h3\">",
"     Radiographic studies",
"    </span>",
"    &nbsp;&mdash;&nbsp;Serial chest x-rays are a component of the posttreatment surveillance schedule and are performed with the same frequency as tumor markers. Either computed tomography (CT) or magnetic resonance imaging (MRI) scans are used to monitor for disease recurrence in the abdomen or pelvis. However, there are no firm data supporting the benefit of these studies. (See",
"    <a class=\"local\" href=\"#H7\">",
"     'Guidelines for follow-up'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In one series, 290 men with disseminated testicular cancer were followed on a posttreatment surveillance protocol that included serum tumor markers, physical examination, and chest x-rays after attaining a complete remission from chemotherapy [",
"      <a class=\"abstract\" href=\"UTD.htm?9/45/9943/abstract/11\">",
"       11",
"      </a>",
"      ]. Tumor relapse was documented in 33 (11.4 percent). Relapse was detected by rising tumor markers only in 27 (82 percent) and by rising tumors markers plus abnormal physical examination in four men. A total of 10,160 routine chest x-rays were performed during surveillance, and none played a role in detecting tumor relapse. Prior to the initiation of treatment for relapsed disease, all patients but one had elevated serum tumor markers.",
"     </li>",
"     <li>",
"      The utility of periodic CT scans of the abdomen and pelvis was evaluated in a series of 170 men undergoing surveillance following orchiectomy for stage I NSGCT [",
"      <a class=\"abstract\" href=\"UTD.htm?9/45/9943/abstract/12\">",
"       12",
"      </a>",
"      ]. History and physical examination, serum tumor markers, CT of the abdomen and pelvis, and chest radiography provided the initial evidence of progression in 38, 71, 71, and 8 percent of patients, respectively. Removal of routine chest radiography from the surveillance protocol would not have altered the detection of progressive disease.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    There are real concerns about the risk of second malignancies due to the radiation from CT scans. Efforts to reduce the amount of radiation by using different techniques, such as MRI, or changing the number",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    frequency of CT scans, remain an area of active investigation. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?21/17/21785?source=see_link\">",
"     \"Radiation-related risks of imaging studies\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     Guidelines for follow-up",
"    </span>",
"    &nbsp;&mdash;&nbsp;There are no prospective, randomized trials that have defined the optimal follow-up strategy for men who have completed their initial treatment. Multiple urologic and oncologic groups have published guidelines or recommendations based upon histology (NSGCTs versus seminomas) and stage of disease using data from observational studies [",
"    <a class=\"abstract\" href=\"UTD.htm?9/45/9943/abstract/10,13-18\">",
"     10,13-18",
"    </a>",
"    ]. Although there are some differences in guidelines between these groups, all rely upon interval history and physical examination, assessment of serum tumor markers, chest x-rays to assess pulmonary disease, and CT or MRI to assess the abdomen and pelvis.",
"   </p>",
"   <p>",
"    We agree with the follow-up guidelines by the National Comprehensive Cancer Network [",
"    <a class=\"abstract\" href=\"UTD.htm?9/45/9943/abstract/19\">",
"     19",
"    </a>",
"    ]:",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H900677617\">",
"    <span class=\"h3\">",
"     NSGCT",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      <strong>",
"       Men in active surveillance after inguinal orchiectomy",
"      </strong>",
"      &mdash; A history and physical exam, chest x-ray, and serum tumor markers (AFP, &beta;-hCG, and LDH) should be obtained every one to two months for the first two years then gradually decreasing to every six months in year 3, then annually beginning year 5. Computed tomography (CT) of the abdomen and pelvis should be obtained every three to four months in year 1, every four to six months in year 2, and gradually decreasing to annually starting in year 5. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?3/16/3334?source=see_link\">",
"       \"Active surveillance following orchiectomy for stage I testicular germ cell tumors\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      <strong>",
"       Men treated with chemotherapy and retroperitoneal lymph node dissection (RPLND)",
"      </strong>",
"      &mdash; A history and physical exam, chest x-ray, and tumor markers (AFP, &beta;-hCG, and LDH) should be obtained every two to three months for years 1 and 2, gradually decreasing to every six months in year 4, and then once a year starting in year 6. CT of the abdomen and pelvis should be performed every six months in year 1 and then annually until year 5. It should be performed only as clinically indicated thereafter.",
"     </li>",
"     <li>",
"      <strong>",
"       Men treated with RPLND alone",
"      </strong>",
"      &mdash; A history and physical exam, chest X-ray, and tumor markers should be obtained every two to three months for years 1 and 2, gradually decreasing to every six months in year 4, and then once a year starting in year 6. CT of the abdomen and pelvis should be performed at baseline and then only if clinically indicated thereafter.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H900677624\">",
"    <span class=\"h3\">",
"     Seminoma",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      <strong>",
"       Stage I disease",
"      </strong>",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      <strong>",
"       Men undergoing active surveillance after inguinal orchiectomy",
"      </strong>",
"      &mdash; A history, physical exam, and tumor markers (AFP, &beta;-hCG, and LDH) should be obtained every three to four months for the first two years then gradually decreasing to every 6 to 12 months in year 3, then annually beginning year 5. CT of the abdomen and pelvis should be obtained every six months in the first two years and gradually decreasing to annually starting in year 5. A chest x-ray is performed only if clinically indicated. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?3/16/3334?source=see_link\">",
"       \"Active surveillance following orchiectomy for stage I testicular germ cell tumors\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      <strong>",
"       Men treated with single-agent",
"      </strong>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?37/61/38873?source=see_link\">",
"       carboplatin",
"      </a>",
"      &mdash; A history and physical exam, and tumor markers (AFP, &beta;-hCG, and LDH) should be obtained every three months for years 1, gradually decreasing to every six months for year 3, and then annually. CT of the abdomen and pelvis should be performed annually for years 1 to 3 and then as clinically indicated thereafter. A chest x-ray should be performed only if clinically indicated.",
"     </li>",
"     <li>",
"      <strong>",
"       Men treated with radiation therapy (RT)",
"      </strong>",
"      &mdash; A history and physical exam, and tumor markers (AFP, &beta;-hCG, and LDH) should be obtained every four months for years 1 and 2 then annually until year 10. For patients who received RT solely to the paraaortic nodes, CT of the abdomen and pelvis should be performed annually for years 1 to 3 and then only if clinically indicated. A chest x-ray should be performed only if clinically indicated.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      <strong>",
"       Stage II-III disease",
"      </strong>",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      <strong>",
"       Men treated with RT to the ipsilateral iliac and paraaortic nodes",
"      </strong>",
"      &mdash; A history and physical exam, and tumor markers (AFP, &beta;-hCG, and LDH) should be obtained every three months for years 1, then every six months until year 5, and then annually until year 10. Chest x-ray should be obtained every six months for years 1 and 2. CT of the abdomen and pelvis should be performed every 6 to 12 months for years 1 and 2 then annually starting at year 3.",
"     </li>",
"     <li>",
"      <strong>",
"       Men treated with combination chemotherapy",
"      </strong>",
"      &mdash; A history and physical exam, chest x-ray, and tumor markers (AFP, &beta;-hCG, and LDH) should be obtained every two months for years 1, gradually decreasing to every six months in year 3, and then annually starting year 5. For men treated with RPLND postchemotherapy, a CT of the abdomen and pelvis should be performed three to six months after surgery. Further imaging (eg, chest x-ray, CT scan, or positron emission tomography [PET] scan) should be done only if clinically indicated.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h2\">",
"     Detection of recurrent disease",
"    </span>",
"    &nbsp;&mdash;&nbsp;Rising tumor markers",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    the presence of radiographically documented progressive disease is usually an indication of disease recurrence or progression. Men who exhibit either of these during surveillance are candidates for further treatment. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?2/56/2954?source=see_link\">",
"     \"Treatment of relapsed and refractory testicular germ cell tumors\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2281965821\">",
"    <span class=\"h3\">",
"     Interpreting serum tumor markers",
"    </span>",
"    &nbsp;&mdash;&nbsp;Serum tumor markers are rarely a sign of recurrence among men with seminoma [",
"    <a class=\"abstract\" href=\"UTD.htm?9/45/9943/abstract/8,9\">",
"     8,9",
"    </a>",
"    ]. However, our approach to interpreting serum tumor markers depends on the scenario:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      For men who experienced declining serum tumor markers during treatment but did not normalize by the end of treatment, we consider an increase in the AFP or &beta;-hCG a sign of disease recurrence. However, no particular level of increase is pathognomonic of a tumor recurrence.",
"     </li>",
"     <li>",
"      For men who normalized serum tumor markers, we do not consider values that fluctuate (or increase) but stay within the normal range a sign of relapse.",
"     </li>",
"     <li>",
"      For men with a stable but elevated level of AFP (ie, AFP level 25 percent higher than the upper limit of normal), we consider an increase in the AFP or &beta;-hCG a sign of disease recurrence.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    However, several scenarios may occur that may mimic relapsed disease. As examples:",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h3\">",
"     Pulmonary nodules",
"    </span>",
"    &nbsp;&mdash;&nbsp;Men who received",
"    <a class=\"drug drug_general\" href=\"UTD.htm?38/15/39159?source=see_link\">",
"     bleomycin",
"    </a>",
"    as part of their original treatment are at risk for pulmonary toxicity during follow-up. This may present on imaging (chest x-ray or CT) as nodular lesions shortly after the completion of chemotherapy (",
"    <a class=\"graphic graphic_table graphicRef75991 \" href=\"UTD.htm?0/25/411\">",
"     table 1",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?9/45/9943/abstract/20\">",
"     20",
"    </a>",
"    ]. Characteristically, these are subpleural in location, and serum tumor markers are normal. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?12/31/12794?source=see_link\">",
"     \"Bleomycin-induced lung injury\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?15/41/16025?source=see_link&amp;anchor=H773414661#H773414661\">",
"     \"Approach to the care of long-term testicular cancer survivors\", section on 'Bleomycin-induced lung injury'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h3\">",
"     Growing teratoma syndrome",
"    </span>",
"    &nbsp;&mdash;&nbsp;Benign teratomatous elements may enlarge during or after chemotherapy, mimicking progressive or relapsed disease [",
"    <a class=\"abstract\" href=\"UTD.htm?9/45/9943/abstract/21\">",
"     21",
"    </a>",
"    ]. In such patients, tumor markers may be normal. Complete surgical resection is indicated rather than additional chemotherapy. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?37/33/38425?source=see_link&amp;anchor=H4#H4\">",
"     \"Surgical management of advanced testicular germ cell tumors\", section on 'Significance of teratoma'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h3\">",
"     False-positive elevation of serum beta-hCG",
"    </span>",
"    &nbsp;&mdash;&nbsp;Because there is some cross reactivity with luteinizing hormone (LH), a false positive elevation of serum &beta;-hCG may occur in men with hypogonadism, which may occur following systemic chemotherapy. Administration of testosterone may resolve this issue. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?37/58/38822?source=see_link\">",
"     \"Serum tumor markers in testicular germ cell tumors\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?12/33/12824?source=see_link\">",
"     \"Clinical features and diagnosis of male hypogonadism\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?8/18/8488?source=see_link\">",
"     \"Causes of secondary hypogonadism in males\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?15/41/16025?source=see_link&amp;anchor=H30007340#H30007340\">",
"     \"Approach to the care of long-term testicular cancer survivors\", section on 'Hypogonadism'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h1\">",
"     TREATMENT-RELATED COMPLICATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Of all the chemotherapeutic agents that have activity in testicular cancer,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?20/51/21305?source=see_link\">",
"     cisplatin",
"    </a>",
"    has the greatest potential for toxicity, including nephrotoxicity, neuropathy, high-frequency hearing loss, infertility, and cardiovascular effects. The immediate and late complications of treatment in men with testicular GCTs are discussed in detail elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?19/49/20250?source=see_link\">",
"     \"Treatment-related toxicity in men with testicular germ cell tumors\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?15/41/16025?source=see_link\">",
"     \"Approach to the care of long-term testicular cancer survivors\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h1\">",
"     SUMMARY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Testicular germ cell tumors (GCTs) are one of the most curable solid neoplasms due to advances in treatment, including",
"    <a class=\"drug drug_general\" href=\"UTD.htm?20/51/21305?source=see_link\">",
"     cisplatin",
"    </a>",
"    -based chemotherapy and the use of serum tumor markers to monitor response to treatment and to detect minimal residual disease. Aggressive treatment of relapsed disease is required to maintain the high cure rate while minimizing the toxicity associated with treatment. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?13/7/13432?source=see_link\">",
"     \"Overview of the treatment of testicular germ cell tumors\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?2/56/2954?source=see_link\">",
"     \"Treatment of relapsed and refractory testicular germ cell tumors\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Most patients who will relapse do so within the first one to two years after their initial treatment. Late relapses (after five years) can occur but are rare. The intensity of follow-up is dictated by the histology of the original tumor (seminoma versus nonseminomatous GCT), and the stage and risk of recurrence at original presentation.",
"     </li>",
"     <li>",
"      Oncologic follow-up after initial therapy includes history and physical examination, monitoring serum tumor markers (beta subunit of human chorionic gonadotropin [&beta;-hCG], alpha-fetoprotein [AFP]) for evidence or recurrence, and imaging studies (chest x-ray, MRI or CT of abdomen and pelvis). The optimal schedules for follow-up have not been defined in clinical trials, but empiric guidelines have been established based upon observational experience. (See",
"      <a class=\"local\" href=\"#H7\">",
"       'Guidelines for follow-up'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Several clinical situations may mimic tumor relapse and must be carefully distinguished from a true relapse to prevent overtreatment. These include pulmonary nodules secondary to",
"      <a class=\"drug drug_general\" href=\"UTD.htm?38/15/39159?source=see_link\">",
"       bleomycin",
"      </a>",
"      lung injury, the growing teratoma syndrome, and false-positive elevation of &beta;-hCG that is due to hypogonadism. (See",
"      <a class=\"local\" href=\"#H13\">",
"       'Detection of recurrent disease'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      In addition to oncologic follow-up, men successfully treated for testicular GCTs require surveillance for complications of treatment. (See",
"      <a class=\"local\" href=\"#H17\">",
"       'Treatment-related complications'",
"      </a>",
"      above and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?19/49/20250?source=see_link\">",
"       \"Treatment-related toxicity in men with testicular germ cell tumors\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?15/41/16025?source=see_link\">",
"       \"Approach to the care of long-term testicular cancer survivors\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/45/9943/abstract/1\">",
"      Bayens YC, Helle PA, Van Putten WL, Mali SP. Orchidectomy followed by radiotherapy in 176 stage I and II testicular seminoma patients: benefits of a 10-year follow-up study. Radiother Oncol 1992; 25:97.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/45/9943/abstract/2\">",
"      Ellerbroek NA, Tran LM, Selch MT, et al. Testicular seminoma. A study of 103 cases treated at UCLA. Am J Clin Oncol 1988; 11:93.",
"     </a>",
"    </li>",
"    <li>",
"     Daugaard, G, Roerth, M. Observation and expectant management for low-stage seminoma and nonseminoma. In: Comprehensive Textbook of Genitourinary Oncology, 2nd, Vogelzang, NJ, Scardino, PT, Shipley, WU, Coffey, DS (Eds), Lippincott, Williams and Wilkins, Philadelphia 2000. p.976.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/45/9943/abstract/4\">",
"      Oldenburg J, Alfsen GC, Waehre H, Foss&aring; SD. Late recurrences of germ cell malignancies: a population-based experience over three decades. Br J Cancer 2006; 94:820.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/45/9943/abstract/5\">",
"      Geldart TR, Gale J, McKendrick J, et al. Late relapse of metastatic testicular nonseminomatous germ cell cancer: surgery is needed for cure. BJU Int 2006; 98:353.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/45/9943/abstract/6\">",
"      Shahidi M, Norman AR, Dearnaley DP, et al. Late recurrence in 1263 men with testicular germ cell tumors. Multivariate analysis of risk factors and implications for management. Cancer 2002; 95:520.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/45/9943/abstract/7\">",
"      George DW, Foster RS, Hromas RA, et al. Update on late relapse of germ cell tumor: a clinical and molecular analysis. J Clin Oncol 2003; 21:113.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/45/9943/abstract/8\">",
"      Salem M, Gilligan T. Serum tumor markers and their utilization in the management of germ-cell tumors in adult males. Expert Rev Anticancer Ther 2011; 11:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/45/9943/abstract/9\">",
"      Vesprini D, Chung P, Tolan S, et al. Utility of serum tumor markers during surveillance for stage I seminoma. Cancer 2012; 118:5245.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/45/9943/abstract/10\">",
"      Gilligan TD, Seidenfeld J, Basch EM, et al. American Society of Clinical Oncology Clinical Practice Guideline on uses of serum tumor markers in adult males with germ cell tumors. J Clin Oncol 2010; 28:3388.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/45/9943/abstract/11\">",
"      Gietema JA, Meinardi MT, Sleijfer DT, et al. Routine chest X-rays have no additional value in the detection of relapse during routine follow-up of patients treated with chemotherapy for disseminated non-seminomatous testicular cancer. Ann Oncol 2002; 13:1616.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/45/9943/abstract/12\">",
"      Sharir S, Jewett MA, Sturgeon JF, et al. Progression detection of stage I nonseminomatous testis cancer on surveillance: implications for the followup protocol. J Urol 1999; 161:472.",
"     </a>",
"    </li>",
"    <li>",
"     National Comprehensive Cancer Network (NCCN) guidelines. Available at: www.nccn.org (Accessed on May 15, 2012).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/45/9943/abstract/14\">",
"      Schmoll HJ, Jordan K, Huddart R, et al. Testicular non-seminoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol 2010; 21 Suppl 5:v147.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/45/9943/abstract/15\">",
"      Schmoll HJ, Jordan K, Huddart R, et al. Testicular seminoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol 2010; 21 Suppl 5:v140.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/45/9943/abstract/16\">",
"      Wood L, Kollmannsberger C, Jewett M, et al. Canadian consensus guidelines for the management of testicular germ cell cancer. Can Urol Assoc J 2010; 4:e19.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/45/9943/abstract/17\">",
"      Krege S, Beyer J, Souchon R, et al. European consensus conference on diagnosis and treatment of germ cell cancer: a report of the second meeting of the European Germ Cell Cancer Consensus group (EGCCCG): part I. Eur Urol 2008; 53:478.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/45/9943/abstract/18\">",
"      Krege S, Beyer J, Souchon R, et al. European consensus conference on diagnosis and treatment of germ cell cancer: a report of the second meeting of the European Germ Cell Cancer Consensus Group (EGCCCG): part II. Eur Urol 2008; 53:497.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/45/9943/abstract/19\">",
"      Motzer RJ, Agarwal N, Beard C, et al. Testicular cancer. J Natl Compr Canc Netw 2012; 10:502.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/45/9943/abstract/20\">",
"      Bellamy EA, Husband JE, Blaquiere RM, Law MR. Bleomycin-related lung damage: CT evidence. Radiology 1985; 156:155.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/45/9943/abstract/21\">",
"      Spiess PE, Kassouf W, Brown GA, et al. Surgical management of growing teratoma syndrome: the M. D. Anderson cancer center experience. J Urol 2007; 177:1330.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 2956 Version 9.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0504-115.66.252.144-564C5304BD-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f9_45_9943=[""].join("\n");
var outline_f9_45_9943=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H18\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      ONCOLOGIC FOLLOW-UP",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      Duration of follow-up after treatment",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H1040491266\">",
"      Monitoring approaches",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      - History and physical examination",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      - Serum tumor markers",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      - Radiographic studies",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      Guidelines for follow-up",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H900677617\">",
"      - NSGCT",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H900677624\">",
"      - Seminoma",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      Detection of recurrent disease",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H2281965821\">",
"      - Interpreting serum tumor markers",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      - Pulmonary nodules",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      - Growing teratoma syndrome",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      - False-positive elevation of serum beta-hCG",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      TREATMENT-RELATED COMPLICATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      SUMMARY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"ONC/2956\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"ONC/2956|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?0/25/411\" title=\"table 1\">",
"      Bleomycin pneumonitis appearance",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?3/16/3334?source=related_link\">",
"      Active surveillance following orchiectomy for stage I testicular germ cell tumors",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?15/41/16025?source=related_link\">",
"      Approach to the care of long-term testicular cancer survivors",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?12/31/12794?source=related_link\">",
"      Bleomycin-induced lung injury",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?8/18/8488?source=related_link\">",
"      Causes of secondary hypogonadism in males",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?12/33/12824?source=related_link\">",
"      Clinical features and diagnosis of male hypogonadism",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?2/25/2457?source=related_link\">",
"      Epidemiology of and risk factors for testicular germ cell tumors",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?9/52/10058?source=related_link\">",
"      Extragonadal germ cell tumors involving the mediastinum and retroperitoneum",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?13/7/13432?source=related_link\">",
"      Overview of the treatment of testicular germ cell tumors",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?21/17/21785?source=related_link\">",
"      Radiation-related risks of imaging studies",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?37/58/38822?source=related_link\">",
"      Serum tumor markers in testicular germ cell tumors",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?37/33/38425?source=related_link\">",
"      Surgical management of advanced testicular germ cell tumors",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?2/56/2954?source=related_link\">",
"      Treatment of relapsed and refractory testicular germ cell tumors",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?19/49/20250?source=related_link\">",
"      Treatment-related toxicity in men with testicular germ cell tumors",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f9_45_9944="Sorafenib: Drug information";
var content_f9_45_9944=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Sorafenib: Drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   (For additional information",
"   <a class=\"drug drug_patient\" href=\"UTD.htm?43/42/44709?source=see_link\">",
"    see \"Sorafenib: Patient drug information\"",
"   </a>",
"   )",
"   <br/>",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F2307883\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      NexAVAR&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F6826164\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      Nexavar&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ex_sect_xr thclist drugH1Div drugBrandNames\" id=\"F2307887\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacologic Category",
"    </span>",
"    <ul>",
"     <li>",
"      Antineoplastic Agent, Tyrosine Kinase Inhibitor;",
"     </li>",
"     <li>",
"      Vascular Endothelial Growth Factor (VEGF) Inhibitor",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block doa drugH1Div\" id=\"F2322555\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Adult",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <b>",
"      Advanced renal cell carcinoma:",
"     </b>",
"     Oral: 400 mg twice daily; continue until no longer clinically benefiting or until unacceptable toxicity",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <b>",
"      Hepatocellular cancer:",
"     </b>",
"     Oral: 400 mg twice daily; continue until no longer clinically benefiting or until unacceptable toxicity",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <b>",
"      Angiosarcoma (unlabeled use):",
"     </b>",
"     Oral: 400 mg twice daily (Maki, 2009)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <b>",
"      Gastrointestinal stromal tumor (GIST) (unlabeled use):",
"     </b>",
"     Oral: 400 mg twice daily (Wiebe, 2008)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <b>",
"      Thyroid cancer (unlabeled use):",
"     </b>",
"     Oral: 400 mg twice daily (Gupta-Abramson, 2008)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <i>",
"      Dosage adjustment for concomitant CYP3A4 inducers:",
"     </i>",
"     Avoid the concomitant use of a strong CYP3A4 inducer (eg, carbamazepine, dexamethasone, phenobarbital, phenytoin, rifampin, St. John&rsquo;s wort) with sorafenib.",
"    </p>",
"   </div>",
"   <div class=\"block doe drugH1Div\" id=\"F2530072\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Geriatric",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Refer to adult dosing.",
"    </p>",
"   </div>",
"   <div class=\"block dor drugH1Div\" id=\"F2322556\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Renal Impairment",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:0em;\">",
"     Manufacturer&rsquo;s recommendations: No dosage adjustment necessary for mild, moderate, or severe renal impairment (not dependent on dialysis); has not been studied in dialysis patients.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:0em;\">",
"     Alternate recommendations: Safety and pharmacokinetics were studied in varying degrees of renal dysfunction with the following empiric dose levels recommended based on patient tolerance (Miller, 2009):",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;margin-top:0em;\">",
"     Mild renal dysfunction (Cl",
"     <sub>",
"      cr",
"     </sub>",
"     40-59 mL/minute): 400 mg twice daily",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;margin-top:0em;\">",
"     Moderate renal dysfunction (Cl",
"     <sub>",
"      cr",
"     </sub>",
"     20-39 mL/minute): 200 mg twice daily",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;margin-top:0em;\">",
"     Severe renal dysfunction (Cl",
"     <sub>",
"      cr",
"     </sub>",
"     &lt;20 mL/minute): Data inadequate to define dose",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;margin-top:0em;\">",
"     Hemodialysis (any Cl",
"     <sub>",
"      cr",
"     </sub>",
"     ): 200 mg once daily",
"    </p>",
"   </div>",
"   <div class=\"block doh drugH1Div\" id=\"F2322557\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Hepatic Impairment",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:0em;\">",
"     Manufacturer&rsquo;s recommendations: No adjustment is required for mild (Child-Pugh class A) to moderate (Child-Pugh class B) hepatic impairment at baseline; not studied in severe hepatic impairment (Child-Pugh class C). Discontinue treatment for unexplained significant increases in transaminases.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:0em;\">",
"     Alternate recommendations: Safety and pharmacokinetics were studied in varying degrees of hepatic dysfunction with the following empiric dose levels recommended based on patient tolerance (Miller, 2009):",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;margin-top:0em;\">",
"     Mild hepatic dysfunction (bilirubin &gt;1 to &le;1.5 times ULN and/or AST &gt;ULN): 400 mg twice daily",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;margin-top:0em;\">",
"     Moderate hepatic dysfunction (bilirubin &gt;1.5 to &le;3 times ULN; any AST): 200 mg twice daily",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;margin-top:0em;\">",
"     Severe hepatic dysfunction:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;margin-top:0em;\">",
"     Bilirubin &gt;3-10 x ULN (any AST): 200 mg every 3 days was",
"     <b>",
"      not",
"     </b>",
"     tolerated",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;margin-top:0em;\">",
"     Albumin &lt;2.5 g/dL (any bilirubin and any AST): 200 mg once daily",
"    </p>",
"   </div>",
"   <div class=\"block dot drugH1Div\" id=\"F2322558\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Adjustment for Toxicity",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Temporary interruption and/or dosage reduction may be necessary for management of adverse drug reactions. The dose may be reduced to 400 mg once daily and then further reduced to 400 mg every other day.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <i>",
"      Dose modification for severe/persistent hypertension (despite antihypertensive therapy) or cardiac ischemia/infarction:",
"     </i>",
"     Consider temporarily or permanently discontinuing treatment.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <i>",
"      Dose modification for gastrointestinal perforation:",
"     </i>",
"     Permanently discontinue treatment.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <i>",
"      Dose modification for hemorrhage requiring medical intervention:",
"     </i>",
"     Consider permanently discontinuing treatment.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <i>",
"      Dose modification for skin toxicity:",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;margin-top:0em;\">",
"     Grade 1 (numbness, dysesthesia, paresthesia, tingling, painless swelling, erythema, or discomfort of the hands or feet which do not disrupt normal activities): Continue sorafenib and consider symptomatic treatment with topical therapy.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;margin-top:0em;\">",
"     Grade 2 (painful erythema and swelling of the hands or feet and/or discomfort affecting normal activities):",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;margin-top:0em;\">",
"     1st occurrence: Continue sorafenib and consider symptomatic treatment with topical therapy.",
"     <b>",
"      Note:",
"     </b>",
"     If no improvement within 7 days, see dosing for 2nd or 3rd occurrence.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;margin-top:0em;\">",
"     2nd or 3rd occurrence (or no improvement after 7 days of 1st occurrence): Hold treatment until resolves to grade 0-1; resume treatment with dose reduced by one dose level (400 mg daily or 400 mg every other day)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;margin-top:0em;\">",
"     4th occurrence: Discontinue treatment",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;margin-top:0em;\">",
"     Grade 3 (moist desquamation, ulceration, blistering, or severe pain of the hands or feet or severe discomfort that prevents working or performing daily activities):",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;margin-top:0em;\">",
"     1st or 2nd occurrence: Hold treatment until resolves to grade 0-1; resume treatment with dose reduced by one dose level (400 mg daily or 400 mg every other day)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;margin-top:0em;\">",
"     3rd occurrence: Discontinue treatment",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;margin-top:0em;\">",
"     Suspected Stevens-Johnson syndrome or toxic epidermal necrolysis: Discontinue treatment.",
"    </p>",
"   </div>",
"   <div class=\"block foc drugH1Div\" id=\"F2322564\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Excipient information presented when available (limited, particularly for generics); consult specific product labeling.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Tablet, oral:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     NexAVAR&reg;: 200 mg",
"    </p>",
"   </div>",
"   <div class=\"block geq drugH1Div\" id=\"F2307885\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Generic Equivalent Available: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     No",
"    </p>",
"   </div>",
"   <div class=\"block adm drugH1Div\" id=\"F2309013\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Administration",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Administer on an empty stomach (1 hour before or 2 hours after eating).",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;\">",
"     Hazardous agent; use appropriate precautions for handling and disposal",
"     <a href=\"file://www.cdc.gov/niosh/docs/2012-150/pdfs/2012-150.pdf\" target=\"_blank\">",
"      (NIOSH, 2012)",
"     </a>",
"     .",
"    </p>",
"   </div>",
"   <div class=\"block use drugH1Div\" id=\"F2307889\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Treatment of advanced renal cell cancer (RCC); treatment of unresectable hepatocellular cancer (HCC)",
"    </p>",
"   </div>",
"   <div class=\"block usu drugH1Div\" id=\"F2530071\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use - Unlabeled",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Treatment of advanced thyroid cancer, recurrent or metastatic angiosarcoma, resistant gastrointestinal stromal tumor (GIST)",
"    </p>",
"   </div>",
"   <div class=\"block mst drugH1Div\" id=\"F3402005\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Medication Safety Issues",
"    </span>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      Sound-alike/look-alike issues:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"       NexAVAR&reg; may be confused with NexIUM&reg;",
"      </p>",
"      <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"       SORAfenib may be confused with axitinib, gefitinib, imatinib, regorafenib, SUNItinib, vandetanib, vemurafenib",
"      </p>",
"     </div>",
"    </div>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      High alert medication:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;\">",
"       This medication is in a class the Institute for Safe Medication Practices (ISMP) includes among its list of drug classes which have a heightened risk of causing significant patient harm when used in error.",
"      </p>",
"     </div>",
"    </div>",
"   </div>",
"   <div class=\"block ars drugH1Div\" id=\"F2307899\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Adverse Reactions Significant",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     &gt;10%:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Cardiovascular: Hypertension (9% to 17%; grade 3: 3% to 4%; grade 4: &lt;1%; onset: ~3 weeks)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Central nervous system: Fatigue (37% to 46%), sensory neuropathy (&le;13%), pain (11%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Dermatologic: Rash/desquamation (19% to 40%; grade 3: &le;1%), hand-foot syndrome (21% to 30%; grade 3: 6% to 8%), alopecia (14% to 27%), pruritus (14% to 19%), dry skin (10% to 11%), erythema",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Endocrine &amp; metabolic: Hypoalbuminemia (&le;59%), hypophosphatemia (35% to 45%; grade 3: 11% to 13%; grade 4: &lt;1%), hypocalcemia (12% to 27%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Gastrointestinal: Diarrhea (43% to 55%; grade 3: 2% to 10%; grade 4: &lt;1%), lipase increased (40% to 41% [usually transient]), amylase increased (30% to 34% [usually transient]), abdominal pain (11% to 31%), weight loss (10% to 30%), anorexia (16% to 29%), nausea (23% to 24%), vomiting (15% to 16%), constipation (14% to 15%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Hematologic: Lymphopenia (23% to 47%; grades 3/4: &le;13%), thrombocytopenia (12% to 46%; grades 3/4: 1% to 4%), INR increased (&le;42%), neutropenia (&le;18%; grades 3/4: &le;5%), hemorrhage (15% to 18%; grade 3: 2% to 3%; grade 4: &le;2%), leukopenia",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Hepatic: Liver dysfunction (&le;11%; grade 3: 2%; grade 4: 1%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Neuromuscular &amp; skeletal: Muscle pain, weakness",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Respiratory: Dyspnea (&le;14%), cough (&le;13%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     1% to 10%:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Cardiovascular: Cardiac ischemia/infarction (&le;3%), heart failure (2%; congestive), flushing",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Central nervous system: Headache (&le;10%), depression, fever",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Dermatologic: Acne, exfoliative dermatitis",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Gastrointestinal: Appetite decreased, dyspepsia, dysphagia, esophageal varices bleeding (2%), glossodynia, mucositis, stomatitis, xerostomia",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Genitourinary: Erectile dysfunction",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Hematologic: Anemia",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Hepatic: Transaminases increased (transient)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Neuromuscular &amp; skeletal: Joint pain (&le;10%), arthralgia, myalgia",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Renal: Renal failure",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Respiratory: Hoarseness",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Miscellaneous: Flu-like syndrome",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     &lt;1% (Limited to important or life-threatening): Acute renal failure, alkaline phosphatase increased, anaphylactic reaction, angioedema, aortic dissection, arrhythmia, bilirubin increased, bone pain, cardiac failure, cerebral hemorrhage, cholangitis, cholecystitis, dehydration, eczema, epistaxis, erythema multiforme, folliculitis, gastritis, gastrointestinal hemorrhage, gastrointestinal perforation, gastrointestinal reflux, gynecomastia, hepatic failure, hepatitis, hypersensitivity (skin reaction, urticaria), hypertensive crisis, hyper-/hypothyroidism, hyponatremia, infection, interstitial lung disease (acute respiratory distress, interstitial pneumonia, lung inflammation, pneumonitis, pulmonitis, radiation pneumonitis), jaundice, MI, mouth pain, muscle wasting, myocardial ischemia, nephrotic syndrome, osteonecrosis of the jaw, pancreatitis, pleural effusion, preeclampsia-like syndrome (reversible hypertension and proteinuria), QT prolongation, respiratory hemorrhage, reversible posterior leukoencephalopathy syndrome (RPLS), rhabdomyolysis, rhinorrhea, skin cancer (squamous cell/keratoacanthomas), Stevens-Johnson syndrome, thromboembolism, tinnitus, toxic epidermal necrolysis (TEN), transient ischemic attack, tumor lysis syndrome, tumor pain, voice alteration",
"    </p>",
"   </div>",
"   <div class=\"block coi drugH1Div\" id=\"F2307894\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Contraindications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Hypersensitivity to sorafenib or any component of the formulation; use in combination with carboplatin and paclitaxel in patients with squamous cell lung cancer",
"    </p>",
"   </div>",
"   <div class=\"block war drugH1Div\" id=\"F2307895\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warnings/Precautions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Concerns related to adverse effects:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Bleeding: Increased risk of bleeding may occur; consider permanently discontinuing with serious bleeding events (eg, requires medical intervention).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Cardiac ischemia/infarction: May cause cardiac ischemia or infarction; consider discontinuation (temporary or permanent) in patients who develop these. Use in patients with unstable coronary artery disease or recent myocardial infarction has not been studied.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Dermatologic toxicity: Hand-foot skin reaction and rash are the most common adverse events and typically appear within the first 6 weeks of treatment; usually managed with topical treatment, treatment delays, and/or dose reductions. Consider permanently discontinuing with severe or persistent dermatological toxicities. The risk for hand-foot syndrome increased with cumulative doses of sorafenib. Severe dermatologic toxicities, including Stevens-Johnson syndrome (SJS) and toxic epidermal necrolysis (TEN), have been reported; may be life-threatening. Discontinue sorafenib for suspected SJS or TEN.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Gastrointestinal perforation: Gastrointestinal perforation has been reported (rare); monitor patients for signs/symptoms (abdominal pain, constipation, or vomiting); discontinue treatment if gastrointestinal perforation occurs.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Hypertension: May cause hypertension (generally mild-to-moderate), especially in the first 6 weeks of treatment; monitor. Use caution in patients with underlying or poorly-controlled hypertension. Consider discontinuing (temporary or permanent) in patients who develop severe or persistent hypertension while on appropriate antihypertensive therapy.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; QT prolongation: QT prolongation has been observed; may increase the risk for ventricular arrhythmia. Avoid use in patients with congenital long QT syndrome; use with caution and monitor closely in patients with heart failure, bradyarrhythmias, concurrent medications know to prolong the QT interval, and electrolyte (calcium, magnesium, potassium) imbalances.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Wound healing complications: May complicate wound healing; temporarily withhold treatment for patients undergoing major surgical procedures. The appropriate timing to resume sorafenib after major surgery has not been determined.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Disease-related concerns:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Hepatic impairment: Sorafenib levels in patients with mild-to-moderate hepatic impairment (Child-Pugh classes A and B) were similar to levels observed in patients without hepatic impairment. Not studied in patients with severe hepatic impairment (Child-Pugh class C). In a small study of Asian patients with advanced HCC, sorafenib demonstrated efficacy with adequate tolerability in a hepatitis B-endemic area (Yau, 2009). There have been reports of sorafenib-induced hepatitis (including hepatic failure and death) which is characterized by hepatocellular liver damage and transaminase increases (significant); increased bilirubin and INR may also occur. Monitor hepatic function regularly; discontinue sorafenib for unexplained significant transaminase increases.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Concurrent drug therapy issues:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Bevacizumab: The incidence of hand-foot syndrome is increased in patients treated with sorafenib plus bevacizumab in comparison to those treated with sorafenib monotherapy.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Combination chemotherapy: Use in combination with carboplatin and paclitaxel in patients with squamous cell lung cancer is contraindicated.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; CYP3A4 inducers: Avoid concurrent use with strong CYP3A4 inducers (eg, carbamazepine, dexamethasone, phenobarbital, phenytoin, rifampin, St. John&rsquo;s wort); may decrease sorafenib levels/effects.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; UGT1A1 substrates: Use caution when administering sorafenib with compounds that are metabolized predominantly via UGT1A1 (eg, irinotecan).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Warfarin: Monitor PT/INR in patients on warfarin therapy; due to potential for bleeding events to occur.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Special handling:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Hazardous agent: Use appropriate precautions for handling and disposal",
"     <a href=\"file://www.cdc.gov/niosh/docs/2012-150/pdfs/2012-150.pdf\" target=\"_blank\">",
"      (NIOSH, 2012)",
"     </a>",
"     .",
"    </p>",
"   </div>",
"   <div class=\"block cyt drugH1Div\" id=\"F2309007\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Metabolism/Transport Effects",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     <b>",
"      Substrate",
"     </b>",
"     of CYP3A4 (minor), UGT1A9;",
"     <b>",
"      Note:",
"     </b>",
"     Assignment of Major/Minor substrate status based on clinically relevant drug interaction potential;",
"     <b>",
"      Inhibits",
"     </b>",
"     CYP2B6 (moderate), CYP2C8 (strong), CYP2C9 (moderate), UGT1A1, UGT1A9",
"    </p>",
"   </div>",
"   <div class=\"block dri drugH1Div\" id=\"F2309006\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Drug Interactions",
"    </span>",
"    <br/>",
"    <br/>",
"    <div class=\"lexi\" id=\"lexiInteractAddInfo\">",
"     (For additional information:",
"     <a class=\"dip\" href=\"./drug-interaction\" target=\"_blank\">",
"      Launch Lexi-Interact&trade; Drug Interactions Program",
"     </a>",
"     )",
"    </div>",
"    <div class=\"lexi\" id=\"lexiInteractImgB\">",
"     <img border=\"0\" height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Acetaminophen: May enhance the hepatotoxic effect of SORAfenib. SORAfenib may increase the serum concentration of Acetaminophen.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     BCG: Immunosuppressants may diminish the therapeutic effect of BCG.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Bevacizumab: May enhance the adverse/toxic effect of SORAfenib. Specifically, the risk for hand-foot skin reaction may be increased.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CARBOplatin: SORAfenib may enhance the adverse/toxic effect of CARBOplatin.  Management: Concurrent sorafenib with carboplatin and paclitaxel in patients with squamous cell lung cancer is contraindicated.  Use in other settings is not specifically contraindicated but should be approached with added caution.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Cardiac Glycosides: Antineoplastic Agents may decrease the absorption of Cardiac Glycosides. This may only affect digoxin tablets.",
"     <b>",
"      Exceptions:",
"     </b>",
"     Digitoxin.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Carvedilol: CYP2C9 Inhibitors (Moderate) may increase the serum concentration of Carvedilol. Specifically, concentrations of the S-carvedilol enantiomer may be increased.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CloZAPine: Myelosuppressive Agents may enhance the adverse/toxic effect of CloZAPine. Specifically, the risk for agranulocytosis may be increased.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Coccidioidin Skin Test: Immunosuppressants may diminish the diagnostic effect of Coccidioidin Skin Test.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CYP2B6 Substrates: CYP2B6 Inhibitors (Moderate) may decrease the metabolism of CYP2B6 Substrates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CYP2C8 Substrates: CYP2C8 Inhibitors (Strong) may decrease the metabolism of CYP2C8 Substrates.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CYP2C9 Substrates: CYP2C9 Inhibitors (Moderate) may decrease the metabolism of CYP2C9 Substrates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CYP3A4 Inducers (Strong): May decrease the serum concentration of SORAfenib.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CYP3A4 Inhibitors (Strong): May increase the serum concentration of SORAfenib.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Dacarbazine: SORAfenib may decrease the serum concentration of Dacarbazine. Sorafenib may also increase the concentration of dacarbazine's active metabolite.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Denosumab: May enhance the adverse/toxic effect of Immunosuppressants. Specifically, the risk for serious infections may be increased.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     DOCEtaxel: SORAfenib may increase the serum concentration of DOCEtaxel.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     DOXOrubicin: SORAfenib may increase the serum concentration of DOXOrubicin.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Echinacea: May diminish the therapeutic effect of Immunosuppressants.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Enzalutamide: CYP2C8 Inhibitors (Strong) may increase the serum concentration of Enzalutamide.  Management: Avoid concurrent use of strong CYP2C8 inhibitors and enzalutamide if possible. If the combination must be used, reduce enzalutamide to 80 mg once daily.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Fluorouracil (Systemic): SORAfenib may decrease the serum concentration of Fluorouracil (Systemic). SORAfenib may increase the serum concentration of Fluorouracil (Systemic).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Fluorouracil (Topical): SORAfenib may decrease the serum concentration of Fluorouracil (Topical). SORAfenib may increase the serum concentration of Fluorouracil (Topical).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Irinotecan: SORAfenib may increase the serum concentration of Irinotecan. Sorafenib may also increase the concentration of the active metabolite of irinotecan, SN-38.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Leflunomide: Immunosuppressants may enhance the adverse/toxic effect of Leflunomide. Specifically, the risk for hematologic toxicity such as pancytopenia, agranulocytosis, and/or thrombocytopenia may be increased.  Management: Consider not using a leflunomide loading dose in patients receiving other immunosuppressants.  Patients receiving both leflunomide and another immunosuppressant should be monitored for bone marrow suppression at least monthly.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Natalizumab: Immunosuppressants may enhance the adverse/toxic effect of Natalizumab. Specifically, the risk of concurrent infection may be increased.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Neomycin: May decrease the serum concentration of SORAfenib.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     PACLitaxel: SORAfenib may enhance the adverse/toxic effect of PACLitaxel.  Management: Concurrent sorafenib with carboplatin and paclitaxel in patients with squamous cell lung cancer is contraindicated.  Use in other settings is not specifically contraindicated but should be approached with added caution.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Pimecrolimus: May enhance the adverse/toxic effect of Immunosuppressants.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Pioglitazone: CYP2C8 Inhibitors (Strong) may increase the serum concentration of Pioglitazone.  Management: Limit pioglitazone adult maximum dose to 15 mg/day when used in combination with any strong CYP2C8 inhibitor.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Roflumilast: May enhance the immunosuppressive effect of Immunosuppressants.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Sipuleucel-T: Immunosuppressants may diminish the therapeutic effect of Sipuleucel-T.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     St Johns Wort: May decrease the serum concentration of SORAfenib.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tacrolimus (Topical): May enhance the adverse/toxic effect of Immunosuppressants.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tofacitinib: Immunosuppressants may enhance the immunosuppressive effect of Tofacitinib.  Management: Concurrent use with antirheumatic doses of methotrexate or other non-disease modifying antirheumatic drugs (non-DMARDs) is permitted, and this warning seems to particularly focused on more potent immunosuppressants.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Trastuzumab: May enhance the neutropenic effect of Immunosuppressants.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Treprostinil: CYP2C8 Inhibitors (Strong) may increase the serum concentration of Treprostinil.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Vaccines (Inactivated): Immunosuppressants may diminish the therapeutic effect of Vaccines (Inactivated).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Vaccines (Live): Immunosuppressants may enhance the adverse/toxic effect of Vaccines (Live). Vaccinial infections may develop. Immunosuppressants may diminish the therapeutic effect of Vaccines (Live).  Management: Avoid use of live organism vaccines with immunosuppressants; live-attenuated vaccines should not be given for at least 3 months after immunosuppressants.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Vitamin K Antagonists (eg, warfarin): Antineoplastic Agents may enhance the anticoagulant effect of Vitamin K Antagonists. Antineoplastic Agents may diminish the anticoagulant effect of Vitamin K Antagonists.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Warfarin: SORAfenib may enhance the anticoagulant effect of Warfarin. SORAfenib may increase the serum concentration of Warfarin.  Management: Warfarin dose adjustment will likely be necessary.  Increase frequency of INR monitoring during sorafenib therapy (particularly when starting or stopping therapy), and increase monitoring for signs and symptoms of bleeding.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"   </div>",
"   <div class=\"block foi drugH1Div\" id=\"F2309009\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Ethanol/Nutrition/Herb Interactions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Food: Bioavailability is decreased 29% with a high-fat meal (bioavailability is similar to fasting state when administered with a moderate-fat meal). Management: Administer on an empty stomach 1 hour before or 2 hours after eating.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Herb/Nutraceutical: St John's wort may decrease the levels/effects of sorafenib. Management: Avoid St John's wort.",
"    </p>",
"   </div>",
"   <div class=\"block prf drugH1Div\" id=\"F2307890\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Risk Factor",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     D (",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?16/42/17068\">",
"      show table",
"     </a>",
"     )",
"    </p>",
"   </div>",
"   <div class=\"block pri drugH1Div\" id=\"F2307891\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Implications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Animal reproduction studies have demonstrated teratogenicity and fetal loss. Based on its mechanism of action and because sorafenib inhibits angiogenesis, a critical component of fetal development, adverse effects on pregnancy would be expected. Women of childbearing potential should be advised to avoid pregnancy. Men and women of reproductive potential should use effective birth control during treatment and for at least 2 weeks after treatment is discontinued.",
"    </p>",
"   </div>",
"   <div class=\"block lac drugH1Div\" id=\"F2307893\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Lactation",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Excretion in breast milk unknown/not recommended",
"    </p>",
"   </div>",
"   <div class=\"block brc drugH1Div\" id=\"F5531300\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Breast-Feeding Considerations",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     According to the manufacturer, the decision to discontinue sorafenib or to discontinue breast-feeding during therapy should take into account the benefits of treatment to the mother.",
"    </p>",
"   </div>",
"   <div class=\"block dic drugH1Div\" id=\"F2309012\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dietary Considerations",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Take without food (1 hour before or 2 hours after eating).",
"    </p>",
"   </div>",
"   <div class=\"block fee drugH1Div\" id=\"F16322891\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pricing: U.S. (Medi-Span&reg;)",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Tablets",
"     </b>",
"     (NexAVAR Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     200 mg (120): $11189.22",
"    </p>",
"   </div>",
"   <div class=\"block mop drugH1Div\" id=\"F2322559\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Monitoring Parameters",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CBC with differential, electrolytes, phosphorus, lipase and amylase levels; liver function tests; blood pressure (baseline, weekly for the first 6 weeks, then periodic); monitor for hand-foot syndrome",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Thyroid function testing (Hamnvik, 2011):",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Pre-existing levothyroxine therapy: Obtain baseline TSH levels, then monitor every 4 weeks until levels and levothyroxine dose are stable, then monitor every 2 months",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Without pre-existing thyroid hormone replacement: TSH at baseline, then every 4 weeks for 4 months, then every 2-3 months",
"    </p>",
"   </div>",
"   <div class=\"list fbnlist drugH1Div drugBrandNames\" id=\"F5539965\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     International Brand Names",
"    </span>",
"    <ul>",
"     <li>",
"      Nexavar (AR, AT, AU, BE, BG, BR, CH, CL, CN, CO, CR, CZ, DE, DK, DO, EC, EE, ES, FI, FR, GB, GR, GT, HK, HN, ID, IE, IL, IT, KP, MT, MX, MY, NI, NL, NO, NZ, PA, PE, PH, PL, PT, RU, SE, SG, SK, SV, TH, TR, TW, UY)",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block pha drugH1Div\" id=\"F2322543\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Mechanism of Action",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Multikinase inhibitor; inhibits tumor growth and angiogenesis by inhibiting intracellular Raf kinases (CRAF, BRAF, and mutant BRAF), and cell surface kinase receptors (VEGFR-1, VEGFR-2, VEGFR-3, PDGFR-beta, cKIT, FLT-3, and RET)",
"    </p>",
"   </div>",
"   <div class=\"block phk drugH1Div\" id=\"F2322546\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacodynamics/Kinetics",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Protein binding: 99.5%",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Metabolism: Hepatic, via CYP3A4 (primarily oxidated to the pyridine N-oxide; active, minor) and UGT1A9 (glucuronidation)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Bioavailability: 38% to 49%; reduced when administered with a high-fat meal",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Half-life elimination: 25-48 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Time to peak, plasma: ~3 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Excretion: Feces (77%, 51% of dose as unchanged drug); urine (19%, as metabolites)",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <div class=\"reference\">",
"      Abou-Alfa GK, Johnson P, Knox JJ, et al, &ldquo;Doxorubicin Plus Sorafenib vs Doxorubicin Alone in Patients With Advanced Hepatocellular Carcinoma: A Randomized Trial,&rdquo; J",
"      <i>",
"       AMA",
"      </i>",
"      , 2010, 304(19):2154-60.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?9/45/9944/abstract-text/21081728/pubmed\" id=\"21081728\" target=\"_blank\">",
"        21081728",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Abou-Alfa GK, Schwarts L, Ricci S, et al, &ldquo;Phase II Study of Sorafenib in Patients With Advanced Hepatocellular Carcinoma,&rdquo;",
"      <i>",
"       J Clin Oncol",
"      </i>",
"      , 2006, 24(26):4293-300.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?9/45/9944/abstract-text/16908937/pubmed\" id=\"16908937\" target=\"_blank\">",
"        16908937",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Ahmad T and Eisen T, &ldquo;Kinase Inhibition With BAY 43-9006 in Renal Cell Carcinoma,&rdquo;",
"      <i>",
"       Clin Cancer Res",
"      </i>",
"      , 2004, 10(18 Suppl 2):6388-92.",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Antoun S, Birdsell L, Sawyer MB, et al, &ldquo;Association of Skeletal Muscle Wasting With Treatment With Sorafenib in Patients With Advanced Renal Cell Carcinoma: Results From a Placebo-Controlled Study,&rdquo;",
"      <i>",
"       J Clin Oncol",
"      </i>",
"      , 2010, 28(6):1054-60.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?9/45/9944/abstract-text/20085939/pubmed\" id=\"20085939\" target=\"_blank\">",
"        20085939",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Azad NS, Aragon-Ching JB, Dahut WL, et al, &ldquo;Hand-Foot Skin Reaction Increases With Cumulative Sorafenib Dose and With Combination Anti-Vascular Endothelial Growth Factor Therapy,&rdquo;",
"      <i>",
"       Clin Cancer Res",
"      </i>",
"      , 2009, 15(4):1411-16.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?9/45/9944/abstract-text/19228742/pubmed\" id=\"19228742\" target=\"_blank\">",
"        19228742",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Escudier B, Eisen T, Stadler WM, et al, &ldquo;Sorafenib in Advanced Clear-Cell Renal-Cell Carcinoma,&rdquo;",
"      <i>",
"       N Engl J Med",
"      </i>",
"      , 2007, 356(2):125-34.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?9/45/9944/abstract-text/17215530/pubmed\" id=\"17215530\" target=\"_blank\">",
"        17215530",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Gupta-Abramson V, Troxel AB, Nellore A, et al, &ldquo;Phase II Trial of Sorafenib in Advanced Thyroid Cancer,&rdquo;",
"      <i>",
"       J Clin Oncol",
"      </i>",
"      , 2008, 26(29):4714-9.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?9/45/9944/abstract-text/18541894/pubmed\" id=\"18541894\" target=\"_blank\">",
"        18541894",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Hamnvik OP, Larsen PR, and Marqusee E, &ldquo;Thyroid Dysfunction From Antineoplastic Agents,&rdquo;",
"      <i>",
"       J Natl Cancer Inst",
"      </i>",
"      , 2011, 103(21):1572-87.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?9/45/9944/abstract-text/22010182/pubmed\" id=\"22010182\" target=\"_blank\">",
"        22010182",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Kim JE, Ryoo BY, Ryu MH, et al, &ldquo;Sorafenib for Hepatocellular Carcinoma According to Child-Pugh Class of Liver Function,&rdquo;",
"      <i>",
"       Cancer Chemother Pharmacol",
"      </i>",
"      , 2011, 68(5):1285-90.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?9/45/9944/abstract-text/21445543/pubmed\" id=\"21445543\" target=\"_blank\">",
"        21445543",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Lacouture ME, Wu S, Robert C, et al, &ldquo;Evolving Strategies for the Management of Hand-Foot Skin Reaction Associated With the Multitargeted Kinase Inhibitors Sorafenib and Sunitinib,&rdquo;",
"      <i>",
"       Oncologist",
"      </i>",
"      , 2008, 13(9):1001-11.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?9/45/9944/abstract-text/18779536/pubmed\" id=\"18779536\" target=\"_blank\">",
"        18779536",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Lam ET, Ringel MD, Kloos RT, et al, &ldquo;Phase II Clinical Trial of Sorafenib in Metastatic Medullary Thyroid Cancer,&rdquo;",
"      <i>",
"       J Clin Oncol",
"      </i>",
"      , 2010, 28(14):2323-30.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?9/45/9944/abstract-text/20368568/pubmed\" id=\"20368568\" target=\"_blank\">",
"        20368568",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Llovet J Ricci S, Mazzaferro V, et al, &ldquo;Sorafenib in Advanced Hepatocellular Carcinoma,&rdquo;",
"      <i>",
"       N Engl J Med,",
"      </i>",
"      2008 Jul 24;359(4):378-90.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?9/45/9944/abstract-text/18650514/pubmed\" id=\"18650514\" target=\"_blank\">",
"        18650514",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Maki RG, D'Adamo DR, Keohan ML, et al, &ldquo;Phase II Study of Sorafenib in Patients With Metastatic or Recurrent Sarcomas,&rdquo;",
"      <i>",
"       J Clin Oncol",
"      </i>",
"      , 2009, 27(19):3133-40.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?9/45/9944/abstract-text/19451436/pubmed\" id=\"19451436\" target=\"_blank\">",
"        19451436",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Miller AA, Murry DJ, Owzar K, et al, &ldquo;Phase I and Pharmacokinetic Study of Sorafenib in Patients With Hepatic or Renal Dysfunction: CALGB 60301,&rdquo;",
"      <i>",
"       J Clin Oncol",
"      </i>",
"      , 2009, 27(11):1800-5.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?9/45/9944/abstract-text/19255312/pubmed\" id=\"19255312\" target=\"_blank\">",
"        19255312",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Mross K, Steinbild S, Baas F, et al, &ldquo;Drug-Drug Interaction Pharmacokinetic Study With the Raf Kinase Inhibitor (RKI) BAY 43-9006 Administered in Combination With Irinotecan (CPT-11) in Patients With Solid Tumors,&rdquo;",
"      <i>",
"       Int J Clin Pharmacol Ther",
"      </i>",
"      , 2003, 41(12):618-9.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?9/45/9944/abstract-text/14692719/pubmed\" id=\"14692719\" target=\"_blank\">",
"        14692719",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      National Institute for Occupational Safety and Health (NIOSH), \"NIOSH List of Antineoplastic and Other Hazardous Drugs in Healthcare Settings 2012.\" Available at",
"      <a href=\"file://www.cdc.gov/niosh/docs/2012-150/pdfs/2012-150.pdf\" target=\"_blank\">",
"       file://www.cdc.gov/niosh/docs/2012-150/pdfs/2012-150.pdf",
"      </a>",
"      . Accessed January 21, 2013.",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Overkleeft EN, Goldschmeding R, van Reekum F, &ldquo;Nephrotic Syndrome Caused by the Angiogenesis Inhibitor Sorafenib,&rdquo;",
"      <i>",
"       Ann Oncol",
"      </i>",
"      , 2010, 21(1):184-5.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?9/45/9944/abstract-text/19889617/pubmed\" id=\"19889617\" target=\"_blank\">",
"        19889617",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Patel TV, Morgan JA, Demetri GD, et al, &ldquo;A Preeclampsia-Like Syndrome Characterized by Reversible Hypertension and Proteinuria Induced by the Multitargeted Kinase Inhibitors Sunitinib and Sorafenib,&rdquo;",
"      <i>",
"       J Natl Cancer Inst",
"      </i>",
"      , 2008, 100(4):282-4.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?9/45/9944/abstract-text/18270341/pubmed\" id=\"18270341\" target=\"_blank\">",
"        18270341",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Ratain, MJ, Eisen T, Stadler WM, et al, &ldquo;Phase II Placebo-Controlled Randomized Discontinuation Trial of Sorafenib in Patients With Metastatic Renal Cell Carcinoma,&rdquo;",
"      <i>",
"       J Clin Oncol",
"      </i>",
"      , 2006, 24(16):2505-12.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?9/45/9944/abstract-text/16636341/pubmed\" id=\"16636341\" target=\"_blank\">",
"        16636341",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Scagliotti G, Novello S, von Pawel J, et al, &ldquo;Phase III Study of Carboplatin and Paclitaxel Alone or With Sorafenib in Advanced Non-Small-Cell Lung Cancer,&rdquo;",
"      <i>",
"       J Clin Oncol",
"      </i>",
"      , 2010, 38(11):1835-42.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?9/45/9944/abstract-text/20212250/pubmed\" id=\"20212250\" target=\"_blank\">",
"        20212250",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Schutz FA, Je Y, Richards CJ, et al, Meta-Analysis of Randomized Controlled Trials for the Incidence and Risk of Treatment-Related Mortality in Patients With Cancer Treated With Vascular Endothelial Growth Factor Tyrosine Kinase Inhibitors,&rdquo;",
"      <i>",
"       J Clin Oncol",
"      </i>",
"      , 2012, 30(8):871-7.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?9/45/9944/abstract-text/22312105/pubmed\" id=\"22312105\" target=\"_blank\">",
"        22312105",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Serrano C, Suarez C, Andreu J, et al, &ldquo;Acute Aortic Dissection During Sorafenib-Containing Therapy,&rdquo;",
"      <i>",
"       Ann Oncol",
"      </i>",
"      , 2010, 21(1):181-2.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?9/45/9944/abstract-text/19858082/pubmed\" id=\"19858082\" target=\"_blank\">",
"        19858082",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Veronese ML, Mosenkis A, Flaherty KT, et al, &ldquo;Mechanisms of Hypertension Associated With BAY 43-9006,&rdquo;",
"      <i>",
"       J Clin Oncol",
"      </i>",
"      , 2006, 24(9):1363-9.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?9/45/9944/abstract-text/16446323/pubmed\" id=\"16446323\" target=\"_blank\">",
"        16446323",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Wiebe L, Kasza KE, Maki RG, et al, &ldquo;Activity of Sorafenib (SOR) in Patients (pts) With Imatinib (IM) and Sunitinib (SU)-Resistant (RES) Gastrointestinal Stromal Tumors (GIST): A Phase II Trial of the University of Chicago Phase II Consortium,&rdquo;",
"      <i>",
"       J Clin Oncol",
"      </i>",
"      , 2008, 26(15s):10502 [abstract 10502 from the 2008 ASCO Annual Meeting].",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Yau T, Chan P, Ng KK, et al, &ldquo;Phase 2 Open-Label Study of Single Agent Sorafenib in Treating Advanced Hepatocellular Carcinoma in a Hepatitis B&ndash;Endemic Asian Population,&rdquo;",
"      <i>",
"       Cancer",
"      </i>",
"      , 2009, 115(2):428-36.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?9/45/9944/abstract-text/19107763/pubmed\" id=\"19107763\" target=\"_blank\">",
"        19107763",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 10277 Version 45.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1105-213.131.41.98-E13A3EE944-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f9_45_9944=[""].join("\n");
var outline_f9_45_9944=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F2307883\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F6826164\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F2307887\">",
"      Pharmacologic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F2322555\">",
"      Dosing: Adult",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F2530072\">",
"      Dosing: Geriatric",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F2322556\">",
"      Dosing: Renal Impairment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F2322557\">",
"      Dosing: Hepatic Impairment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F2322558\">",
"      Dosing: Adjustment for Toxicity",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F2322564\">",
"      Dosage Forms: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F2307885\">",
"      Generic Equivalent Available: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F2309013\">",
"      Administration",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F2307889\">",
"      Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F2530071\">",
"      Use - Unlabeled",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F3402005\">",
"      Medication Safety Issues",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F2307899\">",
"      Adverse Reactions Significant",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F2307894\">",
"      Contraindications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F2307895\">",
"      Warnings/Precautions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F2309007\">",
"      Metabolism/Transport Effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F2309006\">",
"      Drug Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F2309009\">",
"      Ethanol/Nutrition/Herb Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F2307890\">",
"      Pregnancy Risk Factor",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F2307891\">",
"      Pregnancy Implications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F2307893\">",
"      Lactation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F5531300\">",
"      Breast-Feeding Considerations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F2309012\">",
"      Dietary Considerations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F16322891\">",
"      Pricing: U.S. (Medi-Span&reg;)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F2322559\">",
"      Monitoring Parameters",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F5539965\">",
"      International Brand Names",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F2322543\">",
"      Mechanism of Action",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F2322546\">",
"      Pharmacodynamics/Kinetics",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/10277\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/10277|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"UTD.htm?43/42/44709?source=related_link\">",
"      Sorafenib: Patient drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f9_45_9945="Clinical manifestations, pathologic features, and diagnosis of adult T cell leukemia-lymphoma";
var content_f9_45_9945=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Clinical manifestations, pathologic features, and diagnosis of adult T cell leukemia-lymphoma",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?9/45/9945/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?9/45/9945/contributors\">",
"     Arnold S Freedman, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?9/45/9945/contributors\">",
"     Jon C Aster, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?9/45/9945/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?9/45/9945/contributors\">",
"     Andrew Lister, MD, FRCP, FRCPath, FRCR",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?9/45/9945/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?9/45/9945/contributors\">",
"     Rebecca F Connor, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?9/45/9945/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Jan 4, 2013.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Adult T cell leukemia-lymphoma (ATL), according to the most recent World Health Organization (WHO) classification of lymphoid neoplasms, is defined as a peripheral T cell neoplasm associated with infection by the human T-lymphotropic virus, type I (HTLV-I) [",
"    <a class=\"abstract\" href=\"UTD.htm?9/45/9945/abstract/1-3\">",
"     1-3",
"    </a>",
"    ]. Although it is considered one of the highly aggressive T cell non-Hodgkin lymphoma (NHL) variants, the disease course is variable and sometimes quite indolent. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?20/53/21337?source=see_link\">",
"     \"Classification of the hematopoietic neoplasms\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Other T cell lymphomas include mycosis fungoides, T cell large granular lymphocytic leukemia, T cell prolymphocytic leukemia, anaplastic large cell lymphoma, peripheral T cell lymphoma, and precursor T cell lymphoblastic leukemia. These disorders are not caused by HTLV-1.",
"   </p>",
"   <p>",
"    Epidemiologic studies suggest that HTLV-I is primarily transmitted by breastfeeding, although spread via blood transfusion, sharing of needles, and sexual intercourse also occurs. This is discussed in more detail separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?5/48/5897?source=see_link\">",
"     \"Human T-lymphotropic virus type I: Virology, pathogenesis, and epidemiology\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The epidemiology, pathogenesis, clinical features, pathology, and diagnosis of ATL will be discussed here; the treatment of ATL is discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?29/36/30281?source=see_link\">",
"     \"Treatment and prognosis of adult T cell leukemia-lymphoma\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     EPIDEMIOLOGY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Adult T cell leukemia-lymphoma (ATL) is an uncommon lymphoid neoplasm that occurs in patients with human T-lymphotropic virus, type I (HTLV-I) infection. Incidence varies by population according to the prevalence of HTLV-I infection [",
"    <a class=\"abstract\" href=\"UTD.htm?9/45/9945/abstract/4\">",
"     4",
"    </a>",
"    ]. Infection with HTLV-1 is endemic in several islands in southern Japan, the Caribbean basin (eg, Jamaica and Trinidad), western Africa, Peru, northeast Iran, and the southeastern portion of the United States; most affected patients live in or originate from these areas [",
"    <a class=\"abstract\" href=\"UTD.htm?9/45/9945/abstract/5-10\">",
"     5-10",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In the United States as a whole, the incidence of ATL is approximately 0.05 cases per 100,000 people [",
"    <a class=\"abstract\" href=\"UTD.htm?9/45/9945/abstract/11\">",
"     11",
"    </a>",
"    ]. ATL is more common in Black Americans than White Americans and there is a slight male predominance overall. The median age at diagnosis is in the sixth decade [",
"    <a class=\"abstract\" href=\"UTD.htm?9/45/9945/abstract/4,12\">",
"     4,12",
"    </a>",
"    ]. However, median age at diagnosis can vary with geographic location. As an example, a study of 126 patients with ATL from Jamaica reported a median age of 43 years [",
"    <a class=\"abstract\" href=\"UTD.htm?9/45/9945/abstract/13\">",
"     13",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Since ATL is associated with HTLV-I infection, patients with ATL are also at risk for HTLV-I-associated myelopathy, also known as tropical spastic paraparesis. HTLV-I-associated myelopathy is discussed in more detail separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?39/54/40808?source=see_link\">",
"     \"Human T-lymphotropic virus type I: Disease associations, diagnosis, and treatment\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     PATHOGENESIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Adult T cell leukemia-lymphoma (ATL) is associated with HTLV-I infection of the tumor clone in 100 percent of cases [",
"    <a class=\"abstract\" href=\"UTD.htm?9/45/9945/abstract/14\">",
"     14",
"    </a>",
"    ]; this infection is thought to play a significant role in the pathogenesis of ATL. In all malignant cells in an affected individual, the HTLV-I pro-viral genome is incorporated into an identical location of the genome. This suggests that the pro-viral genome was incorporated into the original malignant cell prior to its clonal expansion to develop into a tumor. Whether the particular insertion location affects the phenotype of the cell is unclear.",
"   </p>",
"   <p>",
"    Notably, however, the rate of ATL development among HTLV-I infected individuals is relatively low. The long-term risk of developing ATL following infection with HTLV-I in endemic areas has been estimated to be 4 to 5 percent, usually after a latency period of several decades [",
"    <a class=\"abstract\" href=\"UTD.htm?9/45/9945/abstract/15,16\">",
"     15,16",
"    </a>",
"    ]. Exposure to the virus early in life increases the risk of eventual development of ATL. A shorter latency period has been noted in infected patients receiving treatment with immunosuppressive agents for other reasons [",
"    <a class=\"abstract\" href=\"UTD.htm?9/45/9945/abstract/17-19\">",
"     17-19",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The relatively low incidence of ATL in patients with HTLV-I infection and the long period of clinical latency (10 to 30 years) between HTLV-I infection and ATL development suggest that infection with HTLV-I is not sufficient for full malignant transformation [",
"    <a class=\"abstract\" href=\"UTD.htm?9/45/9945/abstract/14,20\">",
"     14,20",
"    </a>",
"    ]. Additional etiologic factors have not yet been identified.",
"   </p>",
"   <p>",
"    The exact mechanism by which HTLV-I contributes to tumor development is unknown. However, increasing evidence suggests that the viral regulatory gene tax (transactivating gene of the X region) encodes an oncoprotein, named tax protein [",
"    <a class=\"abstract\" href=\"UTD.htm?9/45/9945/abstract/21-23\">",
"     21-23",
"    </a>",
"    ]. The gene product induces cellular proliferation, promotes cellular survival, and impairs DNA damage repair mechanisms [",
"    <a class=\"abstract\" href=\"UTD.htm?9/45/9945/abstract/22\">",
"     22",
"    </a>",
"    ]. More specifically, tax protein transactivates a host of cellular genes through transcription factors such as nuclear factor-kB. Expression of tax protein in the cell results in migration of NF-kB from the cytoplasm to the nucleus where it activates genes responsible for cellular proliferation. In addition, tumor survival is promoted by the constitutive activation of the Jak-STAT pathway [",
"    <a class=\"abstract\" href=\"UTD.htm?9/45/9945/abstract/24,25\">",
"     24,25",
"    </a>",
"    ] and by the inactivation of the tumor suppressor p53 [",
"    <a class=\"abstract\" href=\"UTD.htm?9/45/9945/abstract/26\">",
"     26",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    As described below, ATL is frequently associated with hypercalcemia, which can be severe. The hypercalcemia seen in ATL is paraneoplastic in origin, and thought to arise from cytokines liberated from the malignant cells. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?40/48/41734?source=see_link\">",
"     \"Hypercalcemia of malignancy\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Their exact nature is not known, but the following have been proposed:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Constitutive production of parathyroid hormone related protein (PTH-RP) [",
"      <a class=\"abstract\" href=\"UTD.htm?9/45/9945/abstract/27-29\">",
"       27-29",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      Tumor necrosis factor-beta [",
"      <a class=\"abstract\" href=\"UTD.htm?9/45/9945/abstract/30\">",
"       30",
"      </a>",
"      ] or interleukin-1 [",
"      <a class=\"abstract\" href=\"UTD.htm?9/45/9945/abstract/31\">",
"       31",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      Increased expression of the receptor activator of nuclear factor kB (RANK) ligand gene [",
"      <a class=\"abstract\" href=\"UTD.htm?9/45/9945/abstract/32\">",
"       32",
"      </a>",
"      ]",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    These factors may also be the genesis of the lytic bone lesions, increased bone turnover, increased serum alkaline phosphatase, and the \"super scan\" of the skeleton seen on radionuclide imaging [",
"    <a class=\"abstract\" href=\"UTD.htm?9/45/9945/abstract/33,34\">",
"     33,34",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h1\">",
"     CLINICAL FEATURES",
"    </span>",
"    &nbsp;&mdash;&nbsp;The clinical features of ATL include evidence of generalized lymphadenopathy, hepatosplenomegaly, immunosuppression, hypercalcemia, lytic bone lesions, and skin lesions. The frequency of these differs among patient groups and has been the basis upon which clinical variants have been defined.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Clinical variants",
"    </span>",
"    &nbsp;&mdash;&nbsp;Several clinical variants of ATL have been described: acute, lymphomatous, chronic, and smoldering; these appear to have differing genomic alterations and different clinical courses [",
"    <a class=\"abstract\" href=\"UTD.htm?9/45/9945/abstract/35\">",
"     35",
"    </a>",
"    ]. Progression from chronic and smoldering disease to aggressive disease resembling the acute variant eventually occurs in up to 25 percent of cases, and may be associated with specific changes on gene expression profiling [",
"    <a class=\"abstract\" href=\"UTD.htm?9/45/9945/abstract/36\">",
"     36",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h3\">",
"     Acute",
"    </span>",
"    &nbsp;&mdash;&nbsp;The most common presentation of ATL, occurring in about 60 percent of cases, is the acute variant, which has a generally poor prognosis with survival measured in months to a year despite aggressive treatment [",
"    <a class=\"abstract\" href=\"UTD.htm?9/45/9945/abstract/37\">",
"     37",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?29/36/30281?source=see_link\">",
"     \"Treatment and prognosis of adult T cell leukemia-lymphoma\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Patients with the acute variant of ATL most frequently present with systemic symptoms, organomegaly, lymphadenopathy, an elevated lactate dehydrogenase (LDH) level, and circulating malignant cells. Common presenting signs or symptoms include [",
"    <a class=\"abstract\" href=\"UTD.htm?9/45/9945/abstract/33,38-40\">",
"     33,38-40",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      A high peripheral blood white blood cell count is common due to the presence of circulating lymphocytes with highly abnormal convoluted nuclei (",
"      <a class=\"graphic graphic_picture graphicRef82314 \" href=\"UTD.htm?43/46/44771\">",
"       picture 1",
"      </a>",
"      ).",
"     </li>",
"     <li>",
"      Bone marrow involvement is observed in approximately 35 percent of cases.",
"     </li>",
"     <li>",
"      Generalized lymphadenopathy is seen in almost all cases.",
"     </li>",
"     <li>",
"      Hepatosplenomegaly is present in approximately 50 percent.",
"     </li>",
"     <li>",
"      One-half will have hypercalcemia with or without lytic bone lesions at presentation and an additional third will develop hypercalcemia at some point during the course of their disease.",
"     </li>",
"     <li>",
"      Approximately 50 percent will have skin lesions at diagnosis, often simulating those seen in mycosis fungoides. Skin lesions may be patches (7 percent), plaques (27 percent), papules (19 percent), tumors (39 percent), erythrodermic lesions (4 percent), and purpuric lesions (4 percent) [",
"      <a class=\"abstract\" href=\"UTD.htm?9/45/9945/abstract/41\">",
"       41",
"      </a>",
"      ]. The prognosis may vary with different types of skin lesions being better for those with patches or plaques and worst for patients with erythrodermic or purpuric lesions.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Less common clinical features may include [",
"    <a class=\"abstract\" href=\"UTD.htm?9/45/9945/abstract/42,43\">",
"     42,43",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Interstitial pulmonary infiltrates, which may be due to pneumocystis jirovecii pneumonia",
"     </li>",
"     <li>",
"      Central nervous system involvement with mass lesions on imaging",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h3\">",
"     Lymphomatous",
"    </span>",
"    &nbsp;&mdash;&nbsp;The lymphomatous variant accounts for approximately 20 percent of cases and is characterized by prominent lymphadenopathy without blood involvement. Patients frequently have an elevated LDH level and can have hypercalcemia. Prognosis is poor with a survival similar to that of patients with the acute variant.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h3\">",
"     Chronic",
"    </span>",
"    &nbsp;&mdash;&nbsp;Approximately 15 percent of cases are a chronic variant. These patients present with skin lesions, mild lymphadenopathy, and leukocytosis with an absolute lymphocytosis that may be stable for months to years [",
"    <a class=\"abstract\" href=\"UTD.htm?9/45/9945/abstract/44\">",
"     44",
"    </a>",
"    ]. Median survival is two to five years, however, there is a subgroup of patients with unfavorable chronic-type ATL, which is defined by a low serum albumin, high LDH, or high blood urea nitrogen concentration. These patients have a poor prognosis similar to that of the acute and lymphoma variants.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h3\">",
"     Smoldering",
"    </span>",
"    &nbsp;&mdash;&nbsp;The smoldering variant is least common, accounting for approximately 5 percent of cases. These patients are often asymptomatic except for frequent skin",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    pulmonary lesions. They have normal blood lymphocyte counts with &lt;5 percent circulating neoplastic cells and normal calcium levels. Median survival without treatment is approximately three years [",
"    <a class=\"abstract\" href=\"UTD.htm?9/45/9945/abstract/44\">",
"     44",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h2\">",
"     Hypercalcemia and lytic bone lesions",
"    </span>",
"    &nbsp;&mdash;&nbsp;As mentioned above, the frequency of hypercalcemia and lytic bone lesions varies among the variants of ATL. In the acute variant, approximately 70 percent of patients with ATL will have hypercalcemia at some point in their disease course while 40 percent will have lytic bone lesions [",
"    <a class=\"abstract\" href=\"UTD.htm?9/45/9945/abstract/45\">",
"     45",
"    </a>",
"    ]. Hypercalcemia can be severe with calcium levels as high as 21",
"    <span class=\"nowrap\">",
"     mg/dL",
"    </span>",
"    (5.25",
"    <span class=\"nowrap\">",
"     mmol/liter).",
"    </span>",
"    Signs and symptoms related to hypercalcemia such as renal dysfunction or neuropsychiatric disturbances may be prominent among the presenting clinical features. The clinical manifestations of hypercalcemia are discussed in more detail separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?32/56/33669?source=see_link\">",
"     \"Clinical manifestations of hypercalcemia\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h2\">",
"     Immunosuppression",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients with ATL are immunosuppressed and at risk of developing opportunistic infections including pneumocystis jirovecii pneumonia, cryptococcus meningitis, and disseminated herpes zoster [",
"    <a class=\"abstract\" href=\"UTD.htm?9/45/9945/abstract/46\">",
"     46",
"    </a>",
"    ]. Severe, and often fatal, infestation by and dissemination of strongyloides stercoralis is common as well. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?10/59/11193?source=see_link\">",
"     \"Strongyloidiasis\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    A retrospective analysis of 818 patients with ATL found that 213 (26 percent) had infectious complications at the time of diagnosis [",
"    <a class=\"abstract\" href=\"UTD.htm?9/45/9945/abstract/47\">",
"     47",
"    </a>",
"    ]. Infectious complications were more common in patients with the acute, chronic, or smouldering variants than in patients with the lymphomatous variant. Of the 465 patients with acute variant ATL, the following infections were found at diagnosis:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Bacterial (mostly pneumonia) in 55 patients (12 percent)",
"     </li>",
"     <li>",
"      Fungal (mostly cutaneous) in 38 patients (8 percent)",
"     </li>",
"     <li>",
"      Protozoal (mostly strongyloidiasis) in 22 patients (5 percent)",
"     </li>",
"     <li>",
"      Viral (mostly herpes zoster) in 13 patients (3 percent)",
"     </li>",
"     <li>",
"      339 patients were without infection at diagnosis (73 percent)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h1\">",
"     PATHOLOGY",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h2\">",
"     Morphology",
"    </span>",
"    &nbsp;&mdash;&nbsp;The morphology of the tumor cells is quite variable from case to case, and a high index of suspicion on clinicopathologic grounds is helpful in arriving at an expeditious diagnosis. The organs involved vary, but can include the peripheral blood and bone marrow, lymph nodes, and skin.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h3\">",
"     Peripheral blood and bone marrow",
"    </span>",
"    &nbsp;&mdash;&nbsp;The most characteristic morphologic feature of ATL is seen in the peripheral blood of leukemic cases. In such cases, medium sized lymphocytes with condensed chromatin and bizarre hyperlobated nuclei (\"clover leaf\" or \"flower cells\") can be found, often resembling the S&eacute;zary cells of mycosis fungoides (",
"    <a class=\"graphic graphic_picture graphicRef82314 \" href=\"UTD.htm?43/46/44771\">",
"     picture 1",
"    </a>",
"    )&nbsp;[",
"    <a class=\"abstract\" href=\"UTD.htm?9/45/9945/abstract/5\">",
"     5",
"    </a>",
"    ]. In addition, there is often a small proportion of blast-like cells with deeply basophilic cytoplasm. Bone marrow involvement is seen in approximately 35 percent of cases [",
"    <a class=\"abstract\" href=\"UTD.htm?9/45/9945/abstract/45\">",
"     45",
"    </a>",
"    ]. Bone marrow infiltrates are usually patchy, ranging from sparse to moderate.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h3\">",
"     Lymph nodes",
"    </span>",
"    &nbsp;&mdash;&nbsp;Involved lymph nodes typically display diffuse architectural effacement, although at early stages of involvement the cells may preferentially accumulate in the T cell areas or sinusoids of the node. The neoplastic cells are usually medium to large-sized with nuclear pleomorphism; the cytoplasm is amphophilic, basophilic or pale. In the background, there is a mild to moderate proliferation of high endothelial venules. Mitotic activity is variable. Reed-Sternberg-like cells and multinucleated giant cells with convoluted or cerebriform nuclei may be present, causing a resemblance to Hodgkin lymphoma [",
"    <a class=\"abstract\" href=\"UTD.htm?9/45/9945/abstract/48\">",
"     48",
"    </a>",
"    ]. Uncommonly, the tumor can be composed of small-sized lymphoid cells with nuclear pleomorphism, or may resemble anaplastic large cell lymphoma.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h3\">",
"     Other tissues",
"    </span>",
"    &nbsp;&mdash;&nbsp;On occasion, ATL may present with skin infiltrates similar to those seen in cutaneous T cell lymphoma (mycosis fungoides), with epidermotropism and Pautrier's microabscesses; such cases are more likely to be associated with an indolent course. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?4/32/4618?source=see_link\">",
"     \"Clinical manifestations, pathologic features, and diagnosis of mycosis fungoides\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    In a study of 71 patients with ATL from Japan, involvement of the stomach was documented by endoscopic biopsy in 21 (30 percent) [",
"    <a class=\"abstract\" href=\"UTD.htm?9/45/9945/abstract/49\">",
"     49",
"    </a>",
"    ]. The prevalence of infection with Helicobacter pylori was 86 versus 38 percent in those with or without gastric involvement.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h2\">",
"     Immunophenotype",
"    </span>",
"    &nbsp;&mdash;&nbsp;The origin of the malignant cell in ATL is an HTLV-I infected mature (CD4+) T-lymphocyte. In 60 to 70 percent of cases, the tumor cells express the transcription factor FoxP3, a marker of immunosuppressive regulatory T cells (Tregs) [",
"    <a class=\"abstract\" href=\"UTD.htm?9/45/9945/abstract/50,51\">",
"     50,51",
"    </a>",
"    ]. For purposes of diagnosis, suspected cases should be stained for CD3, CD4, CD7, CD8, and CD25 at a minimum. Tumor cells express T cell associated antigens (CD2, CD4, and CD5), but usually lack CD7 and may exhibit dim CD3 expression. Most cases are CD4+ and CD8- [",
"    <a class=\"abstract\" href=\"UTD.htm?9/45/9945/abstract/45\">",
"     45",
"    </a>",
"    ]. Rare cases are",
"    <span class=\"nowrap\">",
"     CD4-/CD8+",
"    </span>",
"    or",
"    <span class=\"nowrap\">",
"     CD4+/CD8+.",
"    </span>",
"    CD25 is expressed in a majority of the cases [",
"    <a class=\"abstract\" href=\"UTD.htm?9/45/9945/abstract/48,52\">",
"     48,52",
"    </a>",
"    ], as is CD52 [",
"    <a class=\"abstract\" href=\"UTD.htm?9/45/9945/abstract/37\">",
"     37",
"    </a>",
"    ]. Anaplastic large cell variants react with CD30, but are negative for ALK protein and lack rearrangements involving the ALK gene.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h2\">",
"     Genetics",
"    </span>",
"    &nbsp;&mdash;&nbsp;There is no distinct molecular or karyotypic abnormality in ATL other than clonally integrated HTLV-1, which is observed in all malignant cells [",
"    <a class=\"abstract\" href=\"UTD.htm?9/45/9945/abstract/45\">",
"     45",
"    </a>",
"    ]. Karyotypic analysis is generally reserved for patients enrolled in clinical trials. The T cell receptor genes are clonally rearranged [",
"    <a class=\"abstract\" href=\"UTD.htm?9/45/9945/abstract/53\">",
"     53",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The most common karyotypic changes involve trisomy or partial trisomy of 3q, 6q, 14q, and inv(14) [",
"    <a class=\"abstract\" href=\"UTD.htm?9/45/9945/abstract/54\">",
"     54",
"    </a>",
"    ]. In three studies, the more clinically aggressive ATL variants had the most complex chromosomal abnormalities [",
"    <a class=\"abstract\" href=\"UTD.htm?9/45/9945/abstract/54-56\">",
"     54-56",
"    </a>",
"    ]. Mapping of chromosome 6q in 22 patients with ATL indicated deletions in nine, eight of whom shared the same deleted region (6q15-21), a possible site for a tumor-suppressor gene [",
"    <a class=\"abstract\" href=\"UTD.htm?9/45/9945/abstract/57\">",
"     57",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Deletion of the p16 gene, also called multiple tumor suppressor 1 gene, an important regulator of the cell cycle, or reduced production of p16 protein may be associated with a more aggressive clinical course and reduced survival [",
"    <a class=\"abstract\" href=\"UTD.htm?9/45/9945/abstract/58,59\">",
"     58,59",
"    </a>",
"    ]. A further description of the p16 gene is presented separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?6/26/6569?source=see_link&amp;anchor=H3#H3\">",
"     \"Inherited susceptibility to melanoma\", section on 'CDKN2A gene'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h1\">",
"     DIAGNOSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The diagnosis of ATL is based upon a combination of characteristic clinical features, morphologic and immunophenotypic changes of the malignant cells, along with confirmation of HTLV-I infection [",
"    <a class=\"abstract\" href=\"UTD.htm?9/45/9945/abstract/60\">",
"     60",
"    </a>",
"    ]. Identification of at least 5 percent tumor cells by cytology and immunophenotype in the peripheral blood with confirmation of HTLV-1 infection is often sufficient to make the diagnosis in patients with acute, chronic, or smoldering type ATL [",
"    <a class=\"abstract\" href=\"UTD.htm?9/45/9945/abstract/47\">",
"     47",
"    </a>",
"    ]. Patients with lymphomatous lesions should undergo an excisional biopsy of an involved lymph node for histopathologic examination and molecular analysis for HTLV-1 provirus integration.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Clinical manifestations &mdash; There are no pathognomonic clinical features that clearly distinguish ATL from other disorders. As previously described, a number of clinical variants have been defined. Common features include generalized lymphadenopathy, hepatosplenomegaly, immunosuppression, hypercalcemia, lytic bone lesions, and skin lesions. (See",
"      <a class=\"local\" href=\"#H4\">",
"       'Clinical features'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      HTLV-1 infection &mdash; Practically all patients with ATL have serologic antibodies to HTLV-I. An enzyme-linked immunosorbent assay (ELISA) is the most frequently used screening test, using antigens prepared from whole virus lysate or by recombinant technology. Western blotting (WB) is normally used for confirmatory testing. WB also distinguishes between infection with HTLV-I and the less pathogenic HTLV-II.",
"      <br/>",
"      <br/>",
"      Polymerase chain reaction (PCR) based testing to detect proviral DNA in tumor cells should be performed in the rare instance where serology is negative but suspicion for ATL is high. This test will also differentiate HTLV-I from HTLV-II infection. Southern blotting can be used to identify the presence of clonal HTLV provirus within tumor cells, but is not available in most clinical centers. Details on the diagnosis of HTLV-I infection are presented separately. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?39/54/40808?source=see_link\">",
"       \"Human T-lymphotropic virus type I: Disease associations, diagnosis, and treatment\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Histology &mdash; As described above, the tumor cell morphology is quite variable. The most characteristic morphologic changes seen in ATL is that of the circulating tumor cells which are characterized by medium sized lymphocytes with condensed chromatin and bizarre hyperlobated nuclei (\"clover leaf\" or \"flower cells\") (",
"      <a class=\"graphic graphic_picture graphicRef82314 \" href=\"UTD.htm?43/46/44771\">",
"       picture 1",
"      </a>",
"      ).",
"     </li>",
"     <li>",
"      Immunophenotype &mdash; The immunophenotype is that of an activated mature T-lymphocyte. The most common immunophenotype is CD4+, CD25+, CD7-, and CD8-.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20\">",
"    <span class=\"h1\">",
"     DIFFERENTIAL DIAGNOSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The differential diagnosis of ATL includes other T cell lymphoid malignancies such as cutaneous T cell lymphoma, T-prolymphocytic leukemia (T-PLL), anaplastic large cell lymphoma, and angioimmunoblastic T cell lymphoma. Some cases of ATL can resemble Hodgkin disease morphologically.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H182686910\">",
"    <span class=\"h2\">",
"     Asymptomatic healthy carriers of HTLV-1",
"    </span>",
"    &nbsp;&mdash;&nbsp;Flower cells similar to those seen in ATL can be seen in the peripheral blood of asymptomatic healthy carriers of HTLV-1 [",
"    <a class=\"abstract\" href=\"UTD.htm?9/45/9945/abstract/61\">",
"     61",
"    </a>",
"    ]. Such cases may be difficult to distinguish from smoldering ATL. However, southern blot will identify the clonal integration of HTLV-1 into the circulating cells of smoldering ATL, but not into the circulating cells of healthy carriers [",
"    <a class=\"abstract\" href=\"UTD.htm?9/45/9945/abstract/62\">",
"     62",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?5/48/5897?source=see_link\">",
"     \"Human T-lymphotropic virus type I: Virology, pathogenesis, and epidemiology\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21\">",
"    <span class=\"h2\">",
"     Cutaneous T cell lymphoma",
"    </span>",
"    &nbsp;&mdash;&nbsp;ATL can be difficult to distinguish from forms of cutaneous T cell lymphoma (CTCL), such as mycosis fungoides and S&eacute;zary syndrome. Both of these disorders can have cutaneous manifestations with malignant T cells circulating in the peripheral blood and skin biopsy findings that are practically identical morphologically. They can also have a similar immunophenotype. Both are CD4+ and CD7-. While ATL has a more uniform, strong positivity for CD25, CD25 positivity is more variable in CTCL. The key differentiating feature is the presence of HTLV-I in the malignant cells of ATL. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?4/32/4618?source=see_link\">",
"     \"Clinical manifestations, pathologic features, and diagnosis of mycosis fungoides\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22\">",
"    <span class=\"h2\">",
"     T-prolymphocytic leukemia",
"    </span>",
"    &nbsp;&mdash;&nbsp;Much like ATL, T-prolymphocytic leukemia (T-PLL) is an aggressive malignancy characterized by circulating malignant T lymphoid cells, marked lymphocytosis, cytopenias, and splenomegaly. Immunophenotype can help distinguish this disorder from ATL. As with ATL, T-PLL is CD4+. However, unlike ATL, T-PLL is CD7+ and CD25-. HTLV-I is not incorporated into the genome of the malignant cell, and more than 80 percent of patients will have genetic abnormalities, usually an inversion of chromosome 14, which fuse the TCL1 gene to the T cell receptor (TCR)",
"    <span class=\"nowrap\">",
"     alpha/delta",
"    </span>",
"    locus and lead to the overexpression of TCL1 protein. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?9/55/10102?source=see_link\">",
"     \"Clinical manifestations, pathologic features, and diagnosis of T cell prolymphocytic leukemia\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H23\">",
"    <span class=\"h2\">",
"     Anaplastic large cell lymphoma",
"    </span>",
"    &nbsp;&mdash;&nbsp;Anaplastic large cell lymphoma (ALCL) is another T cell lymphoid neoplasm that primarily involves the lymph nodes and skin but can demonstrate circulating malignant cells. Cell morphology is varied and the immunophenotype is CD4+ and CD7- much like ATL. Immunohistochemistry staining can be of help since ALCL has strong, uniform expression of CD30 with a membrane and Golgi distribution and is cytotoxic granule-associated protein positive.",
"   </p>",
"   <p>",
"    The diagnosis of ALCL can be confirmed in many cases by demonstrating an ALK1 gene rearrangement or expression of the Alk-1 protein, neither of which can be found in ATL. However, the cutaneous variant of ALCL is less likely than the systemic variant to demonstrate ALK1 positivity. In addition, HTLV-I is not incorporated into the genome of the malignant cell in ALCL. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?24/47/25337?source=see_link\">",
"     \"Clinical manifestations, pathologic features, and diagnosis of anaplastic large cell lymphoma, ALK positive\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H24\">",
"    <span class=\"h2\">",
"     Angioimmunoblastic T cell lymphoma",
"    </span>",
"    &nbsp;&mdash;&nbsp;Angioimmunoblastic T cell lymphoma (AITCL) is one of the more common peripheral T cell lymphomas and usually presents with generalized systemic symptoms, lymphadenopathy, hepatomegaly, bone marrow involvement, and a pruritic skin rash. Most patients demonstrate a polyclonal hypergammaglobulinemia. The morphology of the malignant cells is varied but one common feature is the prominent arborizing high endothelial venules not typically found in ATL. Immunophenotype typically demonstrates CD4 positivity and decreased intensity of CD7. Unlike ATL, HTLV-I is not incorporated into the genome of the malignant cell in ALCL. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?33/14/34023?source=see_link\">",
"     \"Clinical manifestations, pathologic features, and diagnosis of angioimmunoblastic T cell lymphoma\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H25\">",
"    <span class=\"h1\">",
"     TREATMENT",
"    </span>",
"    &nbsp;&mdash;&nbsp;The treatment of ATL is discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?29/36/30281?source=see_link\">",
"     \"Treatment and prognosis of adult T cell leukemia-lymphoma\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H26\">",
"    <span class=\"h1\">",
"     SUMMARY",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Adult T cell leukemia-lymphoma (ATL) is an uncommon lymphoid neoplasm caused by human T-lymphotropic virus, type I (HTLV-I) infection. Incidence varies by population according to the prevalence of HTLV-I infection. (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Epidemiology'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The long-term risk of developing ATL following infection with HTLV-I in endemic areas has been estimated to be 4 to 5 percent, usually after a latency period of several decades. The exact mechanism by which HTLV-I contributes to tumor development is unknown. However, increasing evidence suggests that the viral regulatory gene tax (transactivating gene of the X region) encodes an oncoprotein, which induces cellular proliferation, promotes cellular survival, and impairs DNA damage repair mechanisms (see",
"      <a class=\"local\" href=\"#H3\">",
"       'Pathogenesis'",
"      </a>",
"      above).",
"     </li>",
"     <li>",
"      The clinical features of ATL include evidence of generalized lymphadenopathy, hepatosplenomegaly, immunosuppression, hypercalcemia, lytic bone lesions, and skin lesions. The frequency of these differs among patient groups and has been the basis upon which clinical variants have been defined. There are four basic clinical variants of ATL: acute (60 percent of cases), lymphomatous (20 percent of cases), chronic (15 percent of cases) and smoldering (5 percent of cases). In addition, ATL can progress from a chronic or smoldering variant to an aggressive disease resembling the acute variant. (See",
"      <a class=\"local\" href=\"#H4\">",
"       'Clinical features'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The most characteristic morphologic changes seen in the peripheral blood of ATL patients are cells with bizarre hyperlobulated nuclei (\"clover leaf\" or \"flower cells\") (",
"      <a class=\"graphic graphic_picture graphicRef82314 \" href=\"UTD.htm?43/46/44771\">",
"       picture 1",
"      </a>",
"      ). Bone marrow infiltrates are usually patchy. Involved lymph nodes typically display diffuse architectural effacement. Skin infiltrates can be similar to those seen in cutaneous T cell lymphoma (mycosis fungoides). (See",
"      <a class=\"local\" href=\"#H13\">",
"       'Morphology'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The cell of origin in ATL is an HTLV-I infected (CD4+) T cell. In the majority of cases, the tumor cells express markers suggesting an origin from a CD4+ regulatory T cell (Treg). Tumor cells express T cell associated antigens (CD2, CD4, and CD5), but usually lack CD7. Most cases are CD4+ and CD8-. (See",
"      <a class=\"local\" href=\"#H17\">",
"       'Immunophenotype'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      There is no distinct molecular or karyotypic abnormality in ATL. The T cell receptor genes are clonally rearranged, and all cases demonstrate clonally integrated HTLV-I. The more clinically aggressive ATL variants have the most complex chromosomal abnormalities. (See",
"      <a class=\"local\" href=\"#H18\">",
"       'Genetics'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The diagnosis of ATL is based upon a combination of specific clinical features, the morphology and immunophenotype of the malignant cells along with confirmation of HTLV-I infection. The differential diagnosis of ATL includes other mature T cell lymphoid malignancies. (See",
"      <a class=\"local\" href=\"#H19\">",
"       'Diagnosis'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H20\">",
"       'Differential diagnosis'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/45/9945/abstract/1\">",
"      Harris NL, Jaffe ES, Diebold J, et al. World Health Organization classification of neoplastic diseases of the hematopoietic and lymphoid tissues: report of the Clinical Advisory Committee meeting-Airlie House, Virginia, November 1997. J Clin Oncol 1999; 17:3835.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/45/9945/abstract/2\">",
"      Armitage JO, Weisenburger DD. New approach to classifying non-Hodgkin's lymphomas: clinical features of the major histologic subtypes. Non-Hodgkin's Lymphoma Classification Project. J Clin Oncol 1998; 16:2780.",
"     </a>",
"    </li>",
"    <li>",
"     World Health Organization Classification of Tumours of Haematopoietic and Lymphoid Tissues, Swerdlow SH, Campo E, Harris NL, et al. (Eds), IARC Press, Lyon 2008.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/45/9945/abstract/4\">",
"      Vose J, Armitage J, Weisenburger D, International T-Cell Lymphoma Project. International peripheral T-cell and natural killer/T-cell lymphoma study: pathology findings and clinical outcomes. J Clin Oncol 2008; 26:4124.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/45/9945/abstract/5\">",
"      Jaffe ES, Blattner WA, Blayney DW, et al. The pathologic spectrum of adult T-cell leukemia/lymphoma in the United States. Human T-cell leukemia/lymphoma virus-associated lymphoid malignancies. Am J Surg Pathol 1984; 8:263.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/45/9945/abstract/6\">",
"      Picard FJ, Coulthart MB, Oger J, et al. Human T-lymphotropic virus type 1 in coastal natives of British Columbia: phylogenetic affinities and possible origins. J Virol 1995; 69:7248.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/45/9945/abstract/7\">",
"      Hjelle B, Khabbaz RF, Conway GA, et al. Prevalence of human T cell lymphotropic virus type II in American Indian populations of the southwestern United States. Am J Trop Med Hyg 1994; 51:11.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/45/9945/abstract/8\">",
"      Bitar N, Hajj HE, Houmani Z, et al. Adult T-cell leukemia/lymphoma in the Middle East: first report of two cases from Lebanon. Transfusion 2009; 49:1859.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/45/9945/abstract/9\">",
"      Phillips AA, Shapira I, Willim RD, et al. A critical analysis of prognostic factors in North American patients with human T-cell lymphotropic virus type-1-associated adult T-cell leukemia/lymphoma: a multicenter clinicopathologic experience and new prognostic score. Cancer 2010; 116:3438.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/45/9945/abstract/10\">",
"      Laurini JA, Perry AM, Boilesen E, et al. Classification of non-Hodgkin lymphoma in Central and South America: a review of 1028 cases. Blood 2012; 120:4795.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/45/9945/abstract/11\">",
"      Yamamoto JF, Goodman MT. Patterns of leukemia incidence in the United States by subtype and demographic characteristics, 1997-2002. Cancer Causes Control 2008; 19:379.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/45/9945/abstract/12\">",
"      Matutes E. Adult T-cell leukaemia/lymphoma. J Clin Pathol 2007; 60:1373.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/45/9945/abstract/13\">",
"      Hanchard B. Adult T-cell leukemia/lymphoma in Jamaica: 1986-1995. J Acquir Immune Defic Syndr Hum Retrovirol 1996; 13 Suppl 1:S20.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/45/9945/abstract/14\">",
"      Smith MR, Greene WC. Molecular biology of the type I human T-cell leukemia virus (HTLV-I) and adult T-cell leukemia. J Clin Invest 1991; 87:761.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/45/9945/abstract/15\">",
"      Murphy EL, Hanchard B, Figueroa JP, et al. Modelling the risk of adult T-cell leukemia/lymphoma in persons infected with human T-lymphotropic virus type I. Int J Cancer 1989; 43:250.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/45/9945/abstract/16\">",
"      Matsuoka M. Human T-cell leukemia virus type I and adult T-cell leukemia. Oncogene 2003; 22:5131.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/45/9945/abstract/17\">",
"      Chen YC, Wang CH, Su IJ, et al. Infection of human T-cell leukemia virus type I and development of human T-cell leukemia lymphoma in patients with hematologic neoplasms: a possible linkage to blood transfusion. Blood 1989; 74:388.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/45/9945/abstract/18\">",
"      Hoshida Y, Li T, Dong Z, et al. Lymphoproliferative disorders in renal transplant patients in Japan. Int J Cancer 2001; 91:869.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/45/9945/abstract/19\">",
"      Tamaki H, Matsuoka M. Donor-derived T-cell leukemia after bone marrow transplantation. N Engl J Med 2006; 354:1758.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/45/9945/abstract/20\">",
"      Matsuoka M, Jeang KT. Human T-cell leukaemia virus type 1 (HTLV-1) infectivity and cellular transformation. Nat Rev Cancer 2007; 7:270.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/45/9945/abstract/21\">",
"      Taylor G. Molecular aspects of HTLV-I infection and adult T-cell leukaemia/lymphoma. J Clin Pathol 2007; 60:1392.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/45/9945/abstract/22\">",
"      Matsuoka M, Watanabe T, Kannagi M, et al. Meeting report on the 13th International Conference on Human Retrovirology: human T-cell leukemia virus research 30 years after adult T-cell leukemia. Cancer Res 2007; 67:10638.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/45/9945/abstract/23\">",
"      Banerjee P, Tripp A, Lairmore MD, et al. Adult T-cell leukemia/lymphoma development in HTLV-1-infected humanized SCID mice. Blood 2010; 115:2640.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/45/9945/abstract/24\">",
"      Migone TS, Lin JX, Cereseto A, et al. Constitutively activated Jak-STAT pathway in T cells transformed with HTLV-I. Science 1995; 269:79.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/45/9945/abstract/25\">",
"      Ju W, Zhang M, Jiang JK, et al. CP-690,550, a therapeutic agent, inhibits cytokine-mediated Jak3 activation and proliferation of T cells from patients with ATL and HAM/TSP. Blood 2011; 117:1938.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/45/9945/abstract/26\">",
"      Jeong SJ, Radonovich M, Brady JN, Pise-Masison CA. HTLV-I Tax induces a novel interaction between p65/RelA and p53 that results in inhibition of p53 transcriptional activity. Blood 2004; 104:1490.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/45/9945/abstract/27\">",
"      Motokura T, Fukumoto S, Matsumoto T, et al. Parathyroid hormone-related protein in adult T-cell leukemia-lymphoma. Ann Intern Med 1989; 111:484.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/45/9945/abstract/28\">",
"      Ikeda K, Ohno H, Hane M, et al. Development of a sensitive two-site immunoradiometric assay for parathyroid hormone-related peptide: evidence for elevated levels in plasma from patients with adult T-cell leukemia/lymphoma and B-cell lymphoma. J Clin Endocrinol Metab 1994; 79:1322.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/45/9945/abstract/29\">",
"      Nakamura Y, Bando H, Shintani Y, et al. Serum parathyroid hormone-related protein concentrations in patients with hematologic malignancies or solid tumors. Acta Endocrinol (Copenh) 1992; 127:324.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/45/9945/abstract/30\">",
"      Ishibashi K, Ishitsuka K, Chuman Y, et al. Tumor necrosis factor-beta in the serum of adult T-cell leukemia with hypercalcemia. Blood 1991; 77:2451.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/45/9945/abstract/31\">",
"      Wano Y, Hattori T, Matsuoka M, et al. Interleukin 1 gene expression in adult T cell leukemia. J Clin Invest 1987; 80:911.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/45/9945/abstract/32\">",
"      Nosaka K, Miyamoto T, Sakai T, et al. Mechanism of hypercalcemia in adult T-cell leukemia: overexpression of receptor activator of nuclear factor kappaB ligand on adult T-cell leukemia cells. Blood 2002; 99:634.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/45/9945/abstract/33\">",
"      Bunn PA Jr, Schechter GP, Jaffe E, et al. Clinical course of retrovirus-associated adult T-cell lymphoma in the United States. N Engl J Med 1983; 309:257.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/45/9945/abstract/34\">",
"      Yamaguchi T, Hirano T, Kumagai K, et al. Osteitis fibrosa cystica generalizata with adult T-cell leukaemia: a case report. Br J Haematol 1999; 107:892.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/45/9945/abstract/35\">",
"      Oshiro A, Tagawa H, Ohshima K, et al. Identification of subtype-specific genomic alterations in aggressive adult T-cell leukemia/lymphoma. Blood 2006; 107:4500.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/45/9945/abstract/36\">",
"      Tsukasaki K, Tanosaki S, DeVos S, et al. Identifying progression-associated genes in adult T-cell leukemia/lymphoma by using oligonucleotide microarrays. Int J Cancer 2004; 109:875.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/45/9945/abstract/37\">",
"      Ravandi F, O'Brien S. Chronic lymphoid leukemias other than chronic lymphocytic leukemia: diagnosis and treatment. Mayo Clin Proc 2005; 80:1660.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/45/9945/abstract/38\">",
"      Uchiyama T, Yodoi J, Sagawa K, et al. Adult T-cell leukemia: clinical and hematologic features of 16 cases. Blood 1977; 50:481.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/45/9945/abstract/39\">",
"      Foss FM, Aquino SL, Ferry JA. Case records of the Massachusetts General Hospital. Weekly clinicopathological exercises. Case 10-2003. A 72-year-old man with rapidly progressive leukemia, rash, and multiorgan failure. N Engl J Med 2003; 348:1267.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/45/9945/abstract/40\">",
"      Yamada Y, Kamihira S, Murata K, et al. Frequent hepatic involvement in adult T cell leukemia: comparison with non-Hodgkin's lymphoma. Leuk Lymphoma 1997; 26:327.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/45/9945/abstract/41\">",
"      Sawada Y, Hino R, Hama K, et al. Type of skin eruption is an independent prognostic indicator for adult T-cell leukemia/lymphoma. Blood 2011; 117:3961.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/45/9945/abstract/42\">",
"      Okada F, Ando Y, Kondo Y, et al. Thoracic CT findings of adult T-cell leukemia or lymphoma. AJR Am J Roentgenol 2004; 182:761.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/45/9945/abstract/43\">",
"      Kawasaki C, Ikeda H, Fukumoto T. Cerebral mass lesions associated with adult T-cell leukemia/lymphoma. Int J Hematol 1995; 61:97.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/45/9945/abstract/44\">",
"      Takasaki Y, Iwanaga M, Imaizumi Y, et al. Long-term study of indolent adult T-cell leukemia-lymphoma. Blood 2010; 115:4337.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/45/9945/abstract/45\">",
"      Chadburn A, Athan E, Wieczorek R, Knowles DM. Detection and characterization of human T-cell lymphotropic virus type I (HTLV-I) associated T-cell neoplasms in an HTLV-I nonendemic region by polymerase chain reaction. Blood 1991; 77:2419.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/45/9945/abstract/46\">",
"      Verdonck K, Gonz&aacute;lez E, Van Dooren S, et al. Human T-lymphotropic virus 1: recent knowledge about an ancient infection. Lancet Infect Dis 2007; 7:266.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/45/9945/abstract/47\">",
"      Shimoyama M. Diagnostic criteria and classification of clinical subtypes of adult T-cell leukaemia-lymphoma. A report from the Lymphoma Study Group (1984-87). Br J Haematol 1991; 79:428.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/45/9945/abstract/48\">",
"      Kikuchi M, Mitsui T, Takeshita M, et al. Virus associated adult T-cell leukemia (ATL) in Japan: clinical, histological and immunological studies. Hematol Oncol 1986; 4:67.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/45/9945/abstract/49\">",
"      Ohnita K, Isomoto H, Mizuta Y, et al. Helicobacter pylori infection in patients with gastric involvement by adult T-cell leukemia/lymphoma. Cancer 2002; 94:1507.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/45/9945/abstract/50\">",
"      Roncador G, Garcia JF, Garcia JF, et al. FOXP3, a selective marker for a subset of adult T-cell leukaemia/lymphoma. Leukemia 2005; 19:2247.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/45/9945/abstract/51\">",
"      Karube K, Ohshima K, Tsuchiya T, et al. Expression of FoxP3, a key molecule in CD4CD25 regulatory T cells, in adult T-cell leukaemia/lymphoma cells. Br J Haematol 2004; 126:81.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/45/9945/abstract/52\">",
"      Waldmann TA, Greene WC, Sarin PS, et al. Functional and phenotypic comparison of human T cell leukemia/lymphoma virus positive adult T cell leukemia with human T cell leukemia/lymphoma virus negative S&eacute;zary leukemia, and their distinction using anti-Tac. Monoclonal antibody identifying the human receptor for T cell growth factor. J Clin Invest 1984; 73:1711.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/45/9945/abstract/53\">",
"      Aisenberg AC, Krontiris TG, Mak TW, Wilkes BM. Rearrangement of the gene for the beta chain of the T-cell receptor in T-cell chronic lymphocytic leukemia and related disorders. N Engl J Med 1985; 313:529.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/45/9945/abstract/54\">",
"      Sanada I, Tanaka R, Kumagai E, et al. Chromosomal aberrations in adult T cell leukemia: relationship to the clinical severity. Blood 1985; 65:649.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/45/9945/abstract/55\">",
"      Itoyama T, Chaganti RS, Yamada Y, et al. Cytogenetic analysis and clinical significance in adult T-cell leukemia/lymphoma: a study of 50 cases from the human T-cell leukemia virus type-1 endemic area, Nagasaki. Blood 2001; 97:3612.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/45/9945/abstract/56\">",
"      Tsukasaki K, Krebs J, Nagai K, et al. Comparative genomic hybridization analysis in adult T-cell leukemia/lymphoma: correlation with clinical course. Blood 2001; 97:3875.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/45/9945/abstract/57\">",
"      Hatta Y, Yamada Y, Tomonaga M, et al. Detailed deletion mapping of the long arm of chromosome 6 in adult T-cell leukemia. Blood 1999; 93:613.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/45/9945/abstract/58\">",
"      Pombo-de-Oliveira MS, Dobbin JA, Loureiro P, et al. Genetic mutation and early onset of T-cell leukemia in pediatric patients infected at birth with HTLV-I. Leuk Res 2002; 26:155.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/45/9945/abstract/59\">",
"      Takasaki Y, Yamada Y, Sugahara K, et al. Interruption of p16 gene expression in adult T-cell leukaemia/lymphoma: clinical correlation. Br J Haematol 2003; 122:253.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/45/9945/abstract/60\">",
"      Tsukasaki K, Hermine O, Bazarbachi A, et al. Definition, prognostic factors, treatment, and response criteria of adult T-cell leukemia-lymphoma: a proposal from an international consensus meeting. J Clin Oncol 2009; 27:453.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/45/9945/abstract/61\">",
"      Wattel E, Vartanian JP, Pannetier C, Wain-Hobson S. Clonal expansion of human T-cell leukemia virus type I-infected cells in asymptomatic and symptomatic carriers without malignancy. J Virol 1995; 69:2863.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/45/9945/abstract/62\">",
"      Tsukasaki K, Tsushima H, Yamamura M, et al. Integration patterns of HTLV-I provirus in relation to the clinical course of ATL: frequent clonal change at crisis from indolent disease. Blood 1997; 89:948.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 4697 Version 9.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1104-203.80.222.8-5CA963D2D9-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f9_45_9945=[""].join("\n");
var outline_f9_45_9945=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H26\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      EPIDEMIOLOGY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      PATHOGENESIS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      CLINICAL FEATURES",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Clinical variants",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      - Acute",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      - Lymphomatous",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      - Chronic",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      - Smoldering",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      Hypercalcemia and lytic bone lesions",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      Immunosuppression",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      PATHOLOGY",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      Morphology",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      - Peripheral blood and bone marrow",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      - Lymph nodes",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      - Other tissues",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      Immunophenotype",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      Genetics",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      DIAGNOSIS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H20\">",
"      DIFFERENTIAL DIAGNOSIS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H182686910\">",
"      Asymptomatic healthy carriers of HTLV-1",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H21\">",
"      Cutaneous T cell lymphoma",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H22\">",
"      T-prolymphocytic leukemia",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H23\">",
"      Anaplastic large cell lymphoma",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H24\">",
"      Angioimmunoblastic T cell lymphoma",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H25\">",
"      TREATMENT",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H26\">",
"      SUMMARY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"HEME/4697\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"HEME/4697|PIC\">",
"      <a href=\"#\" title=\"PICTURES\">",
"       PICTURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?43/46/44771\" title=\"picture 1\">",
"      ATL peripheral blood smear",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?20/53/21337?source=related_link\">",
"      Classification of the hematopoietic neoplasms",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?32/56/33669?source=related_link\">",
"      Clinical manifestations of hypercalcemia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?9/55/10102?source=related_link\">",
"      Clinical manifestations, pathologic features, and diagnosis of T cell prolymphocytic leukemia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?24/47/25337?source=related_link\">",
"      Clinical manifestations, pathologic features, and diagnosis of anaplastic large cell lymphoma, ALK positive",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?33/14/34023?source=related_link\">",
"      Clinical manifestations, pathologic features, and diagnosis of angioimmunoblastic T cell lymphoma",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?4/32/4618?source=related_link\">",
"      Clinical manifestations, pathologic features, and diagnosis of mycosis fungoides",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?39/54/40808?source=related_link\">",
"      Human T-lymphotropic virus type I: Disease associations, diagnosis, and treatment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?5/48/5897?source=related_link\">",
"      Human T-lymphotropic virus type I: Virology, pathogenesis, and epidemiology",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?40/48/41734?source=related_link\">",
"      Hypercalcemia of malignancy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?6/26/6569?source=related_link\">",
"      Inherited susceptibility to melanoma",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?10/59/11193?source=related_link\">",
"      Strongyloidiasis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?29/36/30281?source=related_link\">",
"      Treatment and prognosis of adult T cell leukemia-lymphoma",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f9_45_9946="Bronchioloalveolar carcinoma, including adenocarcinoma in situ";
var content_f9_45_9946=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"5\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Bronchioloalveolar carcinoma, including adenocarcinoma in situ",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?9/45/9946/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?9/45/9946/contributors\">",
"     Howard J West, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?9/45/9946/contributors\">",
"     Section Editors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?9/45/9946/contributors\">",
"     Rogerio C Lilenbaum, MD, FACP",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?9/45/9946/contributors\">",
"     James R Jett, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?9/45/9946/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?9/45/9946/contributors\">",
"     Michael E Ross, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?9/45/9946/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Mar 21, 2013.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;The term bronchioloalveolar carcinoma (BAC) was originally applied to a subtype of adenocarcinoma of the lung that is distinguished by its peripheral location, well-differentiated cytology, growth along intact alveolar septa (the so-called \"lepidic\" growth pattern), and tendency for both aerogenous and lymphatic spread.",
"   </p>",
"   <p>",
"    In the 2004 World Health Organization (WHO) classification of lung tumors, BAC is considered a subset of adenocarcinoma [",
"    <a class=\"abstract\" href=\"UTD.htm?9/45/9946/abstract/1\">",
"     1",
"    </a>",
"    ]. In the WHO system, BAC is divided into mucinous, nonmucinous, and mixed subtypes. This distinction is based upon histologic criteria, and is supported by immunohistochemical and molecular biology differences. Distinguishing mucinous from nonmucinous subtypes of BAC has significant therapeutic and prognostic implications [",
"    <a class=\"abstract\" href=\"UTD.htm?9/45/9946/abstract/2\">",
"     2",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In 2011, a multidisciplinary expert panel representing the International Association for the Study of Lung Cancer (IASLC), the American Thoracic Society (ATS), and the European Respiratory Society (ERS) proposed a major revision of the classification of adenocarcinomas that reclassified what had been called BAC into newly defined histologic subgroups and recommended discontinuation of the term BAC [",
"    <a class=\"abstract\" href=\"UTD.htm?9/45/9946/abstract/3\">",
"     3",
"    </a>",
"    ]. The proposed revisions are briefly presented in the relevant sections below and discussed in detail elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?21/43/22201?source=see_link&amp;anchor=H1177702#H1177702\">",
"     \"Pathology of lung malignancies\", section on '2011 IASLC/ATS/ERS classification of adenocarcinoma'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Currently, the term BAC continues to be used operationally by pathologists and clinicians to describe not only the non-invasive &ldquo;pure&rdquo; form but also some cases of mixed adenocarcinoma with a BAC component that share clinical characteristics. Key features of BAC and the management of this more broadly defined population will be reviewed here.",
"   </p>",
"   <p>",
"    The treatment of other forms of NSCLC is discussed elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?20/57/21401?source=see_link\">",
"     \"Overview of the treatment of advanced non-small cell lung cancer\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?12/61/13273?source=see_link\">",
"     \"Overview of the initial evaluation, treatment and prognosis of lung cancer\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h1\">",
"     PATHOLOGY AND DEFINITION",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Histologic features",
"    </span>",
"    &nbsp;&mdash;&nbsp;The traditional approach to defining BAC has been encompassed in the WHO system; more recently, the importance of early lesions has been incorporated into the",
"    <span class=\"nowrap\">",
"     IASLC/ATS/ERS",
"    </span>",
"    classification.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1301125\">",
"    <span class=\"h3\">",
"     WHO system",
"    </span>",
"    &nbsp;&mdash;&nbsp;In the WHO classification system, BAC is characterized by the following pathologic features [",
"    <a class=\"abstract\" href=\"UTD.htm?9/45/9946/abstract/4\">",
"     4",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      An origin distal to grossly recognizable bronchi",
"     </li>",
"     <li>",
"      Well-differentiated cytology",
"     </li>",
"     <li>",
"      A propensity for aerogenous and lymphatic spread, which can result in the multicentric development of lesions separate from the main tumor",
"     </li>",
"     <li>",
"      Growth along intact alveolar septa (the so-called \"lepidic\" growth pattern), with preservation of the underlying lung architecture",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The 1999 and 2004 WHO classification of adenocarcinoma of the lung restricts the definition of the pure BAC subtype to those tumors with a pure bronchioloalveolar growth pattern in which there is no evidence of invasion of stroma, pleura, or lymphatic spaces [",
"    <a class=\"abstract\" href=\"UTD.htm?9/45/9946/abstract/5\">",
"     5",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?21/43/22201?source=see_link\">",
"     \"Pathology of lung malignancies\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    In mixed adenocarcinoma with a BAC component, the proportion of BAC can vary widely, from tumors with a predominantly BAC pattern and minimal invasion to those in which BAC is present only focally. Under the 1999 WHO guidelines, adenocarcinomas that demonstrate the histologic features of BAC but had evidence of invasion were classified as adenocarcinoma, mixed type with a predominant BAC pattern.",
"   </p>",
"   <p>",
"    The 2004 WHO revisions to the lung tumor classification scheme did not affect the definition of the BAC subtype, leaving intact the requirement that the BAC subtype lack any other component of invasive adenocarcinoma [",
"    <a class=\"abstract\" href=\"UTD.htm?9/45/9946/abstract/1\">",
"     1",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    There are conflicting data addressing whether a distinction between pure BAC, minimally invasive BAC, and adenocarcinoma with BAC features has important clinical implications. Mounting evidence suggests that an increasing proportion of non-invasive adenocarcinoma correlates with an improved outcome [",
"    <a class=\"abstract\" href=\"UTD.htm?9/45/9946/abstract/6-8\">",
"     6-8",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1301144\">",
"    <span class=\"h3\">",
"     IASLC/ATS/ERS classification",
"    </span>",
"    &nbsp;&mdash;&nbsp;The reclassification of adenocarcinoma recommended by the",
"    <span class=\"nowrap\">",
"     IASLC/ATS/ERS",
"    </span>",
"    discontinues the use of the term bronchioloalveolar carcinoma [",
"    <a class=\"abstract\" href=\"UTD.htm?9/45/9946/abstract/3\">",
"     3",
"    </a>",
"    ]. The",
"    <span class=\"nowrap\">",
"     IASLC/ATS/ERS",
"    </span>",
"    system describes five different groups with better defined subpopulations:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Adenocarcinoma in situ (AIS) with no invasive features is a localized, small (&le;3 cm) adenocarcinoma with growth restricted to a noninvasive lepidic pattern and an absence of papillary or micropapillary patterns or intraalveolar tumor cells. AIS is subdivided into nonmucinous and mucinous variants, although it is typically nonmucinous and rarely mucinous. When AIS occurs as a solitary lesion, the reported five-year disease-free survival rate after resection is 100 percent [",
"      <a class=\"abstract\" href=\"UTD.htm?9/45/9946/abstract/9-11\">",
"       9-11",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Minimally invasive adenocarcinoma () is a small, solitary adenocarcinoma (&le;3 cm), with a predominantly lepidic pattern and an area of &le;5 mm of invasion in greatest dimension in any one focus. The tumor cannot invade lymphatics, blood vessels or pleura, nor can it contain areas of necrosis. MIA is subdivided into nonmucinous and mucinous variants, though it is typically nonmucinous and rarely mucinous. MIA is a solitary lesion by definition; this diagnosis can be made in the presence of multiple lesions only if it is presumed that the others are synchronous tumors. In most case series, resection of a solitary MIA results in a five-year disease-free survival that approaches 100 percent [",
"      <a class=\"abstract\" href=\"UTD.htm?9/45/9946/abstract/8,12,13\">",
"       8,12,13",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Lepidic predominant adenocarcinoma is a solitary nonmucinous adenocarcinoma greater than 3 cm in greatest diameter or multiple nodules that are primarily non-invasive and would be considered as AIS if they appeared as a solitary nodule. The disease-free survival in this setting is less certain, because most series on noninvasive adenocarcinomas are comprised primarily of solitary tumors less than 3 cm in diameter. An invasive component cannot be ruled out as confidently as with complete evaluation of a smaller solitary lesion, particularly if the full extent of disease (whether one larger lesion or multiple lesions) has not been completely sampled. This classification should not be used for invasive mucinous adenocarcinoma with a predominantly lepidic growth pattern.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Adenocarcinoma, predominantly invasive with some nonmucinous lepidic component, is an invasive adenocarcinoma for which the pathologist should describe the extent of adenocarcinoma subtypes within 5 percent increments.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Invasive mucinous adenocarcinoma is the terminology now recommended for a mucinous lesion larger than 3 cm in greatest diameter, for which an invasive component is presumed. &nbsp;",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    This topic will discuss BAC as defined by the operational definition that has been applied clinically for the past several years, rather than the proposed adenocarcinoma reclassification, except as otherwise noted.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     Differential diagnosis",
"    </span>",
"    &nbsp;&mdash;&nbsp;The differential diagnosis of BAC includes other forms of pulmonary adenocarcinoma, as well as atypical adenomatous hyperplasia (AAH), a preinvasive lesion that can resemble nonmucinous BAC. In addition, BAC must be distinguished from metastases from primary colon cancer, which can mimic the histologic appearance of mucinous BAC.",
"   </p>",
"   <p>",
"    A core needle biopsy or surgical specimen is required to distinguish BAC from other forms of pulmonary adenocarcinoma. A fine needle aspirate (FNA) does not allow assessment for the invasion that differentiates BAC from adenocarcinoma with BAC features. The importance of making this histologic distinction is unclear, since both tumors are treated similarly.",
"   </p>",
"   <p>",
"    Distinguishing BAC from metastatic adenocarcinoma may require immunohistochemical staining. Useful markers include the following:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Cytokeratin 7 &ndash; Staining for cytokeratin 7 (CK7) is positive in more than 90 percent of all lung adenocarcinomas, including those with BAC [",
"      <a class=\"abstract\" href=\"UTD.htm?9/45/9946/abstract/14-18\">",
"       14-18",
"      </a>",
"      ]. However, CK7 was positive in only 23 percent of cases with metastatic colon cancer [",
"      <a class=\"abstract\" href=\"UTD.htm?9/45/9946/abstract/15,18\">",
"       15,18",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Cytokeratin 20 &ndash; Staining for cytokeratin 20 (CK20) has given mixed results in patients with BAC. This marker is positive in less than 10 percent of patients with nonmucinous BAC, but 60 to 90 percent of those with mucinous BAC stain positively for CK20 [",
"      <a class=\"abstract\" href=\"UTD.htm?9/45/9946/abstract/14-17,19\">",
"       14-17,19",
"      </a>",
"      ]. CK20 was positive in more than 95 percent of patients with metastatic colorectal cancer [",
"      <a class=\"abstract\" href=\"UTD.htm?9/45/9946/abstract/15,19\">",
"       15,19",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      CDX2 &ndash; Immunohistochemical staining for CDX2 (caudal-related homeobox 2) is an excellent marker to identify adenocarcinoma of gastrointestinal origin. In one series, staining for CDX2 was positive in 97 percent of colorectal adenocarcinomas, while it was negative in all patients with BAC [",
"      <a class=\"abstract\" href=\"UTD.htm?9/45/9946/abstract/15\">",
"       15",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     Mucinous versus nonmucinous BAC",
"    </span>",
"    &nbsp;&mdash;&nbsp;BAC is divided into mucinous and nonmucinous subtypes (",
"    <a class=\"graphic graphic_picture graphicRef63152 \" href=\"UTD.htm?6/62/7140\">",
"     picture 1",
"    </a>",
"    and",
"    <a class=\"graphic graphic_picture graphicRef50383 \" href=\"UTD.htm?37/28/38342\">",
"     picture 2",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?9/45/9946/abstract/1\">",
"     1",
"    </a>",
"    ]. In addition, some BACs that contain both mucinous and nonmucinous elements are classified as an indeterminate form. There is increasing evidence that mucinous and nonmucinous forms have differing prognoses and responses to therapy [",
"    <a class=\"abstract\" href=\"UTD.htm?9/45/9946/abstract/2\">",
"     2",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h3\">",
"     Histopathology",
"    </span>",
"    &nbsp;&mdash;&nbsp;Mucinous BAC is probably derived from respiratory goblet cells, while the non-mucinous variants show ultrastructural and immunophenotypic features of either Clara cells or type II pneumocytes. The mucinous form constitutes 30 to 40 percent of BACs, whereas the nonmucinous form accounts for 50 to 60 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?9/45/9946/abstract/20-22\">",
"     20-22",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Significant differences in histochemical staining are found between the mucinous and nonmucinous subtypes [",
"    <a class=\"abstract\" href=\"UTD.htm?9/45/9946/abstract/2,19,23\">",
"     2,19,23",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Thyroid transcription factor-1 (TTF-1) is positive in more than 90 percent of patients with nonmucinous BAC, while TTF-1 positivity is uncommon in mucinous BAC.",
"     </li>",
"     <li>",
"      CK20 is positive in fewer than 10 percent of nonmucinous BACs, while 60 to 90 percent of mucinous BAC stain positively for this marker [",
"      <a class=\"abstract\" href=\"UTD.htm?9/45/9946/abstract/14,16,17,19\">",
"       14,16,17,19",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Diastase resistant periodic acid Schiff (PAS) staining is positive in almost all mucinous BACs, while only a minority of nonmucinous BACs stain with PAS [",
"      <a class=\"abstract\" href=\"UTD.htm?9/45/9946/abstract/24\">",
"       24",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h3\">",
"     Molecular abnormalities",
"    </span>",
"    &nbsp;&mdash;&nbsp;The frequency and types of molecular biology abnormalities differ markedly between the mucinous and nonmucinous subtypes of BAC. Mutations in the epidermal growth factor receptor (EGFR) tyrosine kinase (TK) are common in nonmucinous BAC but are only rarely seen in mucinous tumors. In contrast, mutations in the k-ras oncogene are seen in most mucinous BACs but not in nonmucinous tumors [",
"    <a class=\"abstract\" href=\"UTD.htm?9/45/9946/abstract/25-29\">",
"     25-29",
"    </a>",
"    ]. These differences have important implications for the treatment of patients with advanced disease. (See",
"    <a class=\"local\" href=\"#H24\">",
"     'EGFR mutation positive NSCLC'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    The presence of an ALK fusion oncogene defines another important, although significantly less common, subset of NSCLC patients with adenocarcinoma. The ALK fusion oncogene has been described in patients with BAC, although its frequency is uncertain [",
"    <a class=\"abstract\" href=\"UTD.htm?9/45/9946/abstract/30,31\">",
"     30,31",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?39/31/40440?source=see_link\">",
"     \"Anaplastic lymphoma kinase (ALK) fusion oncogene positive non-small cell lung cancer\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H452554975\">",
"    <span class=\"h1\">",
"     EPIDEMIOLOGY AND RISK FACTORS",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H452554997\">",
"    <span class=\"h2\">",
"     Incidence",
"    </span>",
"    &nbsp;&mdash;&nbsp;Over the last several decades, the proportion of lung cancers classified as adenocarcinoma has steadily increased and now represents approximately one-half of all cases [",
"    <a class=\"abstract\" href=\"UTD.htm?9/45/9946/abstract/20\">",
"     20",
"    </a>",
"    ]. Among those classified as having adenocarcinoma, the incidence of the adenocarcinoma in situ (BAC) subset is uncertain. In the United States, estimates of the incidence of BAC have varied from as high as 24 percent in a single institution series [",
"    <a class=\"abstract\" href=\"UTD.htm?9/45/9946/abstract/20\">",
"     20",
"    </a>",
"    ] to less than 5 percent in a large series based upon the Surveillance, Epidemiology and End Results (SEER) database [",
"    <a class=\"abstract\" href=\"UTD.htm?9/45/9946/abstract/32\">",
"     32",
"    </a>",
"    ]. These differences probably reflect variation in the application of pathologic criteria for the diagnosis of BAC. (See",
"    <a class=\"local\" href=\"#H6\">",
"     'Histologic features'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    The newly recommended system for classification of lung adenocarcinomas by the",
"    <span class=\"nowrap\">",
"     IASLC/ATS/ERS",
"    </span>",
"    has not yet been incorporated into routine practice [",
"    <a class=\"abstract\" href=\"UTD.htm?9/45/9946/abstract/3\">",
"     3",
"    </a>",
"    ]; the incidence of the newly defined adenocarcinoma subgroups therefore remains unknown at this time.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H452555102\">",
"    <span class=\"h2\">",
"     Risk factors",
"    </span>",
"    &nbsp;&mdash;&nbsp;Smoking clearly plays a role in the development of some cases of BAC. Patients with BAC are three to four times more likely to have ever smoked than age-matched controls, and the risk is increased with heavier and more prolonged smoking [",
"    <a class=\"abstract\" href=\"UTD.htm?9/45/9946/abstract/33-35\">",
"     33-35",
"    </a>",
"    ]. However, approximately one-third of cases occur in individuals who have never smoked and another one-third are former or intermittent smokers [",
"    <a class=\"abstract\" href=\"UTD.htm?9/45/9946/abstract/20,34,35\">",
"     20,34,35",
"    </a>",
"    ], compared with 10 to 20 percent of the broader lung cancer population. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?12/6/12394?source=see_link\">",
"     \"Lung cancer in never smokers\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Other postulated risk factors for BAC include:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Scarring &ndash; The presence of scarring and fibrosis in the lungs of patients with BAC led to the hypothesis that antecedent pulmonary parenchymal damage due to pulmonary fibrosis or chronic infection may contribute to the development of BAC. However, there are no firm data that support this hypothesis.",
"     </li>",
"     <li>",
"      Occupational exposures &ndash; A slightly increased risk of BAC has been observed in sugarcane farmers, petroleum manufacturers, and workers in the construction, shipping, wood, and paper mill industries [",
"      <a class=\"abstract\" href=\"UTD.htm?9/45/9946/abstract/33,36,37\">",
"       33,36,37",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Viral infection &ndash; A naturally occurring form of lung cancer in sheep is similar to human BAC both clinically and pathologically [",
"      <a class=\"abstract\" href=\"UTD.htm?9/45/9946/abstract/38-40\">",
"       38-40",
"      </a>",
"      ]. This ovine pulmonary adenocarcinoma (OPA) is caused by the jaagsiekte sheep retrovirus (JSRV), and its infectious spread has been documented in herds of sheep after infected animals were imported from other areas [",
"      <a class=\"abstract\" href=\"UTD.htm?9/45/9946/abstract/41\">",
"       41",
"      </a>",
"      ]. An infectious etiology was also supported in a separate study in which newborn lambs developed OPA after intratracheal inoculation of the concentrated virus [",
"      <a class=\"abstract\" href=\"UTD.htm?9/45/9946/abstract/42\">",
"       42",
"      </a>",
"      ]. There are no epidemiologic data that support an infectious etiology for BAC in man.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h1\">",
"     CLINICAL PRESENTATION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Bronchioloalveolar carcinoma (BAC) can have a highly variable clinical presentation, which ranges from a small solitary nodule or limited number of nodules, to more extensive miliary disease, or diffuse parenchymal infiltrates that are similar in appearance to a bacterial pneumonia [",
"    <a class=\"abstract\" href=\"UTD.htm?9/45/9946/abstract/43,44\">",
"     43,44",
"    </a>",
"    ]. &nbsp;",
"   </p>",
"   <p>",
"    In addition to the heterogeneity in the extent of disease at presentation, there can be substantial variation in the natural history and rates of disease progression, which only partially correlates with the extent of disease. Furthermore, different areas of disease may progress at different rates within the same patient, and foci of disease that are initially indolent may become more rapidly progressive over time.",
"   </p>",
"   <p>",
"    The presence of symptoms, rate of disease progression, and the heterogeneity of disease all need to be considered in formulating a treatment plan.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h2\">",
"     Solitary peripheral nodule",
"    </span>",
"    &nbsp;&mdash;&nbsp;Presentation with localized disease is more common in patients with BAC compared to those with other types of NSCLC. In two series involving a total of 164 patients with BAC, 38 percent presented with a solitary nodule [",
"    <a class=\"abstract\" href=\"UTD.htm?9/45/9946/abstract/20,45\">",
"     20,45",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?43/31/44537?source=see_link\">",
"     \"Diagnostic evaluation and management of the solitary pulmonary nodule\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Patients with pure BAC (AIS, MIA) presenting as a small peripheral nodule appear to have a better prognosis than those with invasive adenocarcinoma without any element of BAC, while those with adenocarcinomas that include both BAC and a component of invasive adenocarcinoma have an intermediate prognosis [",
"    <a class=\"abstract\" href=\"UTD.htm?9/45/9946/abstract/8\">",
"     8",
"    </a>",
"    ]. As noted previously, patients with resected solitary adenocarcinoma lesions smaller than 2 to 3 cm that have no invasive component (AIS) [",
"    <a class=\"abstract\" href=\"UTD.htm?9/45/9946/abstract/9-11\">",
"     9-11",
"    </a>",
"    ] or a minimal (&le;5 mm in greatest diameter) component of invasive disease (MIA) [",
"    <a class=\"abstract\" href=\"UTD.htm?9/45/9946/abstract/8,12,13\">",
"     8,12,13",
"    </a>",
"    ] demonstrate a five-year disease-free survival that approaches 100 percent.",
"   </p>",
"   <p>",
"    Many small peripheral lesions due to BAC have a characteristic ground glass appearance on chest CT, which correlates with an improved prognosis. Presumably this radiographic pattern defines a patient subset with pure BAC (AIS) or minimally invasive BAC (MIA) that has a particularly indolent growth pattern and rare locoregional or more distant spread [",
"    <a class=\"abstract\" href=\"UTD.htm?9/45/9946/abstract/46,47\">",
"     46,47",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1301335\">",
"    <span class=\"h2\">",
"     Multifocal pulmonary nodules",
"    </span>",
"    &nbsp;&mdash;&nbsp;BAC frequently presents with multiple pulmonary nodules. In the 2010 edition of the tumor node metastasis (TNM) staging system, additional nodules in the same lobe are classified as T3, ipsilateral nodules in another lobe of the same lung are classified as T4, and nodules in the contralateral lung are considered M1a (and thus stage IV) (",
"    <a class=\"graphic graphic_table graphicRef80099 \" href=\"UTD.htm?36/41/37533\">",
"     table 1",
"    </a>",
"    and",
"    <a class=\"graphic graphic_table graphicRef68104 \" href=\"UTD.htm?13/4/13388\">",
"     table 2",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?9/45/9946/abstract/48\">",
"     48",
"    </a>",
"    ]. This may have important implications for treatment. (See",
"    <a class=\"local\" href=\"#H19\">",
"     'Definitive therapy'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h2\">",
"     Lobar consolidation",
"    </span>",
"    &nbsp;&mdash;&nbsp;When disease is more extensive, BAC patients can present with lobar consolidation that resembles bacterial pneumonia. CT scans typically show air bronchograms or even the CT angiogram sign, which is observed when the massive accumulation of mucus in the airspaces delineates the nearby vasculature. By the new classification these are most commonly mucinous adenocarcinomas. The diagnosis of BAC may not be considered until the clinical symptoms and radiographic abnormalities fail to respond to antibacterial treatment. Unfortunately, this so-called \"pneumonic\" form of BAC has been associated with a particularly poor prognosis [",
"    <a class=\"abstract\" href=\"UTD.htm?9/45/9946/abstract/6\">",
"     6",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1301423\">",
"    <span class=\"h2\">",
"     Clinical symptoms",
"    </span>",
"    &nbsp;&mdash;&nbsp;Clinical symptoms usually reflect the extent of disease. Patients with a solitary peripheral nodule are often asymptomatic [",
"    <a class=\"abstract\" href=\"UTD.htm?9/45/9946/abstract/49\">",
"     49",
"    </a>",
"    ]. With the increased use of lung imaging, a larger number of cases are asymptomatic at presentation.",
"   </p>",
"   <p>",
"    The most common symptoms in those with more extensive tumors are signs of pulmonary involvement including cough, shortness of breath, and hemoptysis. Systemic symptoms of weight loss and fever may also be present [",
"    <a class=\"abstract\" href=\"UTD.htm?9/45/9946/abstract/50\">",
"     50",
"    </a>",
"    ]. Systemic metastases may be present and lead to the diagnosis in some patients. The most common sites of metastases include the contralateral lung, bone, adrenal gland, and brain [",
"    <a class=\"abstract\" href=\"UTD.htm?9/45/9946/abstract/51\">",
"     51",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Two uncommon, but potentially life-threatening, symptoms that may occur in patients with BAC are bronchorrhea and hypoxemia. (See",
"    <a class=\"local\" href=\"#H20\">",
"     'Bronchorrhea'",
"    </a>",
"    below and",
"    <a class=\"local\" href=\"#H21\">",
"     'Hypoxemia'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h1\">",
"     DIAGNOSIS AND STAGING",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H784398408\">",
"    <span class=\"h2\">",
"     Initial imaging studies",
"    </span>",
"    &nbsp;&mdash;&nbsp;The preoperative appearance of a lesion on CT may provide information that suggests the diagnosis of bronchioloalveolar carcinoma (BAC). Positron emission tomography (PET) identifies regions of increased metabolic activity due to disease. However, the slow growth of early BACs makes it questionable whether PET scans are useful in the initial evaluation of lesions potentially representing BAC, and a failure of a lesion to be positive on PET may represent a false negative result [",
"    <a class=\"abstract\" href=\"UTD.htm?9/45/9946/abstract/52,53\">",
"     52,53",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Although there are no prospective studies of PET specifically in BAC, information is available from larger, retrospective series that included patients with BAC [",
"    <a class=\"abstract\" href=\"UTD.htm?9/45/9946/abstract/54-57\">",
"     54-57",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The potential for false negatives with PET are illustrated by a series of 83 cases with proven malignancies who underwent both CT and PET prior to resection of a peripheral lung lesion [",
"      <a class=\"abstract\" href=\"UTD.htm?9/45/9946/abstract/56\">",
"       56",
"      </a>",
"      ]. PET detected only 10 of 29 cases (34 percent) with early (Noguchi A-C) BAC lesions in comparison with higher grade lung adenocarcinomas. In contrast, 9 of 11 early adenocarcinomas (82 percent) without a BAC component were positive.",
"     </li>",
"     <li>",
"      The prognostic significance of a negative PET was illustrated by a cohort study of 36 patients with completely resected, node-negative pure BAC or mixed",
"      <span class=\"nowrap\">",
"       adenocarcinoma/BAC",
"      </span>",
"      [",
"      <a class=\"abstract\" href=\"UTD.htm?9/45/9946/abstract/57\">",
"       57",
"      </a>",
"      ]. The three-year survival was 95 percent in the 19 patients with a negative PET (defined as a maximum SUV below 2.5), compared with a three-year overall survival of 49 percent among the 17 patients with PET-positive disease.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Overall, the results indicate that BACs are disproportionately overrepresented among the lung cancers that are PET negative. Current recommendations from the American Association of Chest Physicians (ACCP) specify that negative PET scan results should not be interpreted as ruling out cancer in patients who have a CT appearance suggestive of BAC; instead additional studies, including follow-up imaging or a biopsy, are appropriate [",
"    <a class=\"abstract\" href=\"UTD.htm?9/45/9946/abstract/58\">",
"     58",
"    </a>",
"    ]. Furthermore, lesions that are positive on PET and those with a higher maximum SUV are more likely to be associated with invasive adenocarcinoma and a less favorable prognosis.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H784398105\">",
"    <span class=\"h2\">",
"     Tissue diagnosis",
"    </span>",
"    &nbsp;&mdash;&nbsp;For patients with a solitary peripheral nodule, the diagnosis is generally established with surgery and pathologic examination of the resected tumor. For patients with more extensive lesions (multifocal disease or consolidation), the diagnosis of lung cancer is often made from either a fine needle aspiration or bronchial washings. Cytology and immunohistochemical staining of such specimens often can be sufficient to diagnose a pulmonary malignancy.",
"   </p>",
"   <p>",
"    Although a formal diagnosis of pure BAC cannot be made without being able to assess whether the tumor is invasive, the distinction between pure BAC and adenocarcinoma with a BAC component does not necessarily warrant further invasive testing, since treatment options are similar for both groups.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H784398098\">",
"    <span class=\"h2\">",
"     TNM staging system",
"    </span>",
"    &nbsp;&mdash;&nbsp;The 7th TNM staging system for NSCLC is used in patients with BAC (",
"    <a class=\"graphic graphic_table graphicRef80099 \" href=\"UTD.htm?36/41/37533\">",
"     table 1",
"    </a>",
"    ). A major revision of this system was adopted which incorporated a number of changes from the 6th TNM system (",
"    <a class=\"graphic graphic_table graphicRef68104 \" href=\"UTD.htm?13/4/13388\">",
"     table 2",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?9/45/9946/abstract/48\">",
"     48",
"    </a>",
"    ]. The reclassification of patients with negative nodes (N0) and multiple nodules in one lobe as T3N0 rather than T4N0, and hence as stage IIB rather than IIIB, is particularly pertinent for patients with BAC, as is the reclassification of additional nodules in another lobe of the same lung as T4 rather than M1 (and hence as stage IIIA if N0 or N1, rather than stage IV). Although the risk of recurrence is high in these situations, multinodular lesions can potentially be resected with curative intent. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?14/31/14841?source=see_link\">",
"     \"Diagnosis and staging of non-small cell lung cancer\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?43/21/44373?source=see_link\">",
"     \"Tumor node metastasis (TNM) staging system for non-small cell lung cancer\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The 7th TNM staging system was validated in a series of 1909 patients with BAC from the California Cancer Registry diagnosed between 1999 and 2003 [",
"    <a class=\"abstract\" href=\"UTD.htm?9/45/9946/abstract/59\">",
"     59",
"    </a>",
"    ]. Using the proposed system, 25 percent of the 657 patients with advanced BAC were reclassified, and the resulting staging provided a better discrimination than the 6th TNM staging system based upon lung cancer specific survival.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h1\">",
"     TREATMENT",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h2\">",
"     Locoregional disease",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h3\">",
"     Definitive therapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;For patients with locoregional disease, antitumor treatment is the same as for those with non-small cell lung cancer without a BAC component.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Surgery is the preferred treatment for stage I or II disease , if the patient's overall condition is satisfactory to permit resection. The optimal surgical technique is uncertain; wedge resection may represent an alternative to lobectomy in selected patients with stage I BAC, allowing preservation of lung parenchyma [",
"      <a class=\"abstract\" href=\"UTD.htm?9/45/9946/abstract/9,60-62\">",
"       9,60-62",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?1/5/1114?source=see_link&amp;anchor=H3#H3\">",
"       \"Management of stage I and stage II non-small cell lung cancer\", section on 'Surgery'",
"      </a>",
"      .)",
"      <br/>",
"      <br/>",
"      Surgical resection of a limited number of nodules may be associated with prolonged survival in carefully selected patients [",
"      <a class=\"abstract\" href=\"UTD.htm?9/45/9946/abstract/63,64\">",
"       63,64",
"      </a>",
"      ]. However, it is not clear whether this prolonged survival is secondary to a benefit from surgical resection or to indolent tumor biology in multifocal BAC, which might have led to prolonged survival even in the absence of surgery. Resection is not routinely recommended as a treatment for advanced, multifocal BAC. (See",
"      <a class=\"local\" href=\"#H14\">",
"       'Lobar consolidation'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Radiation therapy (RT) appears to be as effective for BAC as in other types of NSCLC. RT is used as a part of a multimodality approach for patients with stage III disease, and it may be considered for patients with early stage disease who are not candidates for surgery. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?38/36/39498?source=see_link\">",
"       \"Management of stage III non-small cell lung cancer\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?1/5/1114?source=see_link&amp;anchor=H10#H10\">",
"       \"Management of stage I and stage II non-small cell lung cancer\", section on 'Nonsurgical approaches'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      There are no trials that specifically address the role of adjuvant chemotherapy following surgery in patients with BAC. The use of adjuvant chemotherapy for patients with BAC is based upon the trials that included all types of NSCLC. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?17/26/17833?source=see_link\">",
"       \"Adjuvant systemic therapy in resectable non-small cell lung cancer\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20\">",
"    <span class=\"h3\">",
"     Bronchorrhea",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients with mucinous BAC may produce more than 100",
"    <span class=\"nowrap\">",
"     mL/day",
"    </span>",
"    of watery sputum. In addition to respiratory symptoms, bronchorrhea may cause electrolyte imbalances [",
"    <a class=\"abstract\" href=\"UTD.htm?9/45/9946/abstract/65,66\">",
"     65,66",
"    </a>",
"    ]. Although there are no large studies on the treatment of bronchorrhea, case reports described the successful use of several agents in this setting:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Small molecule epidermal growth factor receptor (EGFR) tyrosine kinase (TK) inhibitors may improve tumor-associated bronchorrhea, sometimes within 24 hours [",
"      <a class=\"abstract\" href=\"UTD.htm?9/45/9946/abstract/67-71\">",
"       67-71",
"      </a>",
"      ]. The mechanism of action of these drugs in managing bronchorrhea may be different than its antitumor effect, and response has been observed in a patient without an EGFR mutation [",
"      <a class=\"abstract\" href=\"UTD.htm?9/45/9946/abstract/71\">",
"       71",
"      </a>",
"      ]. (See",
"      <a class=\"local\" href=\"#H24\">",
"       'EGFR mutation positive NSCLC'",
"      </a>",
"      below.)",
"     </li>",
"     <li>",
"      Corticosteroids [",
"      <a class=\"abstract\" href=\"UTD.htm?9/45/9946/abstract/72-74\">",
"       72-74",
"      </a>",
"      ] and macrolides [",
"      <a class=\"abstract\" href=\"UTD.htm?9/45/9946/abstract/72,73\">",
"       72,73",
"      </a>",
"      ] have been used to decrease inflammation, which may contribute to bronchorrhea.",
"     </li>",
"     <li>",
"      Prostaglandins may play a role in increased transepithelial chloride secretion that contributes to the pathogenesis of bronchorrhea in some patients. This provided the rationale for the use of inhaled",
"      <a class=\"drug drug_general\" href=\"UTD.htm?35/50/36649?source=see_link\">",
"       indomethacin",
"      </a>",
"      [",
"      <a class=\"abstract\" href=\"UTD.htm?9/45/9946/abstract/75,76\">",
"       75,76",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      In one case,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?42/7/43128?source=see_link\">",
"       octreotide",
"      </a>",
"      effectively palliated bronchorrhea in a patient with advanced BAC [",
"      <a class=\"abstract\" href=\"UTD.htm?9/45/9946/abstract/77\">",
"       77",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21\">",
"    <span class=\"h3\">",
"     Hypoxemia",
"    </span>",
"    &nbsp;&mdash;&nbsp;For carefully selected patients with hypoxemia resulting from mucus-related intrapulmonary shunting, surgical resection of the involved lobe may provide palliation of the hypoxemia [",
"    <a class=\"abstract\" href=\"UTD.htm?9/45/9946/abstract/78\">",
"     78",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22\">",
"    <span class=\"h2\">",
"     Advanced BAC",
"    </span>",
"    &nbsp;&mdash;&nbsp;Both cytotoxic chemotherapy and targeted therapy have a role in treating patients with advanced disease. Chemotherapy (",
"    <a class=\"drug drug_general\" href=\"UTD.htm?37/61/38873?source=see_link\">",
"     carboplatin",
"    </a>",
"    plus",
"    <a class=\"drug drug_general\" href=\"UTD.htm?16/58/17320?source=see_link\">",
"     paclitaxel",
"    </a>",
"    ) was compared with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?35/13/36056?source=see_link\">",
"     erlotinib",
"    </a>",
"    in a randomized phase II trial (IFCT-0504) in patients with advanced BAC not selected on the basis of EGFR mutation. Patients then crossed over to the opposite regimen upon progression [",
"    <a class=\"abstract\" href=\"UTD.htm?9/45/9946/abstract/79\">",
"     79",
"    </a>",
"    ]. There was no statistically significant difference between the two treatment sequences in terms of overall survival.",
"   </p>",
"   <p>",
"    If feasible, patients should have tumor tissue assessed for the presence of a somatic mutation in the epidermal growth factor receptor (EGFR), which is highly associated with sensitivity to EGFR tyrosine kinase inhibitors, and for the ALK fusion oncogene, which is highly associated with sensitivity to",
"    <a class=\"drug drug_general\" href=\"UTD.htm?29/58/30631?source=see_link\">",
"     crizotinib",
"    </a>",
"    . Patient management can then be dictated by the results of these molecular studies. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?20/57/21401?source=see_link&amp;anchor=H798956916#H798956916\">",
"     \"Overview of the treatment of advanced non-small cell lung cancer\", section on 'Chemotherapy versus targeted therapy'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Patients without a mutation in EGFR or the ALK fusion oncogene should be treated with chemotherapy. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?33/54/34666?source=see_link\">",
"       \"Initial systemic chemotherapy for advanced non-small cell lung cancer without an epidermal growth factor receptor mutation or the ALK fusion oncogene\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Patients with an EGFR mutation are managed with an EGFR tyrosine kinase inhibitor (",
"      <a class=\"drug drug_general\" href=\"UTD.htm?35/13/36056?source=see_link\">",
"       erlotinib",
"      </a>",
"      or",
"      <a class=\"drug drug_general\" href=\"UTD.htm?19/12/19654?source=see_link\">",
"       gefitinib",
"      </a>",
"      ). (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?31/4/31816?source=see_link\">",
"       \"Initial systemic therapy for advanced non-small cell lung cancer with a mutation in the epidermal growth factor receptor\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Those with an ALK fusion oncogene in their tumor are preferentially treated with",
"      <a class=\"drug drug_general\" href=\"UTD.htm?29/58/30631?source=see_link\">",
"       crizotinib",
"      </a>",
"      . (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?39/31/40440?source=see_link\">",
"       \"Anaplastic lymphoma kinase (ALK) fusion oncogene positive non-small cell lung cancer\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H23\">",
"    <span class=\"h3\">",
"     No EGFR mutation and no ALK fusion oncogene",
"    </span>",
"    &nbsp;&mdash;&nbsp;BAC was originally considered more chemoresistant than other histologic types of NSCLC. However, subsequent studies showed that chemotherapy activity in patients with BAC is similar to that in other patients with pulmonary adenocarcinoma.",
"   </p>",
"   <p>",
"    Two prospective, multicenter, phase II studies specifically focused on the role of chemotherapy in patients with BAC. In a Southwest Oncology Group (SWOG) study, a 96-hour",
"    <a class=\"drug drug_general\" href=\"UTD.htm?16/58/17320?source=see_link\">",
"     paclitaxel",
"    </a>",
"    infusion resulted partial responses in 8 of 58 patients (14 percent) and stable disease in 23 of 58 (40 percent) [",
"    <a class=\"abstract\" href=\"UTD.htm?9/45/9946/abstract/80\">",
"     80",
"    </a>",
"    ]. Median survival was 12 months. A smaller study from the European Organization for Research and Treatment of Cancer (EORTC) using a three-hour infusion of paclitaxel gave similar results [",
"    <a class=\"abstract\" href=\"UTD.htm?9/45/9946/abstract/81\">",
"     81",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    There are no trials assessing the role of contemporary chemotherapy regimens in patients with BAC, although patients with BAC have been included in the randomized trials that define the therapeutic approach for advanced NSCLC. For patients with advanced BAC who are unlikely to respond to EGFR TK inhibitors, cytotoxic chemotherapy is preferred, based upon extrapolation from those with other pulmonary adenocarcinomas. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?33/54/34666?source=see_link\">",
"     \"Initial systemic chemotherapy for advanced non-small cell lung cancer without an epidermal growth factor receptor mutation or the ALK fusion oncogene\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H24\">",
"    <span class=\"h3\">",
"     EGFR mutation positive NSCLC",
"    </span>",
"    &nbsp;&mdash;&nbsp;The development of small molecule inhibitors of the epidermal growth factor receptor (EGFR) tyrosine kinase (TK) allows therapy to be individualized for subsets of patients with advanced NSCLC. Various clinical characteristics (nonsmoking, Asian ethnicity, female) and the presence of activating mutations in the EGFR TK are predictors of responsiveness to these agents. Conversely, the presence of mutations in k-ras predicts a low probability of a significant response to this class of agents, although minor responses and prolonged stable disease may still be seen. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?31/4/31816?source=see_link\">",
"     \"Initial systemic therapy for advanced non-small cell lung cancer with a mutation in the epidermal growth factor receptor\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The frequency of EGFR mutations in patients with BAC was illustrated in a series of 86 patients with BAC, in which EGFR mutations were present in 22 (26 percent) [",
"    <a class=\"abstract\" href=\"UTD.htm?9/45/9946/abstract/82\">",
"     82",
"    </a>",
"    ]. Of particular interest, EGFR mutations were limited to those with the nonmucinous form of BAC (22 of 69 versus 0 of 17 with mucinous BAC). In contrast, k-ras mutations were less common in nonmucinous BAC (14 versus 76 percent). Furthermore, EGFR and k-ras mutations were not both found in the same patients.",
"   </p>",
"   <p>",
"    Three multicenter, phase II studies have specifically evaluated the role of EGFR TK inhibitors in patients with BAC [",
"    <a class=\"abstract\" href=\"UTD.htm?9/45/9946/abstract/83-85\">",
"     83-85",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In a four-center study, 101 patients (74 percent of whom previously had not received systemic chemotherapy) were treated with",
"      <a class=\"drug drug_general\" href=\"UTD.htm?35/13/36056?source=see_link\">",
"       erlotinib",
"      </a>",
"      [",
"      <a class=\"abstract\" href=\"UTD.htm?9/45/9946/abstract/83\">",
"       83",
"      </a>",
"      ]. The overall response rate was 22 percent, and the median overall survival was 17 months. The 18 patients with EGFR mutations had a significantly higher response rate and progression-free survival compared to those with wild-type EGFR (83 versus 7 percent and 13 versus 2 months, respectively). In contrast, the presence of a k-ras mutation was associated with a significantly lower response rate (0 versus 32 percent in patients with wild-type k-ras).",
"     </li>",
"     <li>",
"      In a Southwest Oncology Group (SWOG) study, 136 patients with BAC were treated with",
"      <a class=\"drug drug_general\" href=\"UTD.htm?19/12/19654?source=see_link\">",
"       gefitinib",
"      </a>",
"      (500",
"      <span class=\"nowrap\">",
"       mg/day)",
"      </span>",
"      [",
"      <a class=\"abstract\" href=\"UTD.htm?9/45/9946/abstract/84\">",
"       84",
"      </a>",
"      ]. The median survival was 13 months, regardless of whether or not patients had received prior systemic therapy. The objective response rate in previously untreated patients with measurable disease was 17 percent, and 9 percent among those who had received previous systemic treatment. Survival was significantly greater in women versus men (19 versus 8 months), never-smokers versus former or current smokers (26 versus 10 months), those who developed a rash versus those with no rash (16 versus 5 months) and in those patients with a performance status of",
"      <span class=\"nowrap\">",
"       0/1",
"      </span>",
"      versus 2 (15 versus 5 months).",
"      <br/>",
"      <br/>",
"      As in the study with",
"      <a class=\"drug drug_general\" href=\"UTD.htm?35/13/36056?source=see_link\">",
"       erlotinib",
"      </a>",
"      , greater benefit was seen among the patients with nonmucinous versus mucinous BAC [",
"      <a class=\"abstract\" href=\"UTD.htm?9/45/9946/abstract/86\">",
"       86",
"      </a>",
"      ]. Although response rates were not subclassified by histology, the survival among patients with adenocarcinoma with prominent BAC features was similar to that of patients with pure BAC, supporting the observations that the clinical benefit seen with small molecule EGFR inhibitors is not restricted to those patients with pure BAC.",
"     </li>",
"     <li>",
"      A multicenter French study (IFCT-0401) treated 88 chemotherapy-naive BAC patients with",
"      <a class=\"drug drug_general\" href=\"UTD.htm?19/12/19654?source=see_link\">",
"       gefitinib",
"      </a>",
"      (250",
"      <span class=\"nowrap\">",
"       mg/day)",
"      </span>",
"      [",
"      <a class=\"abstract\" href=\"UTD.htm?9/45/9946/abstract/85\">",
"       85",
"      </a>",
"      ]. Overall, 11 patients (13 percent) had partial responses (13 percent) and 14 (16 percent) had stable disease. Median progression-free survival (PFS) and overall survival were 3 and 13 months, respectively.",
"      <br/>",
"      <br/>",
"      The benefit of EGFR TK inhibitor therapy was limited to patients with nonmucinous BAC in this study. Both PFS and overall survival were significantly longer for patients with nonmucinous BAC compared to those with mucinous disease (11.3 versus 2.6 months and 33 versus 10 months). On multivariate analysis, the impact of histologic subtype was independent of other criteria (nonsmoking, female sex), used to predict responsiveness to this class of agents.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H272526094\">",
"    <span class=\"h3\">",
"     ALK fusion oncogene positive NSCLC",
"    </span>",
"    &nbsp;&mdash;&nbsp;The presence of the ALK fusion oncogene is associated with sensitivity to",
"    <a class=\"drug drug_general\" href=\"UTD.htm?29/58/30631?source=see_link\">",
"     crizotinib",
"    </a>",
"    , a specific inhibitor of the anaplastic lymphoma kinase (ALK) tyrosine kinase, in phase II studies. In these studies, 96 percent of the 255 patients had adenocarcinoma, but the reported trial results did not distinguish those that contained a significant component of bronchioloalveolar carcinoma. Although the presence of an ALK fusion oncogene appears to be uncommon in BAC, crizotinib is an appropriate option for patients whose tumors contain this molecular abnormality. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?39/31/40440?source=see_link\">",
"     \"Anaplastic lymphoma kinase (ALK) fusion oncogene positive non-small cell lung cancer\"",
"    </a>",
"    and",
"    <a class=\"local\" href=\"#H10\">",
"     'Molecular abnormalities'",
"    </a>",
"    above.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H25\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The term bronchioloalveolar carcinoma is used in the World Health Organizaton (WHO) classification of lung cancers to refer to a subset of adenocarcinoma that is characterized by peripheral location, well-differentiated histology, a lepidic growth pattern, and the potential for both aerogenous and lymphatic spread. More recently, the International Association for the Study of Lung Cancer (IASLC), the American Thoracic Society (ATS), and the European Respiratory Society (ERS) proposed a major revision of the classification of adenocarcinomas, which has divided these patients into five categories and recommended discontinuation of the term BAC. (see",
"      <a class=\"local\" href=\"#H5\">",
"       'Pathology and definition'",
"      </a>",
"      above)",
"     </li>",
"     <li>",
"      For patients with locoregional BAC or mixed adenocarcinoma with a BAC component, the initial management with surgery, radiotherapy,",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      adjuvant chemotherapy is the same as in other types of NSCLC. (See",
"      <a class=\"local\" href=\"#H18\">",
"       'Locoregional disease'",
"      </a>",
"      above and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?1/5/1114?source=see_link\">",
"       \"Management of stage I and stage II non-small cell lung cancer\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?38/36/39498?source=see_link\">",
"       \"Management of stage III non-small cell lung cancer\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?17/26/17833?source=see_link\">",
"       \"Adjuvant systemic therapy in resectable non-small cell lung cancer\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      A subset of patients with advanced, multifocal disease who are asymptomatic and who demonstrate a rate of progression that appears to be extremely indolent (eg, little or no radiographic change over an interval of six months or more) may not require immediate systemic therapy. For this subset, clinical and radiographic follow-up is an appropriate consideration until a point at which the patient is symptomatic or demonstrates accelerating progression.",
"     </li>",
"     <li>",
"      Whenever possible, tumor should be assessed for the presence of an EGFR mutation and the ALK fusion oncogene as a guide to subsequent treatment. There is increasing evidence supporting the correlation of EGFR mutations with profound clinical benefit from oral epidermal growth factor receptor (EGFR) tyrosine kinase (TK) inhibitors in these patients. (See",
"      <a class=\"local\" href=\"#H22\">",
"       'Advanced BAC'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      For patients with advanced disease that is felt to merit systemic therapy:",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      For those with a mutation in the EGFR, we recommend initial treatment with an EGFR TK inhibitor (",
"      <a class=\"drug drug_general\" href=\"UTD.htm?19/12/19654?source=see_link\">",
"       gefitinib",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?35/13/36056?source=see_link\">",
"       erlotinib",
"      </a>",
"      ) rather than cytotoxic chemotherapy (",
"      <a class=\"grade\" href=\"._grade_2?title=Grade 1B\">",
"       Grade 1B",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H24\">",
"       'EGFR mutation positive NSCLC'",
"      </a>",
"      above and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?31/4/31816?source=see_link\">",
"       \"Initial systemic therapy for advanced non-small cell lung cancer with a mutation in the epidermal growth factor receptor\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      For those whose tumor contains the ALK fusion oncogene, we suggest initial treatment with",
"      <a class=\"drug drug_general\" href=\"UTD.htm?29/58/30631?source=see_link\">",
"       crizotinib",
"      </a>",
"      (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H272526094\">",
"       'ALK fusion oncogene positive NSCLC'",
"      </a>",
"      above and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?39/31/40440?source=see_link\">",
"       \"Anaplastic lymphoma kinase (ALK) fusion oncogene positive non-small cell lung cancer\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      For those without either a mutated EGFR or the ALK fusion oncogene, and for those whose tumor has not been evaluated but is unlikely to possess an EGFR mutation (eg, mucinous BAC), we recommend the use of a contemporary cytotoxic chemotherapy regimen rather than an EGFR TK inhibitor (",
"      <a class=\"grade\" href=\"._grade_2?title=Grade 1B\">",
"       Grade 1B",
"      </a>",
"      ). The specific choice of chemotherapy regimen and duration of treatment should follow the guidelines for other types of NSCLC. (See",
"      <a class=\"local\" href=\"#H23\">",
"       'No EGFR mutation and no ALK fusion oncogene'",
"      </a>",
"      above and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?33/54/34666?source=see_link\">",
"       \"Initial systemic chemotherapy for advanced non-small cell lung cancer without an epidermal growth factor receptor mutation or the ALK fusion oncogene\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      For patients with advanced BAC whose tumor has not been assessed for an EGFR mutation but has an increased probability of having such a mutation (eg, nonmucinous BAC), we suggest initial treatment with a contemporary cytotoxic chemotherapy regimen rather than an EGFR TK inhibitor (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). The specific choice of chemotherapy regimen and duration of treatment should follow the guidelines for other types of NSCLC. Treatment with an EGFR TK inhibitor may be indicated if the presence of an EGFR mutation is subsequently demonstrated, or as second line therapy if the EGFR status remains unknown. (See",
"      <a class=\"local\" href=\"#H23\">",
"       'No EGFR mutation and no ALK fusion oncogene'",
"      </a>",
"      above and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?33/54/34666?source=see_link\">",
"       \"Initial systemic chemotherapy for advanced non-small cell lung cancer without an epidermal growth factor receptor mutation or the ALK fusion oncogene\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     Travis WD. Pathology and Genetics of Tumours of the Lung, Pleura, Thymus and Heart, World Health Organization, International Agency for Research on Cancer, International Association for the Study of Lung Cancer, International Academy of Pathology (Eds), IARC Press, Oxford University Press, Lyon Oxford 2004.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/45/9946/abstract/2\">",
"      West HL, Garfield DH. Bronchioloalveolar carcinoma: not as easy as \"BAC\". J Thorac Oncol 2009; 4:1047.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/45/9946/abstract/3\">",
"      Travis WD, Brambilla E, Noguchi M, et al. International association for the study of lung cancer/american thoracic society/european respiratory society international multidisciplinary classification of lung adenocarcinoma. J Thorac Oncol 2011; 6:244.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/45/9946/abstract/4\">",
"      LIEBOW AA. Bronchiolo-alveolar carcinoma. Adv Intern Med 1960; 10:329.",
"     </a>",
"    </li>",
"    <li>",
"     Travis W, Colby TV, Corrin B, et al. Histological typing of lung and pleural tumors, 3rd, Berlin, Berlin 1999.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/45/9946/abstract/6\">",
"      Ebright MI, Zakowski MF, Martin J, et al. Clinical pattern and pathologic stage but not histologic features predict outcome for bronchioloalveolar carcinoma. Ann Thorac Surg 2002; 74:1640.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/45/9946/abstract/7\">",
"      Lin DM, Ma Y, Zheng S, et al. Prognostic value of bronchioloalveolar carcinoma component in lung adenocarcinoma. Histol Histopathol 2006; 21:627.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/45/9946/abstract/8\">",
"      Noguchi M, Morikawa A, Kawasaki M, et al. Small adenocarcinoma of the lung. Histologic characteristics and prognosis. Cancer 1995; 75:2844.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/45/9946/abstract/9\">",
"      Watanabe S, Watanabe T, Arai K, et al. Results of wedge resection for focal bronchioloalveolar carcinoma showing pure ground-glass attenuation on computed tomography. Ann Thorac Surg 2002; 73:1071.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/45/9946/abstract/10\">",
"      Sakurai H, Dobashi Y, Mizutani E, et al. Bronchioloalveolar carcinoma of the lung 3 centimeters or less in diameter: a prognostic assessment. Ann Thorac Surg 2004; 78:1728.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/45/9946/abstract/11\">",
"      Yoshida J, Nagai K, Yokose T, et al. Limited resection trial for pulmonary ground-glass opacity nodules: fifty-case experience. J Thorac Cardiovasc Surg 2005; 129:991.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/45/9946/abstract/12\">",
"      Borczuk AC, Qian F, Kazeros A, et al. Invasive size is an independent predictor of survival in pulmonary adenocarcinoma. Am J Surg Pathol 2009; 33:462.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/45/9946/abstract/13\">",
"      Yim J, Zhu LC, Chiriboga L, et al. Histologic features are important prognostic indicators in early stages lung adenocarcinomas. Mod Pathol 2007; 20:233.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/45/9946/abstract/14\">",
"      Shah RN, Badve S, Papreddy K, et al. Expression of cytokeratin 20 in mucinous bronchioloalveolar carcinoma. Hum Pathol 2002; 33:915.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/45/9946/abstract/15\">",
"      Saad RS, Cho P, Silverman JF, Liu Y. Usefulness of Cdx2 in separating mucinous bronchioloalveolar adenocarcinoma of the lung from metastatic mucinous colorectal adenocarcinoma. Am J Clin Pathol 2004; 122:421.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/45/9946/abstract/16\">",
"      Simsir A, Wei XJ, Yee H, et al. Differential expression of cytokeratins 7 and 20 and thyroid transcription factor-1 in bronchioloalveolar carcinoma: an immunohistochemical study in fine-needle aspiration biopsy specimens. Am J Clin Pathol 2004; 121:350.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/45/9946/abstract/17\">",
"      Lau SK, Desrochers MJ, Luthringer DJ. Expression of thyroid transcription factor-1, cytokeratin 7, and cytokeratin 20 in bronchioloalveolar carcinomas: an immunohistochemical evaluation of 67 cases. Mod Pathol 2002; 15:538.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/45/9946/abstract/18\">",
"      Jerome Marson V, Mazieres J, Groussard O, et al. Expression of TTF-1 and cytokeratins in primary and secondary epithelial lung tumours: correlation with histological type and grade. Histopathology 2004; 45:125.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/45/9946/abstract/19\">",
"      Goldstein NS, Thomas M. Mucinous and nonmucinous bronchioloalveolar adenocarcinomas have distinct staining patterns with thyroid transcription factor and cytokeratin 20 antibodies. Am J Clin Pathol 2001; 116:319.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/45/9946/abstract/20\">",
"      Barsky SH, Cameron R, Osann KE, et al. Rising incidence of bronchioloalveolar lung carcinoma and its unique clinicopathologic features. Cancer 1994; 73:1163.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/45/9946/abstract/21\">",
"      Dumont P, Gasser B, Roug&eacute; C, et al. Bronchoalveolar carcinoma: histopathologic study of evolution in a series of 105 surgically treated patients. Chest 1998; 113:391.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/45/9946/abstract/22\">",
"      Tao LC, Delarue NC, Sanders D, Weisbrod G. Bronchiolo-alveolar carcinoma: a correlative clinical and cytologic study. Cancer 1978; 42:2759.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/45/9946/abstract/23\">",
"      Kris MG, Giaccone G, Davies A, et al. Systemic therapy of bronchioloalveolar carcinoma: results of the first IASLC/ASCO consensus conference on bronchioloalveolar carcinoma. J Thorac Oncol 2006; 1:S32.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/45/9946/abstract/24\">",
"      Spitz MR, Hsu TC, Wu X, et al. Mutagen sensitivity as a biological marker of lung cancer risk in African Americans. Cancer Epidemiol Biomarkers Prev 1995; 4:99.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/45/9946/abstract/25\">",
"      Garfield DH, Cadranel J, West HL. Bronchioloalveolar carcinoma: the case for two diseases. Clin Lung Cancer 2008; 9:24.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/45/9946/abstract/26\">",
"      Wislez M, Antoine M, Baudrin L, et al. Non-mucinous and mucinous subtypes of adenocarcinoma with bronchioloalveolar carcinoma features differ by biomarker expression and in the response to gefitinib. Lung Cancer 2010; 68:185.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/45/9946/abstract/27\">",
"      Hata A, Katakami N, Fujita S, et al. Frequency of EGFR and KRAS mutations in Japanese patients with lung adenocarcinoma with features of the mucinous subtype of bronchioloalveolar carcinoma. J Thorac Oncol 2010; 5:1197.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/45/9946/abstract/28\">",
"      Sakuma Y, Matsukuma S, Yoshihara M, et al. Distinctive evaluation of nonmucinous and mucinous subtypes of bronchioloalveolar carcinomas in EGFR and K-ras gene-mutation analyses for Japanese lung adenocarcinomas: confirmation of the correlations with histologic subtypes and gene mutations. Am J Clin Pathol 2007; 128:100.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/45/9946/abstract/29\">",
"      Finberg KE, Sequist LV, Joshi VA, et al. Mucinous differentiation correlates with absence of EGFR mutation and presence of KRAS mutation in lung adenocarcinomas with bronchioloalveolar features. J Mol Diagn 2007; 9:320.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/45/9946/abstract/30\">",
"      Inamura K, Takeuchi K, Togashi Y, et al. EML4-ALK fusion is linked to histological characteristics in a subset of lung cancers. J Thorac Oncol 2008; 3:13.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/45/9946/abstract/31\">",
"      Sasaki T, Rodig SJ, Chirieac LR, J&auml;nne PA. The biology and treatment of EML4-ALK non-small cell lung cancer. Eur J Cancer 2010; 46:1773.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/45/9946/abstract/32\">",
"      Read WL, Page NC, Tierney RM, et al. The epidemiology of bronchioloalveolar carcinoma over the past two decades: analysis of the SEER database. Lung Cancer 2004; 45:137.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/45/9946/abstract/33\">",
"      Falk RT, Pickle LW, Fontham ET, et al. Epidemiology of bronchioloalveolar carcinoma. Cancer Epidemiol Biomarkers Prev 1992; 1:339.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/45/9946/abstract/34\">",
"      Morabia A, Wynder EL. Relation of bronchioloalveolar carcinoma to tobacco. BMJ 1992; 304:541.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/45/9946/abstract/35\">",
"      Rolen, KA, Fulton, JP, Tamura, DJ, Strauss GM. Bronchioloalveolar carcinoma (BAC) of the lung is related to cigarette smoking: A case-control study from Rhode Island (RI). Proc Am Soc Clin Oncol 2003; 22:674.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/45/9946/abstract/36\">",
"      Morton WE, Treyve EL. Histologic differences in occupational risks of lung cancer incidence. Am J Ind Med 1982; 3:441.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/45/9946/abstract/37\">",
"      Rothschild H, Mulvey JJ. An increased risk for lung cancer mortality associated with sugarcane farming. J Natl Cancer Inst 1982; 68:755.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/45/9946/abstract/38\">",
"      Garc&iacute;a-Goti M, Gonz&aacute;lez L, Cousens C, et al. Sheep pulmonary adenomatosis: characterization of two pathological forms associated with jaagsiekte retrovirus. J Comp Pathol 2000; 122:55.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/45/9946/abstract/39\">",
"      Palmarini M, Fan H. Retrovirus-induced ovine pulmonary adenocarcinoma, an animal model for lung cancer. J Natl Cancer Inst 2001; 93:1603.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/45/9946/abstract/40\">",
"      Leroux C, Girard N, Cottin V, et al. Jaagsiekte Sheep Retrovirus (JSRV): from virus to lung cancer in sheep. Vet Res 2007; 38:211.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/45/9946/abstract/41\">",
"      SIGURDSSON B. Adenomatosis of sheep's lungs; experimental transmission. Arch Gesamte Virusforsch 1958; 8:51.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/45/9946/abstract/42\">",
"      Palmarini M, Sharp JM, de las Heras M, Fan H. Jaagsiekte sheep retrovirus is necessary and sufficient to induce a contagious lung cancer in sheep. J Virol 1999; 73:6964.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/45/9946/abstract/43\">",
"      Akira M, Atagi S, Kawahara M, et al. High-resolution CT findings of diffuse bronchioloalveolar carcinoma in 38 patients. AJR Am J Roentgenol 1999; 173:1623.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/45/9946/abstract/44\">",
"      Thompson WH. Bronchioloalveolar carcinoma masquerading as pneumonia. Respir Care 2004; 49:1349.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/45/9946/abstract/45\">",
"      Trigaux JP, Gevenois PA, Goncette L, et al. Bronchioloalveolar carcinoma: computed tomography findings. Eur Respir J 1996; 9:11.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/45/9946/abstract/46\">",
"      Aoki T, Tomoda Y, Watanabe H, et al. Peripheral lung adenocarcinoma: correlation of thin-section CT findings with histologic prognostic factors and survival. Radiology 2001; 220:803.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/45/9946/abstract/47\">",
"      Yang ZG, Sone S, Takashima S, et al. High-resolution CT analysis of small peripheral lung adenocarcinomas revealed on screening helical CT. AJR Am J Roentgenol 2001; 176:1399.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/45/9946/abstract/48\">",
"      Goldstraw P, Crowley J, Chansky K, et al. The IASLC Lung Cancer Staging Project: proposals for the revision of the TNM stage groupings in the forthcoming (seventh) edition of the TNM Classification of malignant tumours. J Thorac Oncol 2007; 2:706.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/45/9946/abstract/49\">",
"      Greco RJ, Steiner RM, Goldman S, et al. Bronchoalveolar cell carcinoma of the lung. Ann Thorac Surg 1986; 41:652.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/45/9946/abstract/50\">",
"      Lee KS, Kim Y, Han J, et al. Bronchioloalveolar carcinoma: clinical, histopathologic, and radiologic findings. Radiographics 1997; 17:1345.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/45/9946/abstract/51\">",
"      Breathnach OS, Ishibe N, Williams J, et al. Clinical features of patients with stage IIIB and IV bronchioloalveolar carcinoma of the lung. Cancer 1999; 86:1165.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/45/9946/abstract/52\">",
"      Aquino SL, Halpern EF, Kuester LB, Fischman AJ. FDG-PET and CT features of non-small cell lung cancer based on tumor type. Int J Mol Med 2007; 19:495.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/45/9946/abstract/53\">",
"      Huang TW, Lin LF, Hsieh CM, et al. Positron emission tomography in bronchioloalveolar carcinoma of the lung. Eur J Surg Oncol 2012; 38:1156.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/45/9946/abstract/54\">",
"      Higashi K, Ueda Y, Seki H, et al. Fluorine-18-FDG PET imaging is negative in bronchioloalveolar lung carcinoma. J Nucl Med 1998; 39:1016.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/45/9946/abstract/55\">",
"      Heyneman LE, Patz EF. PET imaging in patients with bronchioloalveolar cell carcinoma. Lung Cancer 2002; 38:261.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/45/9946/abstract/56\">",
"      Tsunezuka Y, Shimizu Y, Tanaka N, et al. Positron emission tomography in relation to Noguchi's classification for diagnosis of peripheral non-small-cell lung cancer 2 cm or less in size. World J Surg 2007; 31:314.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/45/9946/abstract/57\">",
"      Raz DJ, Odisho AY, Franc BL, Jablons DM. Tumor fluoro-2-deoxy-D-glucose avidity on positron emission tomographic scan predicts mortality in patients with early-stage pure and mixed bronchioloalveolar carcinoma. J Thorac Cardiovasc Surg 2006; 132:1189.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/45/9946/abstract/58\">",
"      Gould MK, Fletcher J, Iannettoni MD, et al. Evaluation of patients with pulmonary nodules: when is it lung cancer?: ACCP evidence-based clinical practice guidelines (2nd edition). Chest 2007; 132:108S.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/45/9946/abstract/59\">",
"      Zell JA, Ignatius Ou SH, Ziogas A, Anton-Culver H. Validation of the proposed International Association for the Study of Lung Cancer non-small cell lung cancer staging system revisions for advanced bronchioloalveolar carcinoma using data from the California Cancer Registry. J Thorac Oncol 2007; 2:1078.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/45/9946/abstract/60\">",
"      Breathnach OS, Kwiatkowski DJ, Finkelstein DM, et al. Bronchioloalveolar carcinoma of the lung: recurrences and survival in patients with stage I disease. J Thorac Cardiovasc Surg 2001; 121:42.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/45/9946/abstract/61\">",
"      Harpole DH, Bigelow C, Young WG Jr, et al. Alveolar cell carcinoma of the lung: a retrospective analysis of 205 patients. Ann Thorac Surg 1988; 46:502.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/45/9946/abstract/62\">",
"      Yamato Y, Tsuchida M, Watanabe T, et al. Early results of a prospective study of limited resection for bronchioloalveolar adenocarcinoma of the lung. Ann Thorac Surg 2001; 71:971.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/45/9946/abstract/63\">",
"      Battafarano RJ, Meyers BF, Guthrie TJ, et al. Surgical resection of multifocal non-small cell lung cancer is associated with prolonged survival. Ann Thorac Surg 2002; 74:988.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/45/9946/abstract/64\">",
"      Roberts PF, Straznicka M, Lara PN, et al. Resection of multifocal non-small cell lung cancer when the bronchioloalveolar subtype is involved. J Thorac Cardiovasc Surg 2003; 126:1597.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/45/9946/abstract/65\">",
"      Hidaka N, Nagao K. Bronchioloalveolar carcinoma accompanied by severe bronchorrhea. Chest 1996; 110:281.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/45/9946/abstract/66\">",
"      Dwek JH, Charytan C, Stachura I, Kaganowicz A. Salt-wasting bronchorrhea and its mechanisms. Arch Intern Med 1977; 137:791.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/45/9946/abstract/67\">",
"      Kitazaki T, Fukuda M, Soda H, Kohno S. Novel effects of gefitinib on mucin production in bronchioloalveolar carcinoma; two case reports. Lung Cancer 2005; 49:125.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/45/9946/abstract/68\">",
"      Milton DT, Kris MG, Gomez JE, Feinstein MB. Prompt control of bronchorrhea in patients with bronchioloalveolar carcinoma treated with gefitinib (Iressa). Support Care Cancer 2005; 13:70.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/45/9946/abstract/69\">",
"      Yano S, Kanematsu T, Miki T, et al. A report of two bronchioloalveolar carcinoma cases which were rapidly improved by treatment with the epidermal growth factor receptor tyrosine kinase inhibitor ZD1839 (\"Iressa\"). Cancer Sci 2003; 94:453.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/45/9946/abstract/70\">",
"      Thotathil Z, Long J. Erlotinib effective against refractory bronchorrhea from advanced non-small cell lung cancer. J Thorac Oncol 2007; 2:881.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/45/9946/abstract/71\">",
"      Popat N, Raghavan N, McIvor RA. Severe bronchorrhea in a patient with bronchioloalveolar carcinoma. Chest 2012; 141:513.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/45/9946/abstract/72\">",
"      Hiratsuka T, Mukae H, Ihiboshi H, et al. [Severe bronchorrhea accompanying alveolar cell carcinoma: treatment with clarithromycin and inhaled beclomethasone]. Nihon Kokyuki Gakkai Zasshi 1998; 36:482.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/45/9946/abstract/73\">",
"      Marom ZM, Goswami SK. Respiratory mucus hypersecretion (bronchorrhea): a case discussion--possible mechanisms(s) and treatment. J Allergy Clin Immunol 1991; 87:1050.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/45/9946/abstract/74\">",
"      Nakajima T, Terashima T, Nishida J, et al. Treatment of bronchorrhea by corticosteroids in a case of bronchioloalveolar carcinoma producing CA19-9. Intern Med 2002; 41:225.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/45/9946/abstract/75\">",
"      Tamaoki J, Kohri K, Isono K, Nagai A. Inhaled indomethacin in bronchorrhea in bronchioloalveolar carcinoma: role of cyclooxygenase. Chest 2000; 117:1213.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/45/9946/abstract/76\">",
"      Homma S, Kawabata M, Kishi K, et al. Successful treatment of refractory bronchorrhea by inhaled indomethacin in two patients with bronchioloalveolar carcinoma. Chest 1999; 115:1465.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/45/9946/abstract/77\">",
"      Hudson E, Lester JF, Attanoos RL, et al. Successful treatment of bronchorrhea with octreotide in a patient with adenocarcinoma of the lung. J Pain Symptom Manage 2006; 32:200.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/45/9946/abstract/78\">",
"      Falcoz PE, Hoan NT, Le Pimpec-Barthes F, Riquet M. Severe hypoxemia due to intrapulmonary shunting requiring surgery for bronchioloalveolar carcinoma. Ann Thorac Surg 2009; 88:287.",
"     </a>",
"    </li>",
"    <li>",
"     Cadranel J, Gervais M, Wislez P, et al. IFCT-0504 trial: Mucinous and nonmucinous cytologic subtypes interaction effect in first-line treatment of advanced broncioloalveolar carcinoma by erlotinib or carboplatin/paclitaxel (abstract 7521). J Clin Oncol 2011; 29:481s.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/45/9946/abstract/80\">",
"      West HL, Crowley JJ, Vance RB, et al. Advanced bronchioloalveolar carcinoma: a phase II trial of paclitaxel by 96-hour infusion (SWOG 9714): a Southwest Oncology Group study. Ann Oncol 2005; 16:1076.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/45/9946/abstract/81\">",
"      Scagliotti GV, Smit E, Bosquee L, et al. A phase II study of paclitaxel in advanced bronchioloalveolar carcinoma (EORTC trial 08956). Lung Cancer 2005; 50:91.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/45/9946/abstract/82\">",
"      Marchetti A, Martella C, Felicioni L, et al. EGFR mutations in non-small-cell lung cancer: analysis of a large series of cases and development of a rapid and sensitive method for diagnostic screening with potential implications on pharmacologic treatment. J Clin Oncol 2005; 23:857.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/45/9946/abstract/83\">",
"      Miller VA, Riely GJ, Zakowski MF, et al. Molecular characteristics of bronchioloalveolar carcinoma and adenocarcinoma, bronchioloalveolar carcinoma subtype, predict response to erlotinib. J Clin Oncol 2008; 26:1472.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/45/9946/abstract/84\">",
"      West HL, Franklin WA, McCoy J, et al. Gefitinib therapy in advanced bronchioloalveolar carcinoma: Southwest Oncology Group Study S0126. J Clin Oncol 2006; 24:1807.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/45/9946/abstract/85\">",
"      Cadranel J, Quoix E, Baudrin L, et al. IFCT-0401 Trial: a phase II study of gefitinib administered as first-line treatment in advanced adenocarcinoma with bronchioloalveolar carcinoma subtype. J Thorac Oncol 2009; 4:1126.",
"     </a>",
"    </li>",
"    <li>",
"     Franklin WA, Chansky K, Gumerlock PH, et al. Association between activation of ErbB pathway genes and survival following gefitinib treatment in advanced BAC (SWOG 0126). Journal of Clinical Oncology 2004 (abstract #7015).",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 4643 Version 12.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0602-199.231.185.123-BC6E475435-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f9_45_9946=[""].join("\n");
var outline_f9_45_9946=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H25\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      PATHOLOGY AND DEFINITION",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Histologic features",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H1301125\">",
"      - WHO system",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H1301144\">",
"      - IASLC/ATS/ERS classification",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      Differential diagnosis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      Mucinous versus nonmucinous BAC",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      - Histopathology",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      - Molecular abnormalities",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H452554975\">",
"      EPIDEMIOLOGY AND RISK FACTORS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H452554997\">",
"      Incidence",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H452555102\">",
"      Risk factors",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      CLINICAL PRESENTATION",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      Solitary peripheral nodule",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H1301335\">",
"      Multifocal pulmonary nodules",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      Lobar consolidation",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H1301423\">",
"      Clinical symptoms",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      DIAGNOSIS AND STAGING",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H784398408\">",
"      Initial imaging studies",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H784398105\">",
"      Tissue diagnosis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H784398098\">",
"      TNM staging system",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      TREATMENT",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      Locoregional disease",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      - Definitive therapy",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H20\">",
"      - Bronchorrhea",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H21\">",
"      - Hypoxemia",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H22\">",
"      Advanced BAC",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H23\">",
"      - No EGFR mutation and no ALK fusion oncogene",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H24\">",
"      - EGFR mutation positive NSCLC",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H272526094\">",
"      - ALK fusion oncogene positive NSCLC",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H25\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"ONC/4643\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"ONC/4643|PIC\">",
"      <a href=\"#\" title=\"PICTURES\">",
"       PICTURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?6/62/7140\" title=\"picture 1\">",
"      Mucinous BAC high power",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?37/28/38342\" title=\"picture 2\">",
"      Nonmucinous BAC hobnail",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"ONC/4643|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?36/41/37533\" title=\"table 1\">",
"      Lung cancer TMN staging 7th edition",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?13/4/13388\" title=\"table 2\">",
"      Changes 7th ed TNM lung ca",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?17/26/17833?source=related_link\">",
"      Adjuvant systemic therapy in resectable non-small cell lung cancer",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?39/31/40440?source=related_link\">",
"      Anaplastic lymphoma kinase (ALK) fusion oncogene positive non-small cell lung cancer",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?14/31/14841?source=related_link\">",
"      Diagnosis and staging of non-small cell lung cancer",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?43/31/44537?source=related_link\">",
"      Diagnostic evaluation and management of the solitary pulmonary nodule",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?33/54/34666?source=related_link\">",
"      Initial systemic chemotherapy for advanced non-small cell lung cancer without an epidermal growth factor receptor mutation or the ALK fusion oncogene",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?31/4/31816?source=related_link\">",
"      Initial systemic therapy for advanced non-small cell lung cancer with a mutation in the epidermal growth factor receptor",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?12/6/12394?source=related_link\">",
"      Lung cancer in never smokers",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?1/5/1114?source=related_link\">",
"      Management of stage I and stage II non-small cell lung cancer",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?38/36/39498?source=related_link\">",
"      Management of stage III non-small cell lung cancer",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?12/61/13273?source=related_link\">",
"      Overview of the initial evaluation, treatment and prognosis of lung cancer",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?20/57/21401?source=related_link\">",
"      Overview of the treatment of advanced non-small cell lung cancer",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?21/43/22201?source=related_link\">",
"      Pathology of lung malignancies",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?43/21/44373?source=related_link\">",
"      Tumor node metastasis (TNM) staging system for non-small cell lung cancer",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f9_45_9947="Patency definitions";
var content_f9_45_9947=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=NEPH%2F70111&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=6\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=NEPH%2F70111&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=6\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Patency definitions",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Primary patency",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Interval following intervention until next procedure or thrombosis. The interval ends with a treatment of a lesion anywhere within the access circuit from arterial inflow through the superior vena cava.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Assisted primary patency",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Interval following intervention until thrombosis or surgical intervention (treatment with a different modality). Percutaneous treatments of either restenosis or occlusion of the previously treated lesion or a new lesion are compatible with primary assisted patency.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Secondary patency",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Interval following intervention until the access is abandoned because of inability to treat original lesion. Percutaneous thrombectomy or thrombolysis is compatible with secondary patency.",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f9_45_9947=[""].join("\n");
var outline_f9_45_9947=null;
var title_f9_45_9948="Thoracolumbar spinal cord injury score";
var content_f9_45_9948=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=NEURO%2F82245&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=NEURO%2F82245&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    The thoracolumbar spinal cord injury classification severity score",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        &nbsp;",
"       </td>",
"       <td class=\"subtitle1\">",
"        Score",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_left\" colspan=\"2\">",
"        1. Morphology type",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\" colspan=\"2\">",
"        Compression:",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent2\">",
"        Compression fracture",
"       </td>",
"       <td>",
"        1",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent2\">",
"        Burst fracture",
"       </td>",
"       <td>",
"        1",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Translational/rotational",
"       </td>",
"       <td>",
"        3",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Distraction",
"       </td>",
"       <td>",
"        4",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_left\" colspan=\"2\">",
"        2. Neurologic involvement",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Intact",
"       </td>",
"       <td>",
"        0",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Nerve root",
"       </td>",
"       <td>",
"        2",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\" colspan=\"2\">",
"        Conus medullaris:",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent2\">",
"        Incomplete",
"       </td>",
"       <td>",
"        3",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent2\">",
"        Complete",
"       </td>",
"       <td>",
"        2",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Cauda equina",
"       </td>",
"       <td>",
"        3",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_left\" colspan=\"2\">",
"        3. Posterior ligament complex",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Intact",
"       </td>",
"       <td>",
"        0",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Injury suspected/indeterminate",
"       </td>",
"       <td>",
"        2",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Injured",
"       </td>",
"       <td>",
"        3",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Data from: Vaccaro, AR, Zeiller, SC, Hulbert, RJ, et al. The thoracolumbar injury severity score: a proposed treatment algorithm. J Spinal Disord Tech 2005; 18:209.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f9_45_9948=[""].join("\n");
var outline_f9_45_9948=null;
var title_f9_45_9949="Operative versus nonoperative management";
var content_f9_45_9949=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=SURG%2F62297&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=SURG%2F62297&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Operative versus nonoperative management",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        Group",
"       </td>",
"       <td class=\"subtitle1\">",
"        Leak",
"       </td>",
"       <td class=\"subtitle1\">",
"        Overall status",
"       </td>",
"       <td class=\"subtitle1\">",
"        Initial management",
"       </td>",
"       <td class=\"subtitle1\">",
"        Considerations",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        <strong>",
"         1A",
"        </strong>",
"       </td>",
"       <td>",
"        No leak",
"       </td>",
"       <td>",
"        Stable/improving",
"       </td>",
"       <td>",
"        Nonoperative treatment",
"       </td>",
"       <td>",
"        Monitor status*",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        <strong>",
"         1B",
"        </strong>",
"       </td>",
"       <td>",
"        No leak",
"       </td>",
"       <td>",
"        Deteriorating",
"       </td>",
"       <td>",
"        Reassess diagnosis",
"        <sup>",
"         &bull;",
"        </sup>",
"       </td>",
"       <td>",
"        Operate only if dx remains perforated peptic ulcer",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        <strong>",
"         2A",
"        </strong>",
"       </td>",
"       <td>",
"        Localized/ contained",
"       </td>",
"       <td>",
"        Stable at 6-12 h, improving thereafter",
"       </td>",
"       <td>",
"        Nonoperative treatment",
"       </td>",
"       <td>",
"        Monitor status*; consider repeat imaging after 12 h",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        <strong>",
"         2B",
"        </strong>",
"       </td>",
"       <td>",
"        Moderate",
"       </td>",
"       <td>",
"        Stable at 6-12 h, improving thereafter",
"       </td>",
"       <td>",
"        Nonoperative treatment",
"       </td>",
"       <td>",
"        Monitor status*; consider repeat imaging after 12 h; consider operating if leak is not decreasing",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        <strong>",
"         2C",
"        </strong>",
"       </td>",
"       <td>",
"        Large",
"       </td>",
"       <td>",
"        Operative candidate",
"       </td>",
"       <td>",
"        Operate",
"       </td>",
"       <td>",
"        The chance of rapid closure with nonoperative care is unknown",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        <strong>",
"         2D",
"        </strong>",
"       </td>",
"       <td>",
"        Any free perforation",
"       </td>",
"       <td>",
"        Deteriorating or failing to improve after 12-24 h",
"       </td>",
"       <td>",
"        Operate",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        <strong>",
"         3",
"        </strong>",
"       </td>",
"       <td>",
"        Any leak",
"       </td>",
"       <td>",
"        Severe comorbidity",
"       </td>",
"       <td>",
"        Nonoperative treatment",
"       </td>",
"       <td>",
"        Monitor status*; monitor leak",
"        <sup>",
"         &Delta;",
"        </sup>",
"        , consider local drainage",
"        <sup>",
"         &loz;",
"        </sup>",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    These considerations guide decision making at 6 to 12 hours once a gastroduodenal perforated ulcer can be confidently diagnosed based on clinical and imaging data and an imaging study with oral contrast has established whether contrast is leaking across a perforation.",
"    <div class=\"footnotes\">",
"     * Monitor status: Track these measures of clinical status: pain, physical exam for peritonitis, temperature, leukocytosis, urine, fluid status (to assess third spacing), pain, overall status. Function of the nasogastric (NG) tube should be checked to ensure that the gastric residual is minimal. Acute nonoperative care combines close monitoring with continued fluid management, NG suction, antibiotics, intravenous proton pump inhibitor (PPI), and preventive antithrombosis measures.",
"     <br>",
"      <span class=\"bullet\">",
"       &bull;",
"      </span>",
"      Reassess diagnosis: Re-evaluate the patient and all laboratory and imaging data to exclude other processes that may explain deteriorating status, such as pneumonia, pyelonephritis, cholecystitis, pancreatitis, or other acute abdominal pathology.",
"      <br>",
"       ��������� Monitor the leak: Consider repeat imaging to assess the magnitude of the leak; nonoperative care is advisable only if the leak is resolving, although the time frame of healing is not known with optimal nonoperative care.",
"       <br>",
"        <span class=\"lozenge\">",
"         &loz;",
"        </span>",
"        Local percutaneous drainage of extravasated fluid is a consideration if the patients too ill to undergo surgery.",
"        <sup>",
"         [1]",
"        </sup>",
"       </br>",
"      </br>",
"     </br>",
"    </div>",
"    <div class=\"reference\">",
"     Reference:",
"     <br>",
"      <ol>",
"       <li>",
"        Rahman MM, Islam MS, Flora S, et al. Mortality in perforated peptic ulcer patients after selective management of stratified poor risk cases. World J Surg 2007; 31:2341.",
"       </li>",
"      </ol>",
"     </br>",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f9_45_9949=[""].join("\n");
var outline_f9_45_9949=null;
var title_f9_45_9950="Inhibitors and inducers of cytochrome P450 3A4";
var content_f9_45_9950=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=CARD%2F76992&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=CARD%2F76992&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Inhibitors and inducers of cytochrome P450 3A4",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\" class=\"container\">",
"     <colgroup span=\"3\" width=\"33%\">",
"     </colgroup>",
"     <tbody>",
"      <tr>",
"       <td class=\"container\">",
"        <table cellspacing=\"0\">",
"         <tbody>",
"          <tr>",
"           <td class=\"subtitle1_single\">",
"            Strong inhibitors",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Atazanavir",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Boceprevir",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Chloramphenicol",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Clarithromycin",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Cobicistat containing coformulations",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Conivaptan",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Darunavir",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Delavirdine",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Fosamprenavir",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Imatinib",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Indinavir",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Isoniazid*",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Itraconazole",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Ketoconazole",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Lopinavir",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Nefazodone",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Nelfinavir",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Nicardipine",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Posaconazole",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Ritonavir and ritonavir containing coformulations",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Saquinavir",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Telaprevir",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Telithromycin",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Voriconazole",
"           </td>",
"          </tr>",
"         </tbody>",
"        </table>",
"       </td>",
"       <td class=\"container\">",
"        <table cellspacing=\"0\">",
"         <tbody>",
"          <tr>",
"           <td class=\"subtitle1_single\">",
"            Moderate inhibitors",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Abiraterone",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Amiodarone",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Aprepitant",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Bicalutamide",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Cimetidine",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Ciprofloxacin*",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Clotrimazole",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Crizotinib",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Cyclosporine",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Desipramine",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Diltiazem",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Danazol*",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Dasatinib*",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Dronedarone",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Efavirenz",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Erythromycin",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Fluconazole",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Fosaprepitant",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Grapefruit juice",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Haloperidol",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Lapatinib",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Metronidazole",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Miconazole",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Mifepristone*",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Norfloxacin",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Quinupristin-dalfopristin*",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Sertraline",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Sitaxsentan",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Tamoxifen*",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Tetracycline",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Verapamil",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Zafirlukast*",
"           </td>",
"          </tr>",
"         </tbody>",
"        </table>",
"       </td>",
"       <td class=\"container\">",
"        <table cellspacing=\"0\">",
"         <tbody>",
"          <tr>",
"           <td class=\"subtitle1_single\">",
"            Strong inducers",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Aminoglutethimide",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Armodafinil*",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Bexarotene*",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Bosentan",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Carbamazepine",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Dexamethasone",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Efavirenz",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Enzalutamide",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Etravirine",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Fosphenytoin",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Griseofulvin*",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Mitotane*",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Modafinil*",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Nafcillin",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Nevirapine",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Oxcarbazepine",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Pentobarbital",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Phenobarbital",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Phenytoin",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Primidone",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Rifabutin",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Rifampin (rifampicin)",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Rifapentine",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            St. John's wort*",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Vemurafenib*",
"           </td>",
"          </tr>",
"         </tbody>",
"        </table>",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    Degree of inhibition or induction may be altered by dose and method of administration. Specific drug interactions and management suggestions may be determined by using Lexi-Interact, the drug interactions program included with UpToDate.",
"    <div class=\"footnotes\">",
"     * Less potent effect on CYP3A4 reported in some references.",
"    </div>",
"    <div class=\"reference\">",
"     Data from: Lexicomp Online. Copyright &copy; 1978-2013 Lexicomp, Inc. All Rights Reserved; and Hansten PD, Horn JR. Top 100 drug interactions: guide to patient management, 13th ed, H&amp;H Publications, 2013.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f9_45_9950=[""].join("\n");
var outline_f9_45_9950=null;
var title_f9_45_9951="Papillon-Lefevre syndrome dental effects";
var content_f9_45_9951=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PEDS%2F66117&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PEDS%2F66117&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Dental effects of Papillon-Lefevre syndrome",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 354px; height: 240px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Near loss of the right central incisor in an 8-year-old child with Papillon-Lefevre syndrome.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: Delaney JE, Keels MA. Pediatric oral pathology. Soft tissue and periodontal conditions. Pediatr Clin North Am 2000; 47:1125. Copyright &copy; 2000 W.B. Saunders.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f9_45_9951=[""].join("\n");
var outline_f9_45_9951=null;
